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ABSTRACT 
Leveraging Knowledge-Based Approaches to Promote Antiretroviral Toxicity Monitoring in 
Underserved Settings 
William Ogallo 
As access and use of antiretroviral therapy continue to increase, the need to improve antiretroviral 
toxicity monitoring becomes more critical. This is particularly so in underserved settings, where 
patterns of antiretroviral toxicities possibly alter the need for and frequency of antiretroviral 
toxicity monitoring. However, barriers such as few skilled healthcare providers and poor 
infrastructure make antiretroviral toxicity monitoring in underserved settings difficult. The 
purpose of this dissertation was to investigate how standard clinical guidelines, knowledge-based 
clinical decision support, and task delegation could be leveraged to overcome barriers to 
antiretroviral toxicity monitoring in underserved settings. 
The strategy adopted in this dissertation was guided by the Design Science Research Methodology 
that emphasizes the generation of scientific knowledge through building novel artifacts. Two 
qualitative descriptive studies were conducted to characterize the contextual factors associated 
with antiretroviral toxicity monitoring in underserved settings. Supported by the findings from 
these studies, a knowledge-based software application prototype that implements clinical practice 
guidelines for antiretroviral toxicity monitoring was developed. Next, a quantitative validation 
study was used to evaluate the structure and behavior of the prototype’s knowledge base. Lastly, 
a quantitative usability study was conducted to assess lay health worker perceptions of the 
satisfaction and mental effort associated with the use of checklists generated by the prototype. 
This dissertation research produced empirical evidence about the broad motives and strategies for 
promoting medication adherence, safety, and effectiveness in underserved settings. It also 
identified strengths, weaknesses, barriers, facilitators, and process redesign recommendations for 
antiretroviral toxicity monitoring within ambulatory HIV care workflows in underserved settings. 
Additionally, it provided evidence about the extent to which antiretroviral toxicity domain 
knowledge could be implemented in a knowledge-based application for supporting point-of-care 
antiretroviral toxicity monitoring. Lastly, the research provided previously unavailable empirical 
evidence about the perceptions of lay peer health workers on the use of checklists for the 
documentation of antiretroviral toxicities. 
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Chapter 1. Introduction 
1.1. Background 
With worldwide estimates of 36.7 million people living with HIV, 2.1 million new HIV infections, 
and 1.1 million deaths from HIV-related illnesses in 2015, HIV/AIDS remains a major global 
public health challenge [1]. The clinical burden of this incurable disease is particularly important 
for sub-Saharan Africa which is home to approximately 25.6 million (70%) of the people living 
with HIV worldwide and accounts for two-thirds of all new HIV infections [1]. Fortunately, the 
introduction and use of antiretroviral therapy has not only reduced the morbidity and mortality 
associated with HIV but also improved the longevity and quality of life of people living with HIV 
[2]. It is for these reasons that the rapid scale-up of antiretroviral therapy in low- and middle-
income countries has been hailed as one of the most significant public health intervention in the 
history of humanity [3]. 
However, because of improved access to antiretroviral therapy along with the adoption of new 
guideline recommendations that promote early initiation and prophylactic use of antiretroviral 
drugs, not only has the number of people using antiretroviral drugs increased but also more users 
are exposed to these agents earlier and for longer periods [2, 4]. These trends have raised important 
concerns about the potential increase in the occurrence of antiretroviral toxicities [2, 4, 5]. 
Antiretroviral toxicities are unintended consequences of antiretroviral therapy. They have been 
reported with the use of all antiretroviral drugs and may range from mild side-effects such as 
nausea to life-threatening adverse drug reactions such as renal failure [6]. Antiretroviral toxicities 
are estimated to occur in 10% of participants in clinical trials [6]. It is plausible that the prevalence 
of antiretroviral toxicities is much higher outside of clinical trials, particularly in low- and middle-
income countries which are the largest consumers of antiretroviral therapy [1]. For example, a 
 2 
 
prospective cohort study of 3921 adult HIV patients receiving care at 7 teaching hospitals in 
Ethiopia reported that antiretroviral toxicities occurred in 22.1% of the participants [7]. Similarly, 
a prospective Thai cohort study of 417 HIV patients reported major antiretroviral toxicities in 24% 
of the participants [8]. Although the impact of antiretroviral toxicities remains a research subject, 
they have been shown to be among the most common reasons for medication non-adherence, 
treatment substitutions, treatment discontinuation, and loss to follow-up in HIV care [2, 9]. 
With increased access and use of antiretroviral therapy, there has been a recognized need to 
improve the monitoring of the safety of these life-saving medications [4, 5]. This is particularly so 
in underserved settings, where variations in host genetics, environment, behavior, and comorbid 
disease burdens could influence the range and patterns of antiretroviral toxicities and possibly alter 
the need for and frequency of antiretroviral toxicity monitoring [10]. Unfortunately, it is plausible 
that barriers such as few skilled healthcare professionals, poor infrastructure, and limited financial 
resources make it difficult to implement antiretroviral toxicity monitoring in underserved settings 
[11, 12]. At the same time, several opportunities for improving antiretroviral toxicity monitoring 
in underserved settings exist. For example, clinical practice guidelines are important sources of 
evidence-based knowledge that could be used to meet clinician information needs pertaining to 
point-of-care antiretroviral toxicity monitoring [2, 6]. Additionally, clinical decision support tools 
could be used to promote adherence to clinical practice guidelines as well as assist care providers 
to gather and analyze antiretroviral toxicity data for informed decision-making [13-15]. On the 
other hand, task shifting, which refers to the delegation of responsibilities to health workers with 
shorter training and fewer qualifications but who are more readily available [16, 17], could 




However, despite the fact that opportunities for improving antiretroviral toxicity monitoring in 
underserved settings exist, key knowledge gaps remain. For example, there is limited information 
on the quality of current point-of-care antiretroviral toxicity monitoring activities within clinical 
workflows in underserved settings. Similarly, there is lack of sufficient evidence on the setting-
specific facilitators and inhibitors of point-of-care monitoring of antiretroviral toxicities. Also, 
domain knowledge in clinical practice guidelines that could support clinician reasoning about 
antiretroviral toxicities is mostly available as textual narratives that are not readily usable as point-
of-care interventions. Furthermore, the extent to which clinical practice guidelines could be 
successfully implemented to support antiretroviral toxicity monitoring using approaches that 
involve task shifting is not well understood. Additionally, there has been limited research on the 
pre-implementation evaluation of the HIV care workflows and how these affect the design, 
integration, function, usability, and feasibility of documentation and decision-making aids for 
antiretroviral toxicity monitoring in underserved settings. More research is, therefore, needed to 
provide evidence on the concerted use of clinical guidelines, clinical decision support, and task 
shifting to improve antiretroviral toxicity monitoring efforts in underserved settings. 
1.2. Purpose 
The overarching purpose of this dissertation research was to advance the scientific body of 
knowledge by responding to a number of research questions pertaining to how clinical practice 
guidelines, knowledge-based clinical decision support, and task shifting could be leveraged to 
improve the documentation and analysis of antiretroviral toxicities within ambulatory HIV care 
workflows in underserved settings. The purpose of the dissertation was threefold. First, it aimed 
at increasing the contextual knowledge of the broad motives and strategies for enhancing 
medication safety in underserved settings, as well as the specific the barriers to and facilitators of 
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the documentation and analysis of antiretroviral toxicity within ambulatory HIV care workflows 
in such settings. Second, it aimed at demonstrating how antiretroviral toxicity domain knowledge 
and reasoning derived from existing clinical guidelines could be implemented in a knowledge-
based application, and how the structure and behavior of the knowledge base of such an application 
could be validated. Lastly, it assessed the extent to which lay health workers perceive paper-based 
antiretroviral toxicity symptom checklists generated by the knowledge-based application 
developed in the dissertation as usable. 
1.3. Specific Aims, Research Questions, and Hypotheses 
The research strategy adopted in the dissertation was based on the Design Science Research 
Methodology [18]. This framework describes the key steps followed in the creation of novel 
artifacts while placing emphasis on the fact that new knowledge is generated in the process of 
building the artifacts [18, 19]. Figure 1.1 illustrates the research strategy used in this dissertation 
which consisted of three main aims. The case studies in Aim 1 explored setting-specific factors 
associated with the monitoring of antiretroviral toxicities in underserved settings. Supported by 
the findings from these studies, the objectives of an informatics solution to address the problems 
associated with point-of-care monitoring of antiretroviral toxicities were defined. Subsequently, a 
knowledge-based software application prototype that implements standard care guidelines for the 
monitoring of antiretroviral toxicities was developed. The investigations in Aim 2 validated the 
structure and behavior of the developed prototype’s knowledge base to ascertain its functional 
completeness and predictive accuracy. The investigations in Aim 3 assessed the usability of 
checklists generated by the developed prototype and intended to be used by lay health workers for 





Figure 1.1: Overview of Research Strategy (based on Design Science Research Methodology). ART= 
Antiretroviral Therapy, KB = Knowledge Base. 
 
Aim 1: Characterize setting-specific factors associated with antiretroviral toxicity 
monitoring underserved settings 
Aim 1A: Assess healthcare provider perspectives on medication therapy management in 
underserved settings 
Medication Therapy Management (MTM) services are professional services that are provided in 
addition to medication prescription and dispensing to optimize therapeutic outcomes of patients 
by identifying and resolving drug therapy problems such as medication non-adherence and adverse 
drug reactions [20]. Unlike in resource-rich settings, little is known about the usefulness of MTM 
in underserved settings. Additional research is, therefore, needed to provide insight into short-term 
and long-term strategies for adopting MTM in underserved settings. Given that MTM is a labor- 
and time-intensive process, it is plausible that its implementation in underserved settings should 
involve motives backed by local needs, and strategies driven by the necessity to overcome setting-
specific challenges such as insufficient personnel. Accordingly, the study in Aim 1A (Chapter 3) 
explored the perspectives from health providers working in an underserved setting in western 
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Kenya regarding the provision of MTM services. This was with the overarching goal of identifying 
the motives and strategies for the implementation of MTM services in underserved settings. 
Research Question 
• What are the perspectives of healthcare providers based in an underserved setting on the 
motives and strategies for the provision of MTM services in such settings? 
o To what degree do healthcare providers perceive the task shifting of MTM responsibilities 
to lay providers as useful? 
Aim 1B: Assess ambulatory HIV care workflow patterns in underserved settings 
The detection and early intervention of antiretroviral toxicities (side effects and adverse drug 
reactions) is an important function of any HIV care workflow [2]. However, it is plausible that 
antiretroviral toxicities are not adequately documented and recognized in ambulatory HIV care 
workflows based in underserved settings. This is because care providers lack the time and 
resources required for the labor-intensive antiretroviral toxicity monitoring. Workflow analyses 
and quality improvement studies could help researchers and other stakeholders identify the key 
drivers of suboptimal point-of-care antiretroviral toxicity monitoring in underserved settings. Such 
studies would inform recommendations for change and serve as the basis for the design, 
implementation, and evaluation of informatics interventions that target ambulatory HIV care 
workflows in underserved settings [21]. Aim 1B (Chapter 4) of this dissertation examined different 
aspects of the ambulatory HIV care workflow at an underserved setting in western Kenya, with 
the overarching goal of identifying barriers to and facilitators of point-of-care antiretroviral 
toxicity monitoring in underserved settings. 
Research Questions 
• What constitutes the ambulatory HIV care workflow in an example of an underserved setting? 
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o How does information flow among actors and artifacts in the workflow? 
o What sequential steps constitute the workflow? 
o What cultural influences affect the execution of the workflow? 
o How is the workflow organized physically? 
o What artifacts are important in the workflow? 
• What are the barriers to and facilitators of point-of-care antiretroviral toxicity monitoring in 
underserved settings? 
Aim 2: Validate the structure and behavior of a knowledge base implementing clinical 
guidelines for point-of-care antiretroviral toxicity monitoring  
Based on the findings from the studies in Aim 1, a prototype knowledge-based application that 
implements clinical care guidelines and that is intended for use in point-of-care antiretroviral 
toxicity monitoring was developed. In Aim 2 (Chapter 6), the quality of this prototype’s knowledge 
base was evaluated by determining the validity of its structure and behavior. The purpose of the 
structural validation was to determine if the concept-concept relationships in the prototype’s 
knowledge base were accurate representations of domain knowledge. Structural validation was 
achieved by determining the proportion of relationships in the prototype’s knowledge base that 
were present in publicly available medication toxicity knowledge bases. The purpose of the 
behavioral validation was to determine the functional completeness and predictive accuracy of the 
prototype’s knowledge-base in order to ascertain that the prototype behaves as it supposed to. 
Behavioral validation was achieved by comparing the similarity and accuracy of the detection of 





Research Questions and Hypotheses 
• To what extent is the representation of ingredient-condition relationships in a prototype 
knowledge base implementing clinical guidelines for antiretroviral toxicity monitoring similar 
to the representation of concept-concept relationships in existing medication toxicity 
knowledge bases? 
o What proportion of paired ingredient-condition relationships in the knowledge base exists 
in domain knowledge evidence sources? 
H1: At least 80% of the ingredient-condition relationships in the prototype knowledge base 
are equivalent to ingredient-condition relationships present in domain knowledge evidence 
sources. 
• To what extent are the antiretroviral toxicity reports generated by a prototype knowledge base 
implementing clinical guidelines for antiretroviral toxicity monitoring comparable to the 
antiretroviral toxicity reports generated by human experts for a random sample of test cases? 
o How similar are antiretroviral toxicity reports generated by the prototype and reports 
generated by human experts based on the Jaccard distance? 
 H1: The mean Jaccard distance between the prototype knowledge base and human experts 
is different from the mean Jaccard distances among human experts. 
o What is the difference in the mean proportion of correct responses per case between reports 
generated by the prototype and reports generated by human experts? 
 H1: There is a difference in the mean correctness of responses per case between reports 
generated by the prototype compared to reports generated by human experts. 
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Aim 3: Assess the Usability by Peer Health Workers of Computer-Generated Checklists for 
Point-of-Care Antiretroviral Toxicity Symptom Documentation 
Standard care guidelines recommend a symptom-directed approach to monitoring antiretroviral 
toxicity at the point-of-care [2]. In this approach, clinicians use their knowledge, skills, and 
experience to clinically assess signs and symptoms reported by patients and draw conclusions 
about real and potential antiretroviral toxicities [2, 22]. The symptom-directed approach is, 
however, time- and task-intensive and may not be successfully adopted in ambulatory HIV care 
workflows in underserved settings which experience health workforce challenges. At the same 
time, opportunities exist in the form of shifting of data collection tasks from clinicians to more 
readily available personnel such as lay health workers [21, 23]. Furthermore, using standardized 
tools such as checklists, profiles, and scales [24, 25] could improve the quality of data collected 
through task delegation. However, little is known about the usability of these instruments for 
collecting antiretroviral toxicity monitoring data and as perceived by lay health workers. 
Aim 3 (Chapter 7) investigated the usability of antiretroviral toxicity symptom screening checklists 
generated by the knowledge-based application prototype developed in this dissertation. The 
usability investigations assessed the levels of satisfaction and mental effort required to complete 
the checklists as perceived by lay peer health workers based in an underserved setting. The 
investigations also identified the usability problems of the checklists that needed to be addressed 
in future development iterations. 
Research Questions 
• To what extent do lay peer health workers perceive computer-generated checklists for 
screening antiretroviral toxicity symptoms as satisfactorily useful and easy to use? 
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o To what extent do peer health workers perceive the use of computer-generated checklists 
to document antiretroviral toxicity symptoms as satisfactory? 
H1: The level of peer health worker satisfaction with the use of computer-generated 
checklists for documenting antiretroviral toxicity symptoms is >68 on the System Usability 
Scale (SUS), corresponding to above average usability. 
o To what extent do lay peer health workers perceive the use of computer-generated 
checklists to document antiretroviral toxicity symptoms as difficult (cognitively 
challenging)?  
H1: The median level of mental effort required by lay peer health workers to document 
antiretroviral toxicity symptoms on computer-generated checklists is <20 on the Subjective 
Mental Effort Question (SMEQ) scale, implying the task is not very hard to do. 
1.4. Significance 
Although the clinical significance of antiretroviral toxicities has been well-studied, there is a dearth 
of literature on strategies for increasing the efficacy and efficiency of antiretroviral toxicity 
monitoring in underserved settings. Although researchers acknowledge the fact that HIV care 
programs based in underserved settings have limited capacity to monitor antiretroviral toxicities 
adequately, little is known about how toxicity monitoring is currently conducted and how these 
processes could be improved within the constraints of available resources. Furthermore, although 
standard care guidelines could be useful for enhancing antiretroviral toxicity monitoring in 
underserved settings, research on automated methods for increasing access to guideline 
recommendations at the point-of-care in underserved settings remains scarce. Finally, studies on 
enhancing care guideline adherence through the use of technologies such as mobile health 
(mHealth) applications have primarily focused on evaluating the impact of the interventions on 
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clinical outcomes and studies are therefore needed to demonstrate how the usability, feasibility, 
and workflow integration of such tools can be rigorously evaluated. 
The significance of this dissertation research is that it synthesizes the perspectives from healthcare 
stakeholders based in an underserved setting on the motives and strategies for promoting 
medication safety and effectiveness in such settings. In so doing, this dissertation research 
identifies disease focus areas and service provision approaches that could be prioritized in 
underserved settings. Additionally, this dissertation examines an example of an ambulatory HIV 
care workflow to identify the key drivers of suboptimal antiretroviral toxicity monitoring in 
underserved settings. It subsequently provides informatics-based process redesign 
recommendations that could be adopted to improve the quality of the point-of-care antiretroviral 
toxicity monitoring in such settings. This dissertation research also examines the extent to which 
antiretroviral toxicity information available as textual narratives in standard care guidelines and 
approved drug labels could be coded in a knowledge-based software application using existing 
medical terminology resources. It also reports the challenges involved in translating textual domain 
knowledge into a functional knowledge-based application. Lastly, it provides an understanding of 
the extent to which lay peer health workers based in an underserved setting perceive the use of 
computer-generated checklists for documenting antiretroviral toxicity symptoms as useful and 
easy to use. The findings of the studies conducted in this program of research improve the 
contextual understanding of setting-specific factors associated with the point-of-care monitoring 
of antiretroviral toxicities in underserved settings. This dissertation research also delineates how 
the concerted use of informatics innovations, clinical guidelines, and task redistribution could be 
applied to overcome some of the key barriers associated with monitoring antiretroviral toxicities 
in underserved settings. The resources developed as part of this dissertation research could prove 
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useful in improving the antiretroviral toxicity documentation and decision-making in ambulatory 
HIV care workflows in underserved settings. 
1.5. Outline of the Dissertation 
This dissertation is comprised of 8 chapters. Chapter 1 introduces the research problem and 
purpose of the dissertation, outlines its specific aims, research questions, and hypotheses, and 
highlights its relevance to biomedicine. Chapter 2 presents a review of previously published 
research that is relevant to the dissertation, assesses knowledge gaps in prior work, and delineates 
the contributions of the dissertation with respect to the identified knowledge gaps. Chapters 3 and 
4 report findings on the exploration of healthcare provider perspectives on MTM (Aim 1A) and 
the analysis of ambulatory HIV care workflow patterns in an example of an underserved setting 
(Aim 1B). Chapter 5 describes the objectives and the process of construction of a knowledge-based 
application prototype that addresses the point-of-care antiretroviral toxicity monitoring barriers 
identified by the studies conducted under Aim 1. Chapter 6 reports findings from the evaluation 
of the structure and behavior of the prototype (Aim 2) while Chapter 7 reports findings on the 
usability of antiretroviral toxicity symptom screening checklists generated by the prototype as 
perceived by peer health workers based in an underserved setting (Aim 3). Lastly, Chapter 8 




Chapter 2. Literature Review 
2.1. Introduction 
This chapter presents a synthesis of the current biomedical literature on antiretroviral toxicity 
monitoring. It summarizes the clinical significance of antiretroviral toxicity in the context of other 
drug therapy problems. It describes the current state of knowledge about approaches for 
identifying, documenting, and reporting antiretroviral toxicities, and highlights the challenges 
associated with antiretroviral toxicity monitoring in underserved settings. The chapter concludes 
with a description of the existing knowledge gaps and delineates the contribution of the dissertation 
in light of the identified gaps. 
2.2. The burden of HIV/AIDS 
HIV/AIDS remains one of most significant global public health challenge. The Joint United 
Nations Program on HIV/AIDS (UNAIDS) estimates that in the year 2015, there were 36.7 million 
people living with HIV, 2.1 million new HIV infections, and 1.1 million deaths from HIV-related 
illnesses [1]. Approximately 78 million people have been infected with HIV, and 35 million have 
succumbed to the disease since the start of the epidemic. With an estimated 25.6 million (~70%) 
of all the people living with HIV and accounting for two-thirds of all new HIV infections, sub-
Saharan Africa bears most of the clinical burden of HIV disease [1, 26, 27]. 
The global efforts to scale up access to antiretroviral therapy, especially in low- and middle-income 
countries, has been hailed as one of the most significant public health intervention in the history 
of mankind [3]. In the early 2000s, less than 5% of people living with HIV had access to treatment. 
By 2016, an estimated 18.2 million people, 80% of whom reside in low and middle-income 
countries, had access to antiretroviral therapy [1]. As a result of the increased access to 
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antiretroviral therapy, the morbidities and mortalities associated with the HIV infection have been 
dramatically reduced, and the longevity and quality of life of people living with HIV have been 
improved [26, 27]. This is exemplified by the fact that between 2000 and 2015, HIV-related 
mortality rates fell by 28% and new infection rates fell by 35%. The World Health Organization 
(WHO) also projects that the expansion of antiretroviral therapy to all people living with HIV 
would avert 21 million HIV-related deaths and 28 million new infections by 2030 [27]. 
For a long time, the initiation of antiretroviral therapy was based on the World Health Organization 
(WHO) clinical staging of HIV/AIDS or the CD4 cell count of the patient. It has since been 
established through clinical trials research that early initiation of antiretroviral therapy not only 
makes people living with HIV live longer and healthier but also reduces the risk of transmission 
of HIV [2]. Consequently, clinical practice guidelines for the treatment of HIV infection have been 
revised to reflect that antiretroviral therapy should be initiated regardless of the clinical stage and 
at any CD4 cell count for all age groups [2]. The newfound evidence has also led the UNAIDS to 
set the ambitious 90-90-90 target that requires United Nations member countries to scale up HIV 
testing and treatment such that by the year 2020, 90% of people living with HIV will know their 
HIV status, 90% of people diagnosed with HIV infections will receive antiretroviral therapy, and 
90% of all people receiving antiretroviral therapy will have viral suppression [28]. 
2.3. The burden of antiretroviral toxicities 
Advancement in antiretroviral therapy has been characterized by the development of more potent 
and safer antiretroviral drugs and drug classes [6]. For example, less-safe antiretroviral drugs such 
as didanosine and stavudine have been discontinued from the market, while safer options such as 
tenofovir, etravirine, and dolutegravir are increasingly being used. Additionally, adherence to HIV 
treatment has been enhanced by the availability of antiretroviral therapy as fixed-dose combination 
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products that reduce pill burden and dosing frequency [2, 6]. Also, HIV treatment guidelines are 
continually revised using evidence from research and observational health data to maximize 
efficacy, long-term tolerability, and safety of antiretroviral therapy. 
Despite the concerted efforts to improve the efficacy and safety of antiretroviral therapy, and 
although the benefits of viral suppression and immune function improvement outweigh the risks 
of using antiretroviral therapy, significant challenges associated with the burden of antiretroviral 
treatment drug therapy problems (DTPs) remain [2, 10]. DTPs are undesirable events or risks 
involving the use of medications that interfere with the achievement of desired goals of medical 
care [29]. DTPs have also been described as the actual or potential adverse outcomes resulting 
from the way in which drugs are used [30]. Some of the most important DTPs associated with 
antiretroviral therapy include antiretroviral therapy nonadherence, toxicities, and drug resistance 
[2]. Antiretroviral toxicities are particularly impactful DTPs that have been responsible for a 
variety of challenges including medication nonadherence, treatment substitution, premature 
treatment discontinuation, and loss to follow-up among users of antiretroviral therapy [2, 9]. These 
toxicities may range from mild side-effects to life-threatening adverse drug reactions and have 
been reported with the use of all antiretroviral drugs. Examples of major types of antiretroviral 
toxicities include hypersensitivity reactions, hepatotoxicity, pancreatitis, dyslipidemia, 
rhabdomyolysis and acute kidney injury. 
It is fundamental that care providers anticipate and address the threats posed by real and potential 
antiretroviral toxicities to maximize the benefits of antiretroviral therapy in individual patients. 
When initiating antiretroviral therapy and monitoring treatment progress, care providers should 
consider the risk factors of antiretroviral toxicities which may include the individual patient’s age, 
gender, weight, genetics, comorbidities, concomitant medications, and prior medication 
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intolerance history [6]. They should use the resources at their disposal to enable detection and early 
intervention of antiretroviral toxicities experienced by individual patients [6]. Such active 
monitoring of antiretroviral toxicity would improve individual patient’s medication experience and 
quality of life, reduce chances of medication-related morbidities and mortality, and reduce out-of-
pocket costs for the patient [20, 29]. 
At the population level, as HIV treatment policies continue to evolve, not only is the number of 
people using antiretroviral therapy expected to increase exponentially but also more people are 
starting antiretroviral therapy earlier and using them for much longer than ever before [1, 2, 28]. 
It is, therefore, reasonable to expect that as access and use of antiretroviral drugs for the treatment 
and prevention of HIV increases, problems due antiretroviral toxicity will also increase [31]. This 
new challenge is particularly important for underserved settings which bear most of the world’s 
HIV/AIDS burden [31], yet exhibit variations in host genetics, environment, behavior, and disease 
burdens that could influence the range and patterns of antiretroviral toxicities experienced by 
patients [10, 32]. 
2.4. Challenges of antiretroviral toxicity monitoring in underserved settings 
WHO recommends that as the access to and use of antiretroviral therapy continue to increase, 
toxicity monitoring becomes an integral component of the HIV clinical care process [2]. Based on 
evidence from empirical research, the WHO states that routine toxicity monitoring is crucial for 
providing data on the incidence and clinical significance of major antiretroviral toxicities and their 
impact on medication adherence, patient outcomes, and retention in care [2, 10]. The WHO further 
recommends that countries should use standardized approaches to integrating toxicity monitoring 
into national monitoring and evaluation systems [2]. Additionally, the WHO recommends that 
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when data is needed to inform policy and improve HIV clinical outcomes, routine monitoring 
should be complemented by conducting active surveillance studies of toxicity at sentinel sites [2]. 
According to current WHO guidelines, routine antiretroviral toxicity monitoring should be 
conducted primarily using a symptom-directed approach where clinicians assess and analyze the 
clinical signs and symptoms experienced by patients [2, 22]. Laboratory testing is advised but not 
required for high-risk people using certain drugs [2]. For example, guidelines recommend that 
abacavir should not be used in the presence of the HLA-B*5701 allele that is associated with 
abacavir hypersensitivity reaction. However, the absence of HLA-B*5701 testing does not 
preclude the use of abacavir. The symptom-directed approach to antiretroviral toxicity monitoring 
is particularly useful in underserved settings which often lack the capacity to perform routine 
laboratory monitoring [2]. The key antiretroviral toxicity monitoring indicator is the proportion of 
patients with treatment-limiting antiretroviral toxicities. These are defined as antiretroviral 
toxicities that cause life-threatening illness, death, hospitalization, disability or result in treatment 
discontinuation or substitution [2]. 
Unfortunately, due to a variety of reasons such as poor healthcare infrastructure and competition 
for scarce human and financial resources, many HIV care programs in underserved settings do not 
adequately monitor antiretroviral toxicity [5, 11, 12, 16, 33]. The single most important of these 
challenges is the lack of human resource capacity required to provide such services [11, 12, 16]. 
Of particular concern is the perennial shortage of skilled health workers in underserved settings. 
For example, whereas the World Health Organization recommends a ratio of 2300 persons to 1 
pharmacist, sub-Saharan countries have as few as 1 pharmacist for 100,000 individuals [11]. This 
shortage is compounded by high infectious disease burdens, uneven distribution of pharmacists by 
location (rural vs. urban, high-income vs. low-income countries) and employment areas (private 
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vs. public), and challenging working conditions [11, 12, 16]. Other cited human resource capacity 
challenges include the lack of the professional skills, knowledge, and attitudes needed for 
antiretroviral toxicity monitoring, inadequate regulation, and oversight, and the lack of 
interdisciplinary collaboration among different healthcare cadres [11, 34]. 
Among HIV care programs that monitor antiretroviral toxicities, it is plausible that there are 
variations in the types, methods, and frequency of data collection due to the inadequate adoption 
of standard data definitions, formatting and reporting [35]. Furthermore, due to time and resource 
constraints, toxicity data is documented for selected treatment-limiting antiretroviral toxicities and 
recorded for selected reasons such as switching or discontinuing antiretroviral regimens [2]. These 
challenges possibly result in antiretroviral toxicity data sparseness as well as aggregation and 
analysis difficulties. They extend to medication use in other domains and are exemplified by the 
dearth of biomedical literature on the incidence, prevalence, and clinical significance of 
medication toxicities in underserved settings. 
2.5. Role of task shifting in antiretroviral toxicity monitoring in underserved settings 
Solutions proposed to address challenges in the routine monitoring of antiretroviral toxicities in 
underserved care settings are primarily focused on tackling the healthcare workforce capacity 
problem. The most commonly reported approach for achieving this goal is task shifting [11, 16, 
17]. Task shifting is the rational redistribution of health service responsibilities among health 
workforce cadres. It often involves the moving of tasks from highly qualified health workers to 
health workers with shorter training and fewer qualifications, but who are more readily available 
[11, 16, 17, 36]. 
An increasingly popular task shifting approach involves redistributing tasks to peer health workers. 
A peer is a person who has a shared living experience as another person [23]. Consequently, peer 
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health workers are lay health workers who have similar disease profiles as the persons they care 
for [37]. In HIV care, peer health workers would be HIV-positive persons who have demonstrated 
excellence in self-management and medication adherence [38], and who are trained and 
remunerated by HIV programs to take up HIV care responsibilities such as counseling, educating, 
and collecting data from other HIV patients [23]. Empirical research evidence from different 
domains including diabetes and hypertension suggests that task shifting to peer health workers 
improves clinical data collection, and enhances patient self-management through education and 
psychosocial support [37, 39, 40]. It is, therefore, plausible that peer health workers who have had 
adequate antiretroviral therapy training and experience could safely take up data collection 
responsibilities associated with the routine monitoring of antiretroviral toxicities in underserved 
settings. However, the documentation and recognition of medication toxicities is a labor- and time-
intensive process that requires trained care providers to use their knowledge and skills implicitly 
in synthesizing information from patient-specific demographic, clinical, laboratory and medication 
data [29]. Consequently, to meaningfully delegate antiretroviral toxicity monitoring 
documentation tasks to peer health workers, such task shifting should be complemented with 
adequate decision-making aids that reduce the cognitive burden associated with this activity. 
It is worth noting that task shifting approaches are not intended to replace standard clinical care 
delivery. In fact, guidelines and recommendations on task shifting stress that such strategies should 
be implemented alongside long-term strategies that aim at increasing the total number of qualified 
health workers in all cadres [17]. Researchers have suggested that long-term strategies for 
mitigating health workforce challenges should include training of more pharmacists and the 
extension of pharmacy training curricula to other healthcare cadres [11, 41]. However, the 
outcomes of these proposals remain unknown. For example, many low- and middle-income 
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countries continue to face shortages of qualified health workers and rural-urban distribution 
imbalances despite overall increases in the health workforce. Additionally, many low- and middle-
income countries still lack the capabilities, infrastructure, and political will to train health workers 
in sufficient numbers required to serve their populations adequately [42]. 
2.6. Role of Informatics in antiretroviral toxicity monitoring in underserved settings 
Integrated access to clinical data, information, and knowledge is critical for problem-solving and 
decision-making during healthcare delivery. The implementation of health informatics and health 
information system interventions in underserved settings such as those in sub-Saharan Africa has 
the promise of not only enhancing the quality and efficiency of healthcare delivery but also 
improving intermediate and clinical outcomes in different disease domains [43]. Due to the 
ubiquity of mobile phones, a majority of health informatics interventions in underserved settings 
are mobile Health (mHealth) implementations that leverage the use of mobile phones by patients 
and care providers [44-46]. A majority of mHealth interventions in underserved settings primarily 
aim at improving patient medication adherence through the use of patient reminders [47-51], 
patient education [47, 52], and psychosocial support [48]. Other interventions have aimed at 
enhancing adherence to clinical guidelines by health workers through alerts and decision aids [13, 
14, 53]. Some mHealth interventions have primarily targeted infectious disease such as HIV/AIDS 
[48, 49, 54, 55], malaria [50, 53], and tuberculosis [51], while others have targeted non-
communicable diseases such as diabetes [47, 52, 56] and hypertension [57]. MHealth services are 
delivered through a variety of media. These include short message service (SMS) where users 
communicate unilaterally or bilaterally through text messages [48-50, 54, 58], interactive voice 
response (IVR) where users interact with pre-recorded tailored messages [54, 57], smartphone 
applications that capitalize on graphics, videos and audios [52], or a combination of different 
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modalities such as SMS and IVR [55, 59]. There is no consensus on the standard delivery medium 
for use in underserved settings [48, 60], but research findings suggest that the information content 
and structure, as well as the frequency of information delivery, could affect the patient engagement 
and eventual outcomes of interventions [48]. 
The use of informatics interventions in underserved settings have been associated with improved 
process outcomes such as data quality and accuracy, health behavior and self-efficacy, and care 
provider adherence to guidelines [15, 46]. For example, Were et al. showed that the use of paper 
clinical summaries generated from patient electronic health records improved the quality of care 
by allowing providers to spend more time in the direct care of patients and by reducing the length 
of patient visits [61]. Both Amoroso et al.[62] and Allen et al.[63] report reductions in data errors 
associated with the use of OpenMRS, an open-source medical record system widely used in 
underserved settings [64]. With respect to improved health behavior, a randomized control trial by 
Pop-Eleches et al., 53% of patients in receiving weekly SMS reminders were adherent to their 
medications compared to 40% in the control group [48]. Similarly, in a randomized control study 
by Lester et al., the relative risk of medication non-adherence was lower among participants 
receiving weekly SMS interventions compared to standard care [49]. In a randomized control trial 
comparing patient education via a tablet (iPad) application to printed educational material, Heisler 
et al. found an improvement in knowledge about diabetes albeit with no discernible differences 
between the comparison groups [52]. With respect to guideline adherence, Were et al. 
demonstrated a fourfold increase (85% intervention versus 18% control) in the completion of 
overdue tasks such as ordering CD4 tests when clinicians use computer-generated reminders in 
pediatric HIV care [14]. Similarly, a cluster randomized control trial of 2269 children with malaria 
by Zurovac et al. found that guideline-based case management improved by 24% among 
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community health workers using SMS reminders compared to the control group. Findings from 
clinical trials show that mHealth and other informatics interventions improve clinical outcomes in 
underserved settings, although additional evidence is desired. For example, the randomized control 
trial by Lester et al. also showed that weekly SMS intervention reduced the relative risk of 
virologic failure [49]. 
Unfortunately, there is limited empirical evidence on use and impact of mHealth and other 
informatics interventions for supporting antiretroviral toxicity monitoring in underserved settings. 
However, most of the knowledge gained from the studies highlighted above can be extrapolated 
to the antiretroviral toxicity domain. For example, the use of mHealth is an attractive approach for 
the off-site communication with patients in underserved settings. Interventions could, therefore, 
be developed to enhance the remote collection of antiretroviral toxicity data from patients, and 
communication of standard care recommendations to patients as well as care providers. 
The broader challenges associated with the use of informatics interventions for supporting 
antiretroviral toxicity monitoring would be similar to previously reported challenges. Deployment 
would be hindered by barriers such as lack of stable electricity, lack of stable internet connection, 
and lack of a workforce that can support the technologies [43]. Also, data collection and 
information presentation would be limited by the available technology [46, 57]. For example, IVR 
technology only allows interaction via coded voice messages and dialed responses, while SMS 
technology only allows communications through text and simple multimedia messages. 
Additionally, if mobile phones are used to for patient-centered interventions, then privacy and 
confidentiality concerns must be taken into consideration as shared ownership of mobile phones 
are common in many households in underserved care settings [60, 65]. Lastly, the trade-offs 
between the use of electronic data capture devices at the point-of-care versus the use of paper data 
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collection forms with retrospective data entry should be considered [43]. For example, compared 
to the use of paper forms, the use of electronic data collection systems at the point-of-care could 
result in faster, cheaper, and more accurate data entry [66]. On the other hand, users of electronic 
data entry devices could perceive them as disruptive and unreliable at the point of care [67, 68]. 
2.7. Knowledge Gaps 
Enhancing the symptom-directed approach for monitoring antiretroviral toxicities in underserved 
settings would require the concerted use of task shifting and integration of record-keeping and 
decision-making aids. However, given that this is a relatively new paradigm, several knowledge 
gaps exist in this domain. For example, little is known about how the guideline-recommended 
symptom-directed approach for antiretroviral toxicity monitoring would be implemented in 
underserved settings to optimize treatment outcomes. The key relationships among the structures, 
processes, and outcomes of the symptom-directed approach are not well understood. It is not 
obvious how setting-specific factors such as practice paradigms, users, clinical workflows, and 
facility characteristics would influence the quality of symptom-directed antiretroviral toxicity 
monitoring, as well as the design, implementation, and evaluation of technologies that support this 
approach. 
Furthermore, to standardize documentation, analysis, and reporting of antiretroviral toxicities, it is 
important that record-keeping and decision-making aids for antiretroviral toxicity monitoring in 
underserved settings rely on standardized medical vocabulary. However, little is known about how 
unstructured domain knowledge could be characterized and organized to facilitate automated 
reasoning about antiretroviral toxicity. 
Another important consideration is the fact that software applications developed to support 
antiretroviral toxicity monitoring in underserved settings are likely to be used by multiple users 
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including professional and lay health workers. As such, it important to determine the usability and 
feasibility of the use of such tools across different cadres of care providers. In particular, there is 
a need to ascertain that antiretroviral toxicity monitoring tasks can be effectively redistributed to 
lay health workers. The extent to which this cadre comprehends medical terminology used within 
the antiretroviral toxicity domain should be determined. 
2.8. Contributions of the Dissertation Research  
In light of the knowledge gaps described in the previous section (2.7), this dissertation research 
has several contributions. First, a qualitative descriptive study was used to explore the perspectives 
of healthcare providers on the provision of MTM services in underserved settings (Chapter 3). 
This contributes to the broad understanding of the motives and strategies for promoting medication 
adherence, safety, and effectiveness in underserved settings. Second, a workflow analysis and 
quality improvement case study was conducted to investigate ambulatory HIV care workflow 
patterns in an example of an underserved setting (Chapter 4). In so doing, the dissertation 
contributes to the contextual knowledge of barriers and facilitators of point-of-care antiretroviral 
toxicity monitoring in underserved settings through the concerted use of guideline-based decision 
support and task redistribution. It also demonstrates how graph models and business process model 
notations can be used to model and visualize different aspects of workflows in underserved 
settings. 
At the core of this dissertation research was the development and evaluation of a knowledge-based 
application implementing guidelines for antiretroviral toxicity monitoring. In conducting this 
work, the dissertation demonstrates how concepts and relationships within the antiretroviral 
toxicity domain can be characterized using currently existing biomedical terminology resources 
and implemented in a knowledge-based software application (Chapter 5). It also demonstrates how 
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informatics approaches could be used to validate the structure and behavior of such knowledge-
based applications (Chapter 6). 
Finally, the dissertation investigated the usability of computer-generated checklists for 
documenting antiretroviral toxicity symptoms as perceived by peer health workers (Chapter 7). 
These investigations contribute to knowledge on specific challenges associated with redistributing 
data collection tasks to peer health workers. The investigations also contribute to a better 
understanding of the desired content and functionalities of checklists for monitoring antiretroviral 
toxicities as perceived by lay health workers.   
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Chapter 3. Assessing healthcare provider perspectives on medication therapy management 
in underserved settings  
3.1. Introduction 
Medication Therapy Management (MTM) services are non-dispensing services that optimize 
therapeutic outcomes for patients by identifying and resolving drug therapy problems such as 
nonadherence, adverse drug reactions, and subtherapeutic dosing [20]. MTM services are distinct 
from but complementary to routine medication prescribing and dispensing activities. MTM 
services are the embodiment of the philosophy of pharmaceutical care [69, 70]. This philosophy 
asserts that it is the responsibility of the pharmacist to meet all drug-related needs of the patient, 
to be held accountable for those needs and to assist the patient in achieving his or her therapeutic 
goals through collaboration with other health professionals [29]. 
A commonly used framework for the provision of MTM services is the MTM Service Model in 
pharmacy practice [69]. The model describes five core elements necessary for MTM service 
provision. These are described as follows. Medication therapy review refers to the systematic 
process of collecting patient-specific information, assessing treatments to identify medication-
related problems, developing a prioritized list of the problems, and creating a plan to resolve them. 
The personal medication record is a comprehensive list of the patient’s medications including 
prescription, non-prescription, herbal products and dietary supplements with instructions specified 
for each drug. This record also contains the patient’s demographic data, allergies, and emergency 
contact information. It is provided to the patient as a guide for medication self-management. The 
medication-related action plan is an individualized list of actions used by the patient to track self-
management progress. Interventions and referrals are actions taken by an MTM service providers 
to solve a patient’s problem directly or through consultation with other care providers. Lastly, 
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documentation and follow-up refer to the record-keeping and monitoring activities of MTM 
service provision necessary for facilitating communication among care providers, billing 
justification, and in evaluating care progress and outcomes. 
Possibly because the provision of MTM services is a relatively new paradigm of pharmacy 
practice, its implementation in underserved settings is not sufficiently described in the biomedical 
literature. Nonetheless, it is reasonable to expect that the shortage of healthcare workers, high 
disease burdens, and limited financial resources could be important barriers to the adoption and 
scale-up of MTM services in such settings [11, 12]. Concurrently, the acceptance of task shifting 
as a solution to health workforce challenges [11, 16, 17, 36], and the increased penetration of 
electronic health records and clinical decision support [15, 46] present valuable opportunities for 
alleviating barriers to the adoption of MTM services. However, more studies are required to fill in 
knowledge gaps about the motives, strategies, and constraints associated with the provision of 
MTM services in underserved settings. 
It is plausible that the provision of MTM services in underserved settings would involve motives 
backed by local needs, and strategies driven by the necessity to overcome setting-specific 
challenges. Accordingly, the purpose of the study described in this chapter was to explore the 
perspectives from health providers working in an example of an underserved setting regarding the 
provision of MTM services. This was with the overarching goal of identifying the motives and 
strategies for implementing MTM services in similar underserved settings, and determining the 
degree to which healthcare providers perceive the task shifting of MTM responsibilities to lay 
health workers as useful. The study involved the use of focus group discussions and individual 




3.2.1. Study Design 
A qualitative descriptive study combining the focus group interview and the online survey designs 
was applied to address the research questions in this study. Social network analysis was used to 
identify potential participants of the subsequent focus group discussion and online survey. A social 
network is a group of collaborating or competing entities that are related to each other in a common 
environment [71]. Social network analysis is the quantitative characterization of the interaction 
patterns between the entities in a social network [72]. This technique was used in this study because 
it is thought to be superior to the traditional methods of identifying stakeholders through 
organizational charts as it captures more complex interactions among people as they conduct their 
work [73, 74]. The focus group interview was used to gather care provider views on the broad 
motives and strategies of MTM service provision in underserved settings. The focus group design 
was chosen because it allows participants to stimulate the thoughts and build upon the 
contributions of each other, thereby increasing breadth and depth of the discussion [75]. The online 
survey was used to ascertain the consistency of findings generated by the focus group interview 
and to identify key stakeholder perspectives on the goals and priorities of implementing MTM in 
underserved settings. The method was chosen because it enables faster and easier collection of a 
wider range of potential responses that may not be obtained through consensus-based approaches 
such as focus group discussions [76]. 
3.2.2. Setting 
This study was conducted at the Academic Model Providing Access to Healthcare (AMPATH) in 
Eldoret, Kenya. AMPATH is an umbrella healthcare organization formed as a result of the 
collaboration between Moi University College of Health Sciences, Moi Teaching and Referral 
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Hospital and a consortium of North American Academic Medical Centers led by Indiana 
University School of Medicine [77]. AMPATH provides care to both urban and rural patients at 
its primary site in Eldoret, Kenya and via satellite clinics scattered around western Kenya. Since 
its inception in the year 2001, and by the year 2016, AMPATH had provided care to about 180,000 
HIV/AIDS patients, with almost 2,000 new HIV patients being enrolled each month [78]. The 
organization expanded its initial clinical focus beyond HIV/AIDS care to encompass chronic 
disease management, primary healthcare, and specialty healthcare. To address the healthcare 
workforce challenge brought about by this scale up, AMPATH is actively researching and 
implementing task redistribution to other health professionals, lay or community health workers 
and patient peers [79-81]. To complement these strategies, AMPATH develops documentation and 
decision support tools to aid care providers with record-keeping and decision-making [82, 83]. 
3.2.3. Subject Selection 
This study targeted medical doctors, clinical officers, nurses, pharmacists and pharmacy 
technicians who routinely provide a variety of specialized services including clinical assessment, 
prescribing, dispensing and patient monitoring in the study setting. Social network analysis [72, 
73, 84] was used to identify the subjects who most commonly addressed the medication-related 
needs of patients at the study setting. A self-report survey was administered to a purposive sample 
of 45 care providers working in the study setting to collect data for social network analysis. In the 
survey, each respondent indicated interactions with his/her colleagues by answering 3 main 
questions: 1) Please name up to 5 colleagues you consult whenever you have questions about a 
patient’s medication-related problems. 2) How often do you contact each person? 3) How would 
you rank the value of the advice you receive from each person? Thirty-seven care providers 
completed the survey, giving a response rate of 82%. The survey responses were used to create a 
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social network graph which consisted of 70 nodes (stakeholders) and 181 edges (relationships 
based on consultations about medication-related problems). This graph was subsequently analyzed 
to identify potential participants of the focus group discussion and the online survey. The 
procedure, analysis, and findings of this subject selection process are provided in Appendix 3.1. 
3.2.4. Data Collection 
A focus group discussion involving 7 stakeholders identified from the social network analysis 
subject selection process was conducted. Participants of the discussion included 2 pharmacists, 3 
pharmacy residents, and 3 pharmacy technicians. The discussion was guided using pre-specified 
questions that targeted several aspects of the provision of MTM-related services at the study setting 
(Appendix 3.2). In brief, the questions pertained to identifying healthcare provider perceptions of 
the achievements, barriers, and challenges of the MTM-related processes in the study setting, and 
the approaches that could be used to enhance the provision of MTM services in the setting. 
Examples of key focus group questions include: 1) What are some of the barriers and challenges 
of the medication use process at AMPATH? 2) What are some of the approaches through which 
Medication Therapy Management Services can be offered at AMPATH? 3) Please envision the 
use of an information system that supports the provision of medication therapy management 
services. What functionalities would you desire in such a system? The discussion was audio-
recorded and transcribed. 
Eight key stakeholders selected via social network analysis but who had not participated in the 
focus group discussion responded to an online survey administered via Google Forms. The 
respondents included 3 pharmacists, 1 pharmacy resident, 1 clinical officer (same as a physician 
assistant in the United States), and 3 pharmacy technicians. The survey questions and response 
options were based on the key findings generated from the focus group discussion. The survey 
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required participants to respond to 5-point Likert items, multiple-answer questions, multiple choice 
questions, and free text answer questions (Appendix 3.3). Examples of questions in the survey 
include: 1) Please indicate your level of agreement with respect to whether the following patient 
groups need more rigorous medication therapy management services; 2) Please select the top 
THREE patient groups that you think need more rigorous medication therapy management 
services; 3) What is the single-most-useful approach for providing medication therapy 
management services in a resource-constrained setting? (Please choose one); 4) Please provide any 
comments about the role of health information technology on the provision of medication therapy 
management services in a resource-limited setting. 
3.2.5. Data Analysis 
Transcripts from the focus group discussion and free text responses from the online surveys were 
uploaded to Qualitative Analysis Minier Lite, a free qualitative analysis software by Provalis 
Research [85]. The transcripts were analyzed thematically using the guide proposed by Braun and 
Clarke [86]. The goal of the analysis was to discover semantic themes within the data that describe 
an accurate account of the “who, what, why and how” [87] of MTM service delivery in a resource-
limited setting. Specifically, the analysis aimed at exploring the participant perspectives on why 
MTM was necessary, who needed the services, what components were required to deliver the 
service, and how the services would be delivered. Procedurally, the transcript data were coded to 
identify important semantic features of the data. The codes were collated into potential themes. 
These themes were then reviewed against the coded extracts as well as the entire dataset. Each 
theme was defined and refined, and a report of the findings produced. 
Categorical responses from the online surveys were analyzed quantitatively. Likert items were 
analyzed by determining the most frequent responses option (among Strongly Disagree, Disagree, 
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Neutral, Agree, and Strongly Agree). The Krippendorff's alpha [88] and the intra-class correlation 
coefficient type ICC(2,k) [89] were computed to assess the consistency of agreement among 
survey respondents. Multiple-answer and multiple-choice questions were analyzed by determining 
the frequencies of selected response options. 
3.3. Results 
3.3.1. Qualitative Analysis 
Thematic analysis of the focus group discussion transcripts and online survey text responses 
revealed 7 themes under 4 analytic question topics. These themes, along with the example support 
statements are described in Table 3.1. There were no significant differences of opinion across the 
different work roles of the respondents. 
Why are MTM services needed? 
The respondents opined that MTM services should be provided to evaluate and document 
medication adherence, safety, and effectiveness (Theme 1). This theme falls under a broader theme 
of the need to promote positive patient outcomes. For example, one participant noted that more 
rigorous MTM services would have helped avert the side effects and adverse drug reactions that 
had been previously witnessed in patients receiving care at the setting. Additionally, the 
participants also reported that MTM services would particularly be significant in countering the 
increase in the likelihood of the occurrence of medication-related problems as their organization 
continues to expanded its clinical scope of work and care for more patients. Accordingly, the 






Table 3.1: Key themes and example support statements about Medication Therapy Management (MTM) identified from study transcripts 
Topic Theme Example Support Statement 
Why is MTM 
necessary? 
 
1. MTM is provided to improve 
patient outcomes by ensuring 
medication adherence, safety, 
and effectiveness 
• “…MTM would ensure that patients stick to set goals and would also provide an effective way 
of assessing patient outcomes…” [Focus group participant 3, pharmacy resident] 
• “…some patients endure extended periods of side effects and adverse drug reactions that 




2. Eligibility is influenced by 
risks posed by inadequately 
treated infectious disease 
• “Newly initiated ART patients will benefit the entire population the most if they are adherent 
to their medications. This is because if these patients can maintain a low viral load, they have 
a very low chance of transmitting the virus….” [Survey respondent 3, pharmacist] 
3. Eligibility is influenced by 
the complexity of treatment, 
the risk of non-adherence, 
and the potential for adverse 
drug reactions 
• “I think we have a large number of old patients who are on so many drugs. For example, 
they could be on drugs for their cardiac issues, and they also take drugs for hypertension, 
arthritis, Alzheimer’s disease, etc.” [Respondent 1, pharmacy resident] 
• “Newly-initiated patients are most likely going to get lost to follow-up as it takes a while for 
patients to accept their status. They are also the ones who we need to watch out for adverse 





4. MTM delivery is influenced 
by the provider’s perceptions 
of having the knowledge, 
skills, and time to provide the 
services adequately 
• “The services would require a lot of skilled and educated labor too.” [Focus group participant 
4, pharmacy technician] 
• “High patient volume and low staffing easily tire service providers leading to poor service 
delivery.” [Survey respondent 6, clinical officer] 
5. MTM delivery is influenced 
by the patient’s ability and 
willingness to self-manage 
and engage in the process 
• “I think the patient's willingness to be able to listen to advice is a concern. Some patients just 
perennially in a hurry. Some of them still try to protect their identities, while some remain 
stigmatized throughout their care. Such patients often than not just demand their drugs and go 
without counseling.” [Focus group participant 3, pharmacy resident] 
6. MTM activities should be 
supported by documentation 
and decision-making aids 
• “…I think technology can be used to implement protocols effectively and provide 
accountability.” Focus group participant 7, pharmacy technician 
• “…information technology is important in helping generate and disseminate information 




7. MTM approaches should 
consider human resource 
challenges and incorporate 
social capital 
• “Peers are very efficient at trying to get the truth out of the patients because of the level of 
trust and the nature of their relationship with the patients” [Focus group participant 5, 
pharmacist] 
• “Peers seem to have a better understanding [of the patient] because of past experiences which 
may be similar to what the patient is having.” [Survey respondent 6, clinical officer] 
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Who needs MTM services? 
Some respondents opined that patients whose inadequately-treated infectious disease states pose a 
public health risk of disease transmission should be targeted for MTM services (Theme 2). 
Proponents of this view believed that high-risk disease cohorts included adult HIV patients who 
are sexually active and patients with tuberculosis whose adequate treatment was essential for 
infection control and prevention. Other respondents thought that patients using complex 
medication regimens would benefit the most from MTM services (Theme 3). They provided 
examples of cohorts such as multi-morbid chronic disease patients, geriatrics, pediatric patients, 
and patients on second-line, third-line or salvage HAART and argued that these groups were prone 
to medication non-adherence. Additionally, some respondents opined that patients at risk of 
adverse drug reactions would be good candidates for MTM services (Theme 3). Supporters of this 
view argued in favor of focusing MTM services to HIV patients newly initiated on antiretroviral 
therapy because this group was prone to nonadherence, was most likely to develop adverse drug 
reactions, and was likely to be overburdened by the transition to lifelong use of medications. 
What is required for MTM service delivery? 
From the participants’ responses, it emerged that the delivery of MTM service was dependent on 
three main components. First, MTM service providers needed to have the required knowledge, 
skills and time to provide MTM services adequately (Theme 4). In this regard, the respondents 
identified the lack of sufficient training and high patient-to-provider ratios as important staff-
related barriers to the provision of MTM services. Task shifting, adequate training, and continuing 




The second component necessary for the provision of MTM services identified from the 
participants’ responses was the patient’s willingness and ability to participate and actively engage 
in the process (Theme 5). The respondents thought that patient engagement was essential for MTM 
service delivery particularly because the service was patient-centric. They identified patient 
passivity and stigma, predominantly among HIV patients, as key patient-related barriers to patient 
engagement. The respondents were concerned that some patients left all care-related decision-
making to the healthcare provider. They argued that such patient passivity and disempowerment 
would inadvertently make the provision of MTM services difficult. Furthermore, the respondents 
noted that because of the fear of disclosing their status and being stigmatized, most patients kept 
their treatment information highly confidential. Consequently, MTM requirements such as the 
need for patients to keep self-management records would not be popular among patients. Patient 
counseling and education during clinic visits were perceived to be suitable approaches for 
improving patient engagement and self-efficacy. 
The respondents opined that the third key component necessary for MTM service delivery was an 
information system that supports documentation and decision-making (Theme 6). The respondents 
thought that health information technology (IT) would enable MTM service providers access and 
communicate patient information in a timely manner. They also opined that the use of decision 
support systems could enhance care provider adherence to protocols and guidelines. Some 
respondents, however, cautioned that the implementation of health IT would introduce additional 
overhead costs associated with the need to train users and maintain such systems. Additionally, 





Table 3.2: MTM service provision approaches stratified by care provision strategy and setting 
 Cadre 





























Professional Group  
Care 
 
Task-shifted Group  
Care 
Hybrid Group  
Care 
 
How should MTM services be delivered? 
Six MTM care provision approaches emerged from the qualitative analysis of respondent 
discussions on MTM strategies for underserved settings. These approaches were related to the 
cadre of the MTM service provider and the setting in which the MTM service was delivered (Table 
3.2). The six approaches were labeled professional single-patient care, task-shifted single-patient 
care, hybrid single-patient care, professional group care, task-shifted group care, and hybrid group 
care. There was no consensus on the single most useful approach for the delivery of MTM services, 
but a majority of the respondents opined that successful approaches should overcome workflow 
challenges through strategies that also explore the benefits of social capital (Theme 7). 
In the professional approaches, MTM services would be delivered by a trained and qualified 
professional as the sole care providers. Proponents of these approaches stated that adequately 
trained and skilled professionals could provide MTM services to most patients regardless of the 
patient’s disease state(s) and the complexity of their management. Opponents of the professional 
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approaches argued that although the approaches would be desirable, workforce challenges would 
limit their utility in underserved settings (Theme 4). 
In the task-shifted approaches, all responsibilities of providing MTM services would be 
redistributed from professional to more readily-available non-professional health care workers. A 
predominant view among the proponents of this approach involved the use of lay care providers 
with similar disease experiences as the patients they care for (called peer health workers) in the 
provision of MTM services. Arguments in favor of using trained peer health workers as the primary 
MTM service providers included the fact that patients would be more open to care providers who 
have had similar experiences as they have (Theme 7). This openness would be useful in combating 
passivity and stigma, particularly in HIV. Counter-arguments against task shifting MTM 
responsibilities to lay health workers included overhead costs associated with selecting and 
training the care providers, the inability of the care provider to manage complex cases, and the 
possible lack of acceptance by professionals. 
In the hybrid approaches, both professionals and non-professionals would share responsibilities in 
the provision of MTM services. Proponents of these approaches stated that they would capitalize 
on the advantages of both the professional and the task-shifted approaches. For example, lay MTM 
service providers would handle cases that were simpler but more common, freeing up time for 
professionals to handle the fewer but more complex cases. Alternatively, professionals would 
remain as the primary MTM service providers, but the lay health workers would take up some 
responsibilities that are easy but time-intensive such as data collection, patient counseling, and 
patient education. This would free up time and resources for the professionals to focus on more 
cognitively-demanding tasks such as analyzing MTM information and making care decisions. 
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With respect to the care provision setting, the proponents of group-based approaches opined that 
these approaches would be cost-effective and efficient since care is delivered to multiple persons 
at the same time. They also argued that group-based approaches would provide opportunities for 
patients to learn from and support each other. However, opponents of the group-based approaches 
cautioned that the approach might compromise patient privacy and confidentiality and argued that 
such approaches may only be suitable for non-stigmatizing chronic noncommunicable diseases 
such as diabetes and hypertension. 
3.3.2. Quantitative analysis 
All the 8 survey respondents provided responses to 31 Likert items pertaining to findings of the 
focus group discussion. A majority of the respondents agreed with most of the findings (Figure 
3.1). There was reasonable consistency amongst the agreements as was evidenced by a 
Krippendorff's alpha score 0.355 indicating fair agreement between raters, and an ICC(2,k) score 
of 0.79 (95% CI, 0.66 to 0.88, P<0.001) indicating moderate to a strong average agreement. 
One respondent disagreed, and 2 respondents remained neutral with respect to providing MTM 
services through task shifting to lay health workers. Similarly, 1 respondent disagreed, and 2 
respondents remained neutral with respect to the finding that the lack of skilled providers would 
be a barrier to MTM service provision in underserved settings. 
Interestingly, 4 of the 8 respondents disagreed with the finding that language and communication 
could be a barrier to the provision of MTM services in an underserved setting, and one respondent 
remained neutral. Also, while all participants were either neutral or in agreement with the finding 
that the use of alternative medicines by patients would be a barrier to the provision of MTM 
services, one respondent disagreed that the matter should be addressed as a goal of providing MTM 




Figure 3.1: Diverging stacked bar chart of responses of 8 stakeholders to 31 Likert items pertaining to 
findings of a focus group discussion on the approaches, beneficiaries, barriers, facilitators, goals, and the 
role of informatics in the provision of medication 
 
When asked to identify the top three MTM approaches that would be feasible for an underserved 
setting, 6 respondents selected both the peer-based and group-based approaches among their 
choices. Five respondents included the professional approach among their choices. When asked to 
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identify the single most feasible MTM service delivery approach, task shifting to lay health 
workers and group-based care tied for first place with 3 respondents selecting each approach. The 
professional and task shifting to other professional approaches were each selected once. 
When asked to identify the top three patient types that are most likely to benefit from 
pharmaceutical care in the resource-limited setting, all the 8 respondents included HIV patients 
newly initiated on antiretroviral therapy among their choices. Six respondents included HIV and 
Tuberculosis comorbidity among their top three choices. When asked to identify a single patient 
group that would benefit from MTM, 5 respondents selected HIV patients newly initiated on 
antiretroviral therapy, 2 selected HIV and Tuberculosis comorbid patients and 1 selected chronic 
disease patients. No respondents selected geriatrics, pediatrics or patients on second-line, third-
line or salvage antiretroviral therapy. 
3.4. Discussion 
The purpose of this study was to identify health care provider perspectives on the motives and 
strategies of the provision of medication therapy management (MTM) services in underserved 
settings. To meet the objective of the study, qualitative data from a focus group discussion and an 
online survey with stakeholders based in an example of an underserved setting were analyzed. The 
analysis yielded several themes pertaining to the provision of MTM services in underserved 
settings. There is a dearth of prior research on this subject, and this study can be viewed as a means 
of generating exploratory findings that could be investigated further. 
The findings of this study suggest that the motivations for providing MTM services in underserved 
settings are similar to those previously described in the literature. By definition, MTM is a service 
provided to optimize the therapeutic outcomes of individual patients by improving medication 
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adherence, safety, and effectiveness [20, 29, 90]. The themes about why MTM is necessary for 
underserved settings that were identified in this study are in line with what is known about these 
goals of MTM. Additionally, the findings of this study suggest that in underserved settings, HIV 
patients newly initiated on antiretroviral therapy were most likely to benefit from MTM services. 
Furthermore, the findings of this study suggest that the provision of MTM services in underserved 
settings could be motivated by the need to promote population-level infection control and 
prevention by mitigating risks of suboptimal use of medications among persons with infectious 
diseases such as HIV and tuberculosis. This particular theme has not been emphasized by previous 
researchers. A plausible explanation for the lack of emphasis on the theme is that a majority of 
research on MTM is primarily conducted in high-income settings where infectious disease burdens 
are lower compared to the low-resource setting in which this study was conducted. 
Interestingly, this study reveals several strategies that could be used to provide MTM services in 
underserved settings. The qualitative analysis conducted in the study discerned six patterns based 
on the cadre of care provision (professional vs. task-shifted vs. hybrid) and the setting of care 
provision (single-patient vs. group). Although the findings of this study did not reveal a single 
strategy that would be optimal for providing MTM services in underserved settings, a recurrent 
theme was that successful strategies needed to overcome health facility barriers associated both 
human resource capacity and patient engagement challenges. 
It is well-known that one of the key healthcare delivery barriers in underserved settings is the 
shortage of skilled service providers [11, 12, 16]. Consequently, and as suggested by the findings 
of this study, the professional single-patient care approach identified by this study and equivalent 
to conventional MTM service provision [20] would be desirable but unlikely to be sustainable in 
underserved settings. The training of more professionals is a reasonable long-term solution that 
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would improve the pool of skilled providers in underserved settings [11, 91]. However, research 
has shown that despite increases in the number of professional care providers in underserved 
settings, workforce challenges in these settings are likely to persist due to uneven distribution of 
health workers with respect to location (rural vs. urban, high income vs. low-income countries) 
and employment areas (private vs. public) [12, 92]. 
This study suggests that a task shifting model in which professional MTM service providers team 
up with other professional or lay health workers to share MTM responsibilities would be a 
reasonable approach for overcoming workforce challenges associated with the provision of MTM 
services in underserved settings. The fact that task shifting is a recommended strategy used to 
enhance healthcare delivery in low- and middle-income countries [16, 17, 36] implies that the 
hybrid model described in this study is likely to be acceptable and sustainable in underserved 
settings. Furthermore, the findings of this study suggest that care providers view task shifting to 
peer health workers as possibly having the additional benefit of improving patient engagement in 
MTM services. However, this finding should be interpreted with caution as previous research on 
the role of peers in improving patient self-management, medication adherence, and patient 
engagement report mixed findings [93-96]. The use of peers in supporting MTM activities, 
therefore, needs to be investigated further to optimize MTM outcomes. Similarly, although 
previous research suggests that group-based care could be effective for the management of chronic 
diseases such as diabetes [97], the application of these approaches in the provision of MTM 
requires additional investigations. 
There are several limitations to this study. First, by nature of being a qualitative study, the data 
collected may be biased by selective memory, attribution, and exaggeration of the study 
participants. However, the use of an online survey to verify the consistency of findings generated 
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by the focus group discussions could have mitigated this bias. Second, using social analysis to 
identify potential study participants could have biased the selection of subject since participants 
predominantly hailed from the pharmacy profession. Although this is reasonable given that MTM 
services are primarily provided by pharmacists, it is likely that the views and opinions of this group 
do not reflect those of other professions such as clinicians. Lastly, this study was conducted in a 
single organization that primarily focuses on HIV care and chronic disease management. It is 
possible that in different contexts, different sets of findings would be obtained. 
3.5. Conclusions 
Overall, this study suggests that the provision of MTM services in underserved settings could be 
motivated by the need to improve medication adherence, safety, and effectiveness, as well as to 
avert the public health risks posed by suboptimal treatment of communicable diseases. The study 
identifies several MTM strategies and suggests that a hybrid model involving the collaboration 
among professionals and lay health workers would be reasonable for providing MTM services in 
underserved settings. Because this study was primarily explorative, it raises a number of 
opportunities for future clinical and informatics research. First, further research is needed to 
delineate the feasibility and comparative effectiveness of different MTM approaches in order to 
identify the approaches that are effective, scalable, and sustainable in underserved settings. 
Second, the themes generated by this study could be refined further and used to inform the 
development of formal conceptual frameworks that would subsequently guide the implementation 
and evaluation of MTM services in underserved settings. Lastly, further informatics research is 
needed to understand how different strategies of MTM service provision in underserved settings 
affects the design, evaluation, and implementation of tools that support the workflows associated 




Appendix 3.1: Identification of Study Participants using Social Network Analysis 
Procedure 
A self-report survey (Appendix 1a) was administered to a convenient sample of 45 respondents. 
The survey asked respondents to name the colleagues whom they consult when having patient-
specific medication-related questions. The respondents also indicated the frequency of the 
consultations and ranked the value of advice they received from the named colleagues. The self-
report survey data was extracted and used to construct a social network graph for further analysis. 
Analysis 
Two social network analyses were done on the constructed graph. The first analysis applied the 
edge betweenness community detection algorithm to discover subgraphs that represented the 
community whose members would be suitable focus group discussion participants. The goal of the 
second social network analysis was to identify key opinion leaders who would be suitable 
candidates for the online survey. This was achieved by computing the eigenvector centrality and 
betweenness centrality followed by identifying the opinion leaders as the outliers in the plot of the 
two metrics. 
Findings 
The analyzed graph had 70 nodes and 181 edges. The community detection algorithm identified 
12 communities (Figure 3.2). The yellow cluster in Figure 3.2 was composed of the actors who 
were considered suitable targets for the focus group discussion. Seven actors from this cluster 
ended up participating in the focus group discussion. Figure 3.3 is the plot of eigenvector centrality 
versus betweenness centrality that was used to identify opinion leaders. Fifteen actors were 
considered opinion leaders who were suitable candidates for the online survey. 
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Appendix 3.1a: Social Network Analysis Survey 
 
1. Please enter your name below 
 




3. How long have you worked at AMPATH 
☐Less than 6 months ☐6 months to 1 year ☐1 to3 years ☐3 to 5 years ☐More than 5 years 
4. How long have you worked at your present job position 
☐Less than 6 months ☐6 months to 1 year ☐1 to3 years ☐3 to 5 years ☐More than 5 years 
5. Please name the colleagues you consult whenever you have questions about a patient’s medication-
related problems. ( A maximum of 5 individuals can be named) 
Person 1  
Person 2  
Person 3  
Person 4  
Person 5  
6. How often do you contact each selected person for the advice? 
Person 1 ☐Never     ☐Rarely     ☐Sometimes     ☐Often     ☐Always 
Person 2 ☐Never     ☐Rarely     ☐Sometimes     ☐Often     ☐Always 
Person 3 ☐Never     ☐Rarely     ☐Sometimes     ☐Often     ☐Always 
Person 4 ☐Never     ☐Rarely     ☐Sometimes     ☐Often     ☐Always 
Person 5 ☐Never     ☐Rarely     ☐Sometimes     ☐Often     ☐Always 
7. How would you rank the value of the advice you receive from each person? 
Person 1 ☐Very low   ☐Low   ☐Moderate   ☐High  ☐Very high 
Person 2 ☐Very low   ☐Low   ☐Moderate   ☐High  ☐Very high 
Person 3 ☐Very low   ☐Low   ☐Moderate   ☐High  ☐Very high 
Person 4 ☐Very low   ☐Low   ☐Moderate   ☐High  ☐Very high 
Person 5 ☐Very low   ☐Low   ☐Moderate   ☐High  ☐Very high 









Figure 3.2: Network diagram of Communities Identified by the Edge-Betweenness Community Detection 
Algorithm. Nodes represent individuals, and edges indicate consultations. 
 
 




Appendix 3.2: Focus Group Discussion Guide 
1. With respect to the medication use process (Prescription, Dispensing, Administration, and 
Monitoring), how is care provided to ambulatory patients at AMPATH?  
2. What is your opinion about the medication use process at AMPATH? What aspects are 
adequate? Which aspects need to be improved upon? Why? Why not? 
3. What are some of the barriers and challenges of the medication use process at AMPATH? 
4. Please describe how medication monitoring is currently offered at AMPATH. What are some 
of the ways the current approaches could be improved? 
5. What patient groups would benefit from medication therapy management at AMPATH? 
6. What are some of the approaches through which Medication Therapy Management Services 
can be offered at AMPATH?  
a. What are the pros and cons of these approaches? 
b. How can health information technology support these approaches??  
7. Please envision the use of an information system that supports the provision of medication 




Appendix 3.3: Online Survey 
Medication Therapy Management Approaches 
1. Please indicate your level of agreement with respect to whether the following approaches could 
be used to provide medication therapy management services in a resource-constrained setting: 
 Strongly 
Agree 
Disagree Neutral Agree 
Strongly 
Agree 
Professional: MTM is delivered by a trained 
professionals 
☐ ☐ ☐ ☐ ☐ 
Group-based care: MTM is delivered to groups 
of patients rather than to individual patients 
☐ ☐ ☐ ☐ ☐ 
Task shifting to lay health workers: MTM is 
primarily delivered by trained lay health workers 
e.g. peer health workers 
☐ ☐ ☐ ☐ ☐ 
Task shifting to other professionals: MTM is 
delivered by other cadres of healthcare providers 
e.g. nurses 
☐ ☐ ☐ ☐ ☐ 
Technology-centered: Most MTM activities are 
automated eg. Using IVR technology 
☐ ☐ ☐ ☐ ☐ 
2. Please select the top THREE approaches that you think are most useful in providing medication 
therapy management services in a resource-constrained setting: 
☐ Professional approach 
☐ Group-based care approach 
☐ Task shifting to lay health workers 
☐ Task shifting to other professionals 
☐ Technology-centered approach 
☐ Other:___________________ 
3. What is the single-most-useful approach for providing medication therapy management 
services in a resource-constrained setting? (Please chose one) 
☐ Professional approach 
☐ Group-based care approach 
☐ Task shifting to lay health workers 
☐ Task shifting to other professionals 
☐ Technology-centered approach 
☐ Other:___________________ 
4. Briefly, explain the reason for the choice made in the preceding question 
___________________________________________________________________________ 
5. Please provide any other comments you may have on the approaches that could be used to 




Medication Therapy Management Beneficiaries 
6. Please indicate your level of agreement with respect to whether the following patient groups 
need more rigorous medication therapy management services: 
 Strongly 
Agree 
Disagree Neutral Agree 
Strongly 
Agree 
Chronic disease patients ☐ ☐ ☐ ☐ ☐ 
Geriatrics ☐ ☐ ☐ ☐ ☐ 
HIV/TB coinfected patients ☐ ☐ ☐ ☐ ☐ 
Newly-initiated ART patients ☐ ☐ ☐ ☐ ☐ 
Pediatrics ☐ ☐ ☐ ☐ ☐ 
Second- and third-line ART patients ☐ ☐ ☐ ☐ ☐ 
7. Please select the top THREE patient groups that you think need more rigorous medication 
therapy management services: 
☐ Chronic disease patients 
☐ Geriatrics 
☐ HIV/TB coinfected patients 
☐ Newly-initiated ART patients 
☐ Pediatrics 
☐ Second- and third-line ART patients 
☐ Other:___________________________ 
8. Which single patient group would benefit the most from more rigorous medication therapy 
management services? (Please chose one) 
☐ Chronic disease patients 
☐ Geriatrics 
☐ HIV/TB coinfected patients 
☐ Newly-initiated ART patients 
☐ Pediatrics 
☐ Second- and third-line ART patients 
☐ Other:___________________________ 
9. Briefly, explain the reason for the choice made in the preceding question 
___________________________________________________________________________ 
10. Please provide any other comments you may have on patient groups you think need more 





Barriers and Facilitators 
11. Please indicate your level of agreement with the following statements about the facilitators of 
the provision of medication therapy management services in a resource-limited setting: 
 Strongly 
Agree 
Disagree Neutral Agree 
Strongly 
Agree 
Evidence from previous patient-focused 
interventions such as the diabetes and 
anticoagulation clinics  
☐ ☐ ☐ ☐ ☐ 
Expansions into new frontiers in chronic disease 
management call for more rigorous medication-
related care 
☐ ☐ ☐ ☐ ☐ 
Innovative approaches such as peer-based 
counselling and group-based care that are already 
being researched and are proving to be effective 
☐ ☐ ☐ ☐ ☐ 
There is a recognized requirement to conduct and 
support pharmacovigilance activities 
☐ ☐ ☐ ☐ ☐ 
12. Please provide any comments about the facilitators of the provision of medication therapy 
management services in a resource-limited setting 
___________________________________________________________________________ 
13. Please indicate your level of agreement with the following statements about the barriers to the 
provision of medication therapy management services in a resource-limited setting: 
 Strongly 
Agree 
Disagree Neutral Agree 
Strongly 
Agree 
Use of alternative forms of medicines by patients ☐ ☐ ☐ ☐ ☐ 
Lack of good health information technology 
infrastructure to support care processes 
☐ ☐ ☐ ☐ ☐ 
Language barrier  ☐ ☐ ☐ ☐ ☐ 
Stigma and passiveness of patients ☐ ☐ ☐ ☐ ☐ 
Inadequate knowledge and skill by care providers ☐ ☐ ☐ ☐ ☐ 
High volumes of patients, low staffing levels, and 
lack of time 
☐ ☐ ☐ ☐ ☐ 
14. Please provide any comments about the barriers to the provision of medication therapy 





Goals and Priorities 
15. Please indicate your level of agreement with the following statements about the goals of the 
provision of medication therapy management services in a resource-limited setting: 
 Strongly 
Agree 
Disagree Neutral Agree 
Strongly 
Agree 
Improve counselling, care planning, and 
evaluation of treatment outcomes 
☐ ☐ ☐ ☐ ☐ 
Improve monitoring of medication adherence ☐ ☐ ☐ ☐ ☐ 
Improve implementation and reporting of 
pharmacovigilance activities 
☐ ☐ ☐ ☐ ☐ 
Monitor the use of alternative forms of medicines 
by patients 
☐ ☐ ☐ ☐ ☐ 
Improve the decision-making capacity of care 
providers 
☐ ☐ ☐ ☐ ☐ 
16. Please provide any comments about the goals of the provision of medication therapy 
management services in a resource-limited setting: 
___________________________________________________________________________ 
17. Please rank the following goals to reflect your thoughts on the priorities of the provision of 











Improve counselling, care planning, and 
evaluation of treatment outcomes 
☐ ☐ ☐ ☐ ☐ 
Improve monitoring of medication adherence ☐ ☐ ☐ ☐ ☐ 
Improve implementation and reporting of 
pharmacovigilance activities 
☐ ☐ ☐ ☐ ☐ 
Monitor the use of alternative forms of medicines 
by patients 
☐ ☐ ☐ ☐ ☐ 
Improve the decision-making capacity of care 
providers 
☐ ☐ ☐ ☐ ☐ 
18. Please provide any comments about the priorities of the provision of medication therapy 






Role of Health Information Technology 
19. Please indicate your level of agreement with the following statements about the desired 
functions of an information system that supports the provision of medication therapy 





Disagree Neutral Agree 
Strongly 
Agree 
Patient Identification: the system should help 
identify patients who need additional follow-up 
☐ ☐ ☐ ☐ ☐ 
Clinical Decision Support: the system should 
provide decision-making aids to care providers 
☐ ☐ ☐ ☐ ☐ 
Communication and reporting: the system should 
enable effective communication and reporting 
☐ ☐ ☐ ☐ ☐ 
Data Capture: The system should support 
efficient onsite and remote data entry 
☐ ☐ ☐ ☐ ☐ 
Data Validation: the systems should support data 
validation through well defined checks 
☐ ☐ ☐ ☐ ☐ 
Patient Data Viewing: The system should support 
the integrated view of relevant patient data 
☐ ☐ ☐ ☐ ☐ 
20. Please provide any comments about the role of health information technology on the provision 






Chapter 4. Assessing ambulatory HIV care workflow patterns in underserved settings  
4.1. Introduction 
A workflow is a sequence of tasks where each task can be conceptualized as a unit of work in 
which inputs are transformed into outputs [98]. Workflows can occur between organizations, 
within an organization, and at an individual cognitive level and can generate, consume, or 
transform information [98, 99]. A clinical workflow is a segmental sequence of finite tasks 
performed during the delivery of clinical care to assess, change or maintain the health of a patient 
[100]. Clinical workflows are characterized by how specific clinical tasks are accomplished, the 
order in which the tasks are completed, the persons responsible for task completion, and the 
resources used to complete the task [100]. In the ambulatory care setting, an organizational-level 
clinical workflow may include several tasks such as appointment check-in, clinician assessment, 
laboratory testing, and medication dispensing. 
The point-of-care monitoring of antiretroviral toxicities is an integral function of any HIV care 
workflow [2, 6]. Antiretroviral toxicities may range from mild side-effects to life-threatening 
adverse drug reactions and have been reported with the use of all antiretroviral drugs [6]. They are 
responsible for introducing important barriers such as medication nonadherence, treatment 
substitution, treatment discontinuation, and loss to follow-up that individually or collectively 
counteract the benefits of antiretroviral therapy [2]. 
The use of standardized survey tools and point-of-care clinical decision support (CDS) systems 
could improve the quality of antiretroviral toxicity monitoring within HIV care workflows. 
Compared to self-reporting by patients or open-ended questioning by care providers, screening 
tools such as scales, profiles, and checklists have been shown to elicit more accurate information 
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from patients and improve the documentation of clinical observations [24, 25]. On the other hand, 
point-of-care CDS interventions have been used to address information-related challenges 
experienced during care delivery across different settings [98]. CDS systems reduce the cognitive 
workload associated with care provision by facilitating the collection, analysis, and delivery of 
information necessary for clinical decision-making. CDS systems have been investigated by 
various researchers and implemented across a variety of inpatient and outpatient settings [98]. 
Although studies on the clinical impact of CDS report mixed findings, there is a common belief 
among researchers and implementers that CDS systems could be useful in improving care delivery 
efficiency and effectiveness [98]. In underserved care settings where skilled care providers are 
few, CDS applications have been used to complement task shifting of health care responsibilities 
from professionals to health workers with shorter training and fewer qualifications but who are 
more readily available [82].Whereas the most effective targets of CDS applications in task shifting 
remains a research problem, researchers have developed CDS applications to facilitate different 
task shifting strategies such as nurse management of non-communicable diseases [82, 101] and 
improved range and quality of service delivered by frontline health workers [44, 102]. 
The design of documentation and decision-making aids for improving antiretroviral toxicity 
monitoring at the point-of-care requires a good understanding of HIV care workflows. Such 
understanding could be achieved through workflow analysis and quality improvement studies [21]. 
These are process redesign studies that examine current workflows, identify drivers of suboptimal 
performance in the current workflows, and determine how CDS tools could be designed and 
integrated to improve the efficiency and efficacy of the studied workflows [21]. Sheehan and 
Bakken state that whereas good workflow integration increases the usability, safety, and 
effectiveness of CDS tools, poor workflow integration may lead to care delivery disruptions, 
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compromised patient safety, resource underutilization, and wastage [99]. Workflow analyses are 
particularly important when designing CDS tools for clinical workflows in underserved settings 
[21]. Several factors including poor infrastructure, scarce human resources, and high disease 
burdens in underserved settings contributes to the uniqueness of clinical workflows in such settings 
and could influence the manner in which CDS tools targeting these workflows are designed. 
It is plausible that antiretroviral toxicities are frequently not recognized and documented in 
ambulatory HIV care workflows in underserved settings because care providers lack the time and 
resources required for point-of-care antiretroviral toxicity monitoring. Accordingly, the purpose 
of the study reported in this chapter was to identify barriers to and opportunities for improving the 
quality of point-of-care antiretroviral toxicity monitoring in underserved settings by examining 
different aspects of the ambulatory HIV care workflow in an underserved setting in western Kenya. 
4.2. Methods 
4.2.1. Conceptual Framework 
This workflow analysis study was guided by the Contextual Design framework developed by 
Holtzblatt and Beyer [99]. This user-centered process describes a methodology for studying 
workflows to inform the design of systems that address user needs [99, 103]. Contextual design 
involves the use of ethnographic methods such as field interviews and observations to acquire data 
about user workflows, and the subsequent creation of models that describe different perspectives 
of work. The key phases of the contextual design process are the contextual inquiry, work 
modeling, consolidation, and workflow redesign. These are described below. 
Holtzblatt and Beyer define contextual inquiry as the process of understanding how people 
routinely conduct their work and the subsequent creation of a shared interpretation of the work 
[103]. The process unearths different aspects of work including the motive of the tasks, the strategy 
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for carrying out the tasks, the structures that enable work accomplishment, and the conceptual 
distinctions between different parts of work [99]. 
Workflow modeling refers to the creation of diagrams that describe the work of individuals and 
organizations based on the findings of contextual inquiries. Holtzblatt and Beyer state that 
workflow modeling provides system design stakeholders a language for talking about work, makes 
the structure of work explicit, and makes contextual inquiry data more coherent [103]. Five 
different models can be used to describe different perspectives of work: 1) the flow model 
illustrates how information is communicated from sources to targets in a workflow, 2) the cultural 
model illustrates how institutional culture and policy influences work, 3) the sequence model 
describes the steps needed to accomplish work, 4) the physical model describes the physical 
environment that supports work, and 5) the artifact model describes objects supporting the 
workflow such as electronic medical records and CDS tools. 
Consolidation refers to synthesizing common patterns and structures of work from different 
contextual inquiry sources without losing individual variations [103]. Lastly, workflow redesign 
refers to reviewing consolidated data to identify ways in which technology could be integrated to 
improve studied workflows. 
4.2.2. Study Setting 
AMPATH is an umbrella healthcare organization that provides comprehensive HIV/AIDS and 
chronic disease care in western Kenya [77]. Although AMPATH provides care via several parent 
and satellite clinics scattered around western Kenya, this study was done at AMPATH’s primary 
center in Eldoret, Kenya. At the time this study was conducted, the AMPATH Center in Eldoret 
served approximately 30,000 HIV patients in a catchment area with approximately 289,000 
inhabitants according to the 2009 Kenya population and housing census results [104]. 
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4.2.3. Data Collection 
Contextual inquiry data was collected through individual semi-structured interviews, artifact 
examination, and a rapid literature review. The semi-structured interviews involved two 
stakeholders who were familiar with the workflow. In each interview, the respondents were asked 
to describe their perceptions of the HIV clinic workflow at the study setting by answering the 
questions: a) What does routine monitoring of antiretroviral toxicity mean to you? b) What barriers 
have you encountered when monitoring antiretroviral toxicity? c) How is the monitoring of 
antiretroviral toxicity at AMPATH carried out? The respondents were asked to give examples 
drawn from their individual experiences to illustrate the statements they made. They were asked 
follow-up questions to provide more specific details. Artifact examination involved the review of 
the key documents, medical records, and CDS tools used in the studied workflow. 
The rapid review of literature involved reading and reviewing published literature describing the 
ambulatory HIV clinical workflow at the study setting. A rapid review is an accelerated synthesis 
of evidence from literature conducted to inform timely decision-making and to overcome time and 
resource limitations [105, 106]. Rapid review methodologies vary in breadth and in depth [106]. 
In this study, the process involved identifying publications about AMPATH by searching PubMed 
and extracting descriptions of the ambulatory HIV clinic workflow from the identified studies. The 
search strategy used was: academic model providing access to healthcare OR AMPATH OR 
resource?constrained OR resource?limited AND Kenya AND (HIV?care OR HIV?treatment OR 
HIV?clinic*). The search was limited to original reports published in English between 2008 and 
2017. A total of 86 records were identified and reviewed for eligibility. Studies were included if 
they described the flow, sequence, cultural, artifact or physical model of the ambulatory care HIV 
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care workflow at AMPATH. After two rounds of review, 11 studies were found to be eligible and 
were included in the analysis. 
4.2.4. Data Analysis 
Data from the semi-structured interviews were narratively reviewed, and the synthesis used to 
inform the initial designs of the sequence model and flow model of the studied workflow. 
Similarly, data from the artifact examination was narratively reviewed and used to describe the 
artifact model of the studied workflow. 
The data from the rapid review of the literature was analyzed qualitatively using a systemic 
approach involving coding and identification of patterns about the intent, strategy, structure, and 
conceptual distinctions that constitute the ambulatory HIV care workflow at AMPATH. Articles 
from the rapid review of literature were uploaded to Qualitative Analysis Miner Lite [85] for 
software-aided coding. The goal of the coding process was to transform qualitative text excerpts 
into codes which could be analyzed quantitatively and subsequently used to generate patterns in 
data. The coding process involved the combined use of deductive codes and inductive codes [107]. 
Table 4.1. provides examples of coding text excerpts, codes, and code types in this study. 
Deductive coding involved labeling text excerpts with concepts derived from the Holtzblatt’s and 
Beyer’s Contextual Design framework [99]. For example, text excerpts describing different 
workflows were labeled using codes determined a priori such as “flow model”, “physical model” 
and “artifact model”. Inductive coding involved labeling text excerpts with codes that emerged 
from the reviewed text and were different from the a priori codes. For example, the task-related 
codes such as “interview patient”, “review charts” and “record locator information” emerged from 




Table 4.1: Examples of text excerpts, codes, and code types from the coding process 




“The Eldoret clinic itself was composed of four independently 
functioning modules designated as 1a-1d (3 adult clinics and 1 pediatric 
clinic housed in a single building) for reporting purposes.” [108] 
Artifact model 
“Clinicians caring for AMPATH patients do not enter data directly into 





“Since most clinicians in resource-limited settings are not able to use 
computers directly during patient-care, OpenMRS allows clinicians at 
AMPATH to complete data-driven, pre-printed AMPATH encounter 




“Trained and remunerated HIV-positive peers with records of perfect 
clinic and/or treatment adherence contact patients by phone or through 
home visits if they miss a scheduled clinic visit” [38] 
 
The codes generated through the coding process were used to identify themes about the intent, 
strategy, structure, and conceptual distinctions of the studied workflow. These constructs are 
defined by Holtzblatt and Beyer [110] as follows. Intent is the motive for accomplishing a task and 
is independent of the means used to achieve it. The intent of a dispensing task in a workflow is to 
transform a prescription order into a medication. Strategy is the pattern used to carry out tasks in 
a workflow. For example, the strategy for simple clinical workflow may consist of checking in, 
nurse triage, clinician encounter, dispensing encounter, and checking out in that order. Structure 
refers to the physical, organizational, or conceptual arrangements that enable the implementation 
of a strategy. To implement the strategy in the example above, the physical environment of the 
workflow may be structured into a check-in desk, a nursing station, a clinical assessment office, a 
dispensing pharmacy, and a check-out station. Conceptual distinctions refer to the way people 
think about their work and how to do it. For example, a clinician encounter task in a clinical 
workflow may rely on predefined concepts and terminology conduct and document observations 
made in the encounter. 
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Using the findings from the contextual inquiry, consolidated workflow models that illustrate 
different aspects of the studied workflow were created and described. Lastly, the strengths, 
weaknesses, barriers, facilitators, and process redesign recommendations for antiretroviral toxicity 
monitoring in the studied workflow were described. 
4.3. Results 
4.3.1. Code Frequencies 
The coding process (conducted for the rapid literature review only) yielded 37 codes under the 
actor, artifact, and task categories. These codes were mapped from 58 sentences and paragraph 
text excerpts via 220 excerpt-to-code mappings. The codes clinician and patient had the heaviest 
weights under the actor category (Figure 4.1). The code clinician was present in 9 documents and 
appeared 25 out of 220 times (11.4%) in the collection. The code patient was present in 10 
documents and accounted for 10.9% of the total code frequency in the collection. The code data 
entry clerk was the next most heavily weighted code after clinician and patient under the actor 
category. It was present in 8 documents and accounted for 4% of the total code frequency. Other 
codes under the actor category with weight >0 included registration clerk, nurse, outreach peer, 
and pharmacy technician. 
The codes AMRS (AMPATH Medical Record System) and AMPATH’s paper encounter form had 
the heaviest weights under the artifact category (Figure 4.1). These two codes were present in 10 
documents in the collection, with AMRS accounting for 12.7% and paper encounter form 
accounting for 7.7% of the total code frequency in the collection. Other codes under the artifact 
category with weight >0 included patient charts, patient summary sheet, AMRS decision support, 




Figure 4.1: Weights of codes identified during the thematic analysis of articles describing the ambulatory 
HIV care workflow at AMPATH. AMRS – AMPATH Medical Record System 
 
Under the task category, the most heavily weighted activities included interview patient (4.5% of 
total coding frequency, 10 documents), enter data into AMRS (3.6% of total coding frequency, 8 
documents), review charts (3.6% of total coding frequency, 5 documents), and diagnose and plan 
(3% of total coding frequency, 6 documents) (Figure 4.1). Other codes in this category included 
record locator information, check in the patient, test and record results, register a new patient, 
record weight and vitals, prescribe medications and schedule next visit. 
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4.3.2. Cultural Model 
AMPATH was established to provide free comprehensive HIV care to both rural and urban 
patients residing in western Kenya [108, 111, 112]. The organization pursues a tripartite mission 
of care, training, and research to address health challenges faced in underserved settings [78]. 
AMPATH strives to “lead with care” and provides training and mentorship to its care providers 
and conducts research in order to achieve this goal [78]. 
The cultural model of the ambulatory HIV care workflow at AMPATH demonstrates the central 
role of the clinician in the workflow. The clinicians in the workflow are responsible for the most 
influential care delivery activities including interviewing patients and recording care observations, 
reviewing previous patient data, diagnosing diseases and planning care, ordering laboratory tests, 
writing prescriptions, and scheduling patient visits. The clinicians in the workflow are primarily 
clinical officers (equivalent to physician assistants in the United States) who provide care with 
little to no supervision [14]. Consequently, the key record-keeping and decision-making aids in 
the workflow including the paper encounter form, the patient summary sheet, and the computer-
generated care suggestions target the clinical officer cadre. 
The data collected in the workflow primarily supports clinicians delivering care. The secondary 
uses of the collected data include program reporting to funding agencies and the government, 
quality improvement and research [108, 113]. 
4.3.3. Physical Model 
The physical structure of the ambulatory HIV care workflow at AMPATH is organized into four 
separate ambulatory patient care modules, one clinical laboratory, and one pharmacy located in 
the same building. Three of the 4 patient care modules are adult HIV clinics that offer the same 
service, while one module is dedicated to pediatric HIV care. The patient care modules are 
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typically run by nurses and clinical officers. A patient is enrolled to specific care module during 
his/her initial encounter visit. In subsequent encounter visits, the patient receives clinical care at 
the module assigned to him/her. However, rather than being cared for by the same clinician at each 
encounter, the patient is cared for by any clinician available during the visit. Similar to the patient 
care modules, the AMPATH laboratory and the pharmacy are run by laboratory technicians and 
pharmacy technicians respectively. Patients seeking services from these locations are attended to 
by whichever personnel is available. 
4.3.4. Artifact Model 
The three main artifacts in the ambulatory HIV care workflow at AMPATH are the AMPATH 
medical record system (AMRS), the paper encounter forms, and the patient summary sheets. The 
AMRS is ambulatory electronic health record (EHR) that has been used at AMPATH since 2004 
to store longitudinal patient records for all AMPATH patients. It was the first implementation of 
OpenMRS, an open-source EHR that is widely used in developing countries [14, 114]. The patient 
records in AMRS consist of demographic, clinical, laboratory, and pharmacologic information 
stored as categorical and numeric observations of clinical concepts encoded in the AMRS concept 
dictionary [14, 109]. 
The paper encounter forms are used for the care of both adult and pediatric patients and include 
an initial visit encounter form that is filled in for new patients and a return visit encounter form 
that is filled for returning patient [108, 109]. These structured forms were designed with input from 
clinicians at AMPATH to collect a minimal data set that supports care delivery, reporting, 
monitoring and evaluation, and research [114]. A single form captures over 400 demographic, 
clinical, laboratory and pharmacologic data elements that are observed during an encounter visit 
and that are eventually hand-entered into AMRS [13, 108, 109, 111, 114]. The forms also contain 
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blank free text comment boxes that can be used by clinicians to write supplemental notes whenever 
necessary [109, 113]. The free text comments are matched to known concepts in the concept 
dictionary during data entry, with free text concepts not found in the dictionary submitted to be 
considered for dictionary addition [109]. 
The patient summary sheets are patient-specific reports that summarize information selected from 
the patient’s AMRS records including identifying information, problem list, laboratory results, and 
medications [14, 109]. This summary report serves as a quick reference to a patient’s most relevant 
past records and was developed to minimize the time clinicians needed to go through the patient’s 
past encounter records [14, 109, 114]. The patient summary sheets may also contain care 
suggestions such as reminders to order overdue labs tests on the patient summary sheet [14, 109, 
114]. They are generated as a printable pdf file by a programming module within AMRS called 
the clinical summary module [14, 109, 114]. 
4.3.5. Flow Model 
The flow model of the ambulatory HIV care workflow at AMPATH is illustrated in Figure 4.2. 
This model identified the clinician as the key documenter and consumer of clinical information in 
the workflow. The clinician communicates directly with the patient to gather information about 
the patient’s disease and medication status and to provide care instructions, counseling, and 
education to the patient. The clinician obtains additional information necessary for care delivery 
by reviewing the patient summary sheet or perusing the patient’s paper charts, and by reviewing 
information such as the patient’s weight and vital signs that are already recorded on the encounter 
form. The clinician records his/her clinical observations and care plan on the paper encounter form. 
He communicates indirectly to laboratory technicians and dispensing staff through lab order forms 




Figure 4.2: Information flow model for the ambulatory HIV care workflow at the AMPATH. Nodes depict 
information sources and targets while arrows indicate the information that is communicated from the 
source to the target. Blue nodes depict human actors while green 
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4.3.6. Sequence Model 
The ambulatory HIV care workflow at AMPATH is fairly structured. A high-level Business 
Process Management Notation (BPMN) 2.0 [115, 116] illustration of the sequence model of this 
workflow is shown in Figure 4.3. This model consists of 7 main tasks: check-in, outreach, physical 
exam, clinician assessment, lab assessment, prescription fill and check-out. A more detailed 
illustration of the return-visit sequence model is shown in Figure 4.4. This model shows multiple 
participants (represented as BPMN swim lanes) interacting to achieve the goals of the workflow. 
At the start of the visit encounter, a previously registered patient presents his/her AMRS ID card 
to a registration clerk. The clerk starts the clinic process by checking in the patient and entering 
the patient’s identifier information on a new encounter form. Next, the patient is directed to 
AMPATH’s outreach program where a trained outreach peer health worker collects the patient’s 
up to date locator information including cell phone numbers, physical addresses, and nearest 
landmarks to physical addresses. Once the outreach information is collected, the patient is directed 
to a nursing station. Here, a nurse examines the patient and records the patient’s weight and vital 
signs on the paper encounter form. After the nurse assessment, the patient waits to be seen by a 
clinician for clinical assessment. In the clinical encounter, a clinician interviews the patient and 
records observations about the patient’s disease status (e.g., chief complaint, signs, symptoms, and 
physical findings) and the patient’s medication status (e.g., current medications, adherence, and 
toxicities). The clinician also records the diagnosis and the care plan he/she has come up with on 
the paper encounter form. To help clinicians with decision-making during care planning, a 
summary report of the patient’s previous encounters is made available to the clinician. These 
summary reports are created by a CDS module with AMRS that extracts structured information 




Figure 4.3: A high-level BPMN 2.0 illustration of the sequence of tasks in the ambulatory HIV care 
workflow at AMPATH 
 
 
Figure 4.4: A high-level descriptive BPMN 2.0 illustration of the return-visit ambulatory HIV care 
workflow at AMPATH. AMRS – AMPATH Medical Record System. 
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As part of the care plan, the clinician may order laboratory tests, medications, or both. If the 
clinician orders tests, he/she fills a paper laboratory requisition form and hands it over to the 
patient. The patient goes to the AMPATH laboratory and hands over the requisition form to a 
laboratory technician. The technician collects samples from the patient and conducts the ordered 
laboratory tests. The technician enters the results into the department’s laboratory information 
system. These results are then transmitted to the AMRS and are made available in the subsequent 
visits as part of the patient’s summary report. If the clinician orders medications, he writes a paper 
prescription and hands it over to the patient who goes to the pharmacy where the prescription is 
filled. Patients waiting for their medications to be dispensed may be counseled and educated by 
trained peer health workers albeit informally. If the clinician orders laboratory tests and prescribes 
medications in the same encounter, the patient is instructed to go the laboratory before going to 
the pharmacy. The clinic encounter is completed when the patient leaves the clinic. After the clinic 
visit, data entry clerks retrospectively enter the encounter data from completed paper encounter 
forms into the AMRS. To validate the quality of the data entry process, quality management clerks 
review a random 10% of the paper encounter forms for data entry errors. 
4.3.7. Strengths, Weaknesses, Barriers, and Facilitators 
Table 4.2 summarizes the key strengths, weaknesses, barriers, and facilitators pertaining to the 
point-of-care monitoring of antiretroviral toxicity identified from the analysis of the ambulatory 
HIV care workflow at AMPATH. These factors primarily pertain to the documentation and 
analysis of antiretroviral toxicities and were synthesized from information from the different 




Table 4.2: Summary of the key strengths, weaknesses, barriers, and facilitators of antiretroviral toxicity 
monitoring identified from the workflow analysis 
Category Description 
Strengths • Adequate documentation of patient-reportable medications 
• Adequate documentation of clinician-instituted medication plans 
• Reasonable assessment of medication adherence 
• Comprehensive documentation of physical exam findings 
Weaknesses • Inadequate documentation of patient-reportable symptoms and risk factors 
• Inadequate documentation of clinician-identified medication toxicities  
• Lack of documentation of clinician reasoning about medication toxicities 
Barriers • Clinician time and workload constraints 
• Data collection form design limitations 
• Institutional policies on documentation 
Facilitators • Opportunities for delegating tasks to available lay health workers 
• Potential to use clinic wait times for additional data collection 
• Availability of structured data in electronic health records 
• Clinician experience with electronic health records and clinical decision support 
 
Strengths 
Collectively, the information on patient-reported medications, clinician-ordered medications and 
medication adherence are important in establishing the causality of antiretroviral toxicities. One 
of the key strengths of the AMPATH workflow is the documentation of medications commonly 
prescribed in the workflow. This is done in the current medications section of the encounter form. 
The clinician documents patient-reported medications by checking off lists that describe 
medications used for HIV treatment, Pneumocystis jiroveci pneumonia prophylaxis, cryptococcal 
meningitis treatment, tuberculosis prophylaxis, and tuberculosis treatment. The clinician can also 
document additional medications reported by the patient on a free text ‘other medications’ field 
under this section. A similar approach is used to document the medications prescribed by the 
clinician under the care plan section of the encounter form.   
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In addition to the documentation of medications prescribed, the encounter form reasonably 
captures medication adherence. This is subjectively assessed using patient self-reporting and 
recorded as good, fair, or poor under the adherence section of the encounter form. The reasons for 
non-adherence is captured by checking off a list of potential reasons that contains descriptions 
such as ‘forgot’, ‘felt better’, ‘Lost/ran out of pills’ and ‘Pill burden’. Another strength of the 
AMPATH workflow is the comprehensive documentation of physical examination findings. This 
information could be used to determine manifestations and patterns of antiretroviral toxicities 
experienced by individual patients.  
Weaknesses  
A key weakness of the workflow is the inadequate documentation and interpretation of patient-
reportable symptoms. This is exemplified by the fact there is no dedicated section of the encounter 
form that adequately captures patient-reported symptoms. The only patient-reportable symptoms 
encoded in the AMPATH’s adult return-visit HIV encounter form pertain to the monitoring of 
tuberculosis (12 symptoms) and the risk of HIV transmission (3 symptoms). These symptoms 
overlap with only 5 (25%) of the symptoms in the widely-adopted and validated 20-item HIV 
Symptom Index [117].  
Another weakness of the workflow is that clinician-identifiable toxicities are restricted to few 
treatment-limiting adverse drug reactions. The drug side effects/toxicity section of the encounter 
form allows clinicians to record their judgments on whether a patient experienced an antiretroviral 
toxicity, the drug responsible for the toxicity, the severity of the reaction, the clinician-identified 
symptoms associated with the reaction, and the level of certainty that the drug caused the identified 
symptoms. However, only 9 of the 24 major antiretroviral toxicities described in the World Health 
Organization clinical guidelines for Antiretroviral Therapy [2] are coded in the encounter form. 
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Although it is possible for clinicians to record additional antiretroviral toxicity observations 
through free text fields on the encounter form, the types and completeness of the antiretroviral 
toxicity observations reported using this approach were not discernable in this study. 
Additionally, the reasoning behind clinical decision-making is not captured on the encounter form 
adequately. For example, clinicians can record the antiretroviral toxicities that they have identified 
based on their clinical judgments. However, the relationships between the identified antiretroviral 
toxicities and other observations such as signs and symptoms that are recorded are not explicit. 
This limits the secondary use of the data collected in the workflow as it is nontrivial to ascertain 
how clinicians make inferences from encounter data.   
Barriers 
The main barriers to the antiretroviral toxicity documentation and analysis pertain to clinician time 
and workload constraints. Clinicians are already expected to go through more than 400 observable 
entities on the encounter form during a single encounter with a patient. It may, therefore, be very 
challenging for clinicians to take up the additional documentation tasks required for rigorous 
antiretroviral toxicity monitoring. 
Another key barrier pertains to inadequacies in the design of the encounter forms used in the 
workflow. As alluded to earlier, the encounter forms do not adequately capture information on 
symptoms and risk factors. Additionally, the design of the forms does not allow easy tracking of 
clinician reasoning, making the reuse of the collected data more difficult. Furthermore, possible 
barriers associated with institutional policies and goals could be identified. For example, although 
the content and design of the AMPATH encounter form are determined by clinicians, they are also 
influenced by the need to adhere to requirements set forth by the government and funding agencies. 
This also implies that redesigning existing encounter forms to improve toxicity monitoring is 
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nontrivial and would require consensus among multiple stakeholders. Furthermore, if new forms 
are designed for collecting antiretroviral toxicity data, then new barriers such as the need to adapt 
to the use of new forms, workflow reorganization, and overhead costs arise.  
Facilitators 
Several facilitators of antiretroviral toxicity monitoring in the studied workflow exist. One such 
facilitator is the ability to shift data collection tasks from the overstretched clinicians to more 
readily available health workers. The observation that peer health workers support the collection 
of outreach contact and locator information in the ambulatory HIV care workflow at AMPATH 
demonstrates that task shifting strategies are considered acceptable and can be successfully 
incorporated into HIV workflows in underserved settings. Similar strategies could, therefore, be 
used to enhance antiretroviral toxicity data collection during clinic visits. Additionally, the 
availability of ample clinic wait times which account for most of the time spent by the patient in 
the clinic [21, 113] could facilitate data collection through task delegation.  
The availability of structured, longitudinal EHR data also presents a valuable opportunity for 
improving antiretroviral toxicity management. The information collected in several sections of 
AMPATH’s encounter form and subsequently stored in the AMRS could be used to support 
automated inferences about antiretroviral toxicities. The fact that clinicians in the workflow 
already have experience using EHRs and CDS also presents a valuable opportunity with respect 
to the development of solutions that rely on similar approaches. For example, adopting and 
designing antiretroviral toxicity reports in a manner similar to the patient summary sheets currently 
used at AMPATH would improve their usability and learnability as clinicians are already familiar 




4.3.8. Process Redesign and Quality Improvement Considerations 
Several quality improvement approaches could be considered to enhance antiretroviral toxicity 
monitoring in the ambulatory care workflow at AMPATH. These have been summarized using the 
Clinical Decision Support/Quality Improvement (CDS/QI) worksheet illustrated in Table 4.3. In 
line with the barriers and facilitators discussed in the previous section, the most relevant workflow 
redesign recommendations for improving the quality of antiretroviral toxicity monitoring in the 
studied workflow pertain to enhancing the collection and analysis of antiretroviral toxicity data. 
Figure 4.5 uses a redesigned sequence model of the ambulatory HIV care workflow AMPATH to 
illustrate how such quality enhancements could be achieved.  
The collection of patient-reported antiretroviral toxicity data could be enhanced by incorporating 
more readily-available healthcare personnel into the clinical workflow. For example, peer health 
workers could take up data collection responsibilities as described in Table 4.3 and illustrated in 
Figure 4.5. This task redistribution approach could be standardized by using computer-generated 
survey tools such as checklists whose contents are based on clinical practice guidelines. The 
additional antiretroviral toxicity data collected from the patient could then be presented to the 
clinician to guide further antiretroviral toxicity assessments and decision-making.  
Concurrently, longitudinal EHR data could be analyzed to detect possible antiretroviral toxicities 
in individual patients. The results of such analyses could be made available to clinicians as 
antiretroviral toxicity reports as illustrated in Figure 4.5. Such an endeavor is supported by the fact 
that the clinicians in the ambulatory HIV workflow at AMPATH are already accustomed to using 
clinical summary sheets that may also contain care suggestions [13, 14, 61]. It is, therefore, 
plausible to expect that adopting a similar strategy would enhance the uptake and ease of use of 





Table 4.3: CDS/QI worksheet for Improving Antiretroviral Toxicity Monitoring in the Ambulatory HIV Workflow at AMPATH 
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Figure 4.5: A high-level descriptive BPMN 2.0 illustration of a redesigned return-visit ambulatory HIV 
care workflow at AMPATH. Enhancements are color-coded in blue and show how toxicity data collection 
and analysis could be enhanced. AMRS – AMPATH Medical Record System 
 
4.4. Discussion 
The findings of this study suggest that ambulatory HIV care workflows in underserved settings are 
primarily designed to document care observations using structured encounter forms. Accordingly, 
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barriers to the recognition of antiretroviral toxicities in the workflow were pinpointed to the 
documentation and interpretation of patient-reportable and clinician-identifiable antiretroviral 
toxicity observations. This suggests that efforts should be directed towards improving the point-
of-care processes associated with the collection, analysis, and decision-making of antiretroviral 
toxicity data, possibly through the combined use of task-redistribution and guideline-based clinical 
decision support (CDS). 
The flow and sequence models described in this study corroborated the findings from previous 
studies that identified clinicians, particularly clinical officers (same as physician assistants in the 
United States), as the integral personnel in ambulatory HIV care workflows in underserved settings 
[21, 118]. This study also confirmed that the information generated by the ambulatory HIV care 
workflow is primarily consumed by the clinicians to support care planning activities such as 
prescribing medications, ordering laboratory tests and referring patients to other care providers 
[114]. These observations suggest that the application of CDS tools to enhance the quality of point-
of-care antiretroviral toxicity monitoring in underserved settings should target clinicians are the 
primary users. Furthermore, the content and functionality of such CDS tools should be tailored to 
the level of skills and knowledge of clinical officers (equivalent to physician assistants in the 
United States) who routinely provide HIV care in underserved settings. 
The observation that clinicians were the primary collectors of care information in the ambulatory 
HIV care workflow in underserved settings has important implications for enhancing point-of-care 
antiretroviral toxicity monitoring. The findings of this study suggest that clinicians in underserved 
settings bear the most burden of associated with the documentation of clinical observations. Such 
documentation is expected to be completed within a limited amount of time available to perform 
clinical duties as demonstrated by the time in motion study by Were et al. [21]. At the same time, 
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a considerable portion of the clinician’s time is spent on tasks that do not require specialized skills 
[21]. These observations mutually suggest that it is not desirable to have clinicians collect 
antiretroviral toxicity information data at the point-of-care and that redistributing these tasks to 
less-skilled but more readily available care providers could be more meaningful. Additionally, the 
studies by Were et al. [21] and Tierney et al. [113] demonstrate that patients in ambulatory HIV 
care workflows in underserved settings spend a considerable amount of time waiting to be seen by 
clinicians. This presents a valuable opportunity for collecting patient-reportable antiretroviral 
toxicity data, with the collected information subsequently used by the clinician during care 
delivery.  
This study had some important limitations. First, because the study analyzed the workflow in a 
single setting, the results may not be generalizable to other settings. Second, due to time and 
resource constraints, ethnographic data collection was limited to interviews with two conveniently-
selected stakeholders. This could have limited the variety of responses obtainable from interviews 
and could have made it difficult to ascertain the true state of the studied workflow. Nonetheless, 
supplementing the ethnographic approach with the rapid review of the literature reporting research 
conducted in the studied setting was used to triangulate and clarify the findings of the ethnographic 
interviews. However, using the rapid review process means relying on information that could be 
outdated to describe the workflows that evolve with time. 
4.5. Conclusions 
Overall, this study suggests that the barriers to point-of-care monitoring of antiretroviral toxicities 
within ambulatory HIV care workflows in underserved settings could be pinpointed to processes 
involving the documentation and analysis of patient-reportable and clinician-identifiable 
antiretroviral toxicity data. This research also demonstrates that opportunities for improving the 
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quality of point-of-care antiretroviral toxicity monitoring in underserved settings exist in the form 
of redistributing antiretroviral toxicity data collection tasks from clinicians to more readily 
available care providers, and capitalizing on patient clinic wait times to collect the data necessary 
for antiretroviral toxicity monitoring. Furthermore, opportunities exist for incorporating CDS tools 
that analyze patient-specific antiretroviral toxicity data and provide guideline-based 
recommendations that support clinician decision-making pertaining to antiretroviral toxicity 
monitoring. Future clinical research should explore the barriers and facilitators that are intrinsic to 
human actors in the studied workflow. Further clinical research is also needed to investigate the 
role of peer health workers in collecting patient-reportable antiretroviral toxicity symptoms. Future 
informatics research should explore the use of documentation and decision-aids to support the 
collection of antiretroviral toxicity data by lay health workers, and decision-making by clinicians. 
Additionally, since this study did not focus on workflow efficiency, future informatics research 





Chapter 5. Development of a knowledge-based application prototype implementing clinical 
guidelines for point-of-care antiretroviral toxicity monitoring 
5.1. Introduction 
The World Health Organization (WHO) recognizes the need to improve the monitoring of 
antiretroviral toxicity [2]. It places particular emphasis on underserved settings where the range 
and patterns of antiretroviral toxicities may alter the need for and frequency of antiretroviral 
toxicity monitoring [10]. The WHO recommends a symptom-directed antiretroviral monitoring 
approach where clinicians assess signs and symptoms reported by patients and subsequently draw 
conclusions about antiretroviral toxicities [2, 22]. However, the labor intensity associated with 
data gathering and analysis using the symptom-directed approach limits its utility in underserved 
settings which face health workforce challenges [11, 12]. Consequently, it is essential to develop 
strategies that improve the quality of the symptom-directed antiretroviral toxicity monitoring in 
underserved settings by facilitating documentation and decision-making. Empirical research 
evidence from underserved settings shows that the use of electronic point-of-care clinical decision 
support (CDS) tools in the clinical management of HIV improves adherence to HIV clinical 
guidelines and makes the collection, analysis, and interpretation of clinical data easier [14, 15]. 
However, there is little evidence to demonstrate how such tools could be applied to improve 
symptom-directed monitoring of medication safety within HIV care workflows. Furthermore, 
research in the development and application of standard definitions, formatting, and reporting 
associated with symptom-directed monitoring of antiretroviral toxicity is limited. 
A potentially useful approach to improving the quality of point-of-care antiretroviral toxicity 
monitoring in underserved settings is the adoption of knowledge-based CDS systems. The term 
‘knowledge base’ originates from the field of artificial intelligence and refers to a repository of 
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facts, heuristics, and models that represent domain knowledge that can be used for problem-solving 
and analysis of organized data [119]. Knowledge bases are distinct from databases as the latter are 
collections of individual observations without any problem solving or analytic functionality [119]. 
Unlike mathematical or statistical approaches that use numerical representation and arithmetic 
manipulation to quantitatively model relationships that support inferences in a given domain, 
knowledge-based approaches rely on symbolic manipulations that use ontologies and apply logic 
to draw conclusions from asserted facts [120, 121]. 
A knowledge-based system is a software application that uses the knowledge stored in its 
knowledge base to analyze problems and provide advice within a restricted domain and like human 
domain experts [121]. Knowledge-based systems are primarily developed and used to increase the 
reproducibility, scalability, and accessibility to complex reasoning and decision-making tasks 
[122]. Within the biomedical domain, a good example of a foundational knowledge-based system 
is the MYCIN system. This rule-based computer-assisted decision support system was developed 
in 1976 by Ted Shortliffe et al. to support inference on the selection of antibiotic therapy for 
patients with bacterial infections [121, 123]. Currently, knowledge-based systems are applied in 
several biomedical domains including but not limited to clinical decision support systems, 
surveillance in public health datasets, and hypothesis generation in large-scale research datasets 
[122]. 
The purpose of this chapter is to describe the construction of a knowledge-based application 
prototype that implements clinical practice guidelines for antiretroviral toxicity monitoring and 
that is intended to support the symptom-directed antiretroviral toxicity monitoring within HIV care 
workflows. This chapter presents an overview of the motivation for building the prototype, 
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describes the development process, and discusses the challenges in the design and construction of 
the prototype. 
5.2. Methods 
5.2.1. Problem Identification and Motivation 
The need for improved antiretroviral toxicity monitoring in underserved settings motivated the 
development of the prototype described in this chapter. Based on the studies described in Chapters 
3 and 4, the barriers to antiretroviral toxicity monitoring in underserved settings were pinpointed 
to processes involving documentation and interpretation of antiretroviral toxicity at the point of 
care. In brief, the key barriers include clinician time and workload constraints, limitations in the 
design of data collection forms, and the failure to capture the reasoning behind clinician decision-
making adequately. At the same time, the studies in Chapters 3 and 4 identified several 
opportunities to improve antiretroviral toxicity monitoring. These include the availability and 
acceptability of the use of lay health workers who could be trained to take up data collection duties, 
ample clinic wait times that could be used to collect additional patient-reported data, and the 
availability of electronic health record (EHR) data that could be analyzed for informed decision-
making. Accordingly, the construction of the knowledge-based application prototype described in 
this chapter was motivated by the desire to address the workflow barriers and capitalize on the 
opportunities described above. 
5.2.2. Development Objectives 
The objective of the development was to construct a knowledge-based application prototype that 
facilitates the documentation and analysis of antiretroviral toxicity data within ambulatory HIV 
care workflows. The prototype generates toxicity summary reports that describe possible 
antiretroviral toxicities detected from patient-specific EHR data. It also generates customized 
 82 
 
checklists that can be used to collect patient-reportable data and to identify possible antiretroviral 
toxicities experienced by individual patients. Similar to a diagnostic decision support system [124], 
clinicians can use both outputs of the prototype to confirm or rule out antiretroviral toxicities 
experienced by individual patients, and if necessary conduct additional assessments to narrow 
down diagnoses. These functionalities are described further below. 
a) Detection of antiretroviral toxicities and risk factors from structured EHR data 
The prototype generates summary reports describing possible antiretroviral toxicities and risk 
factors of antiretroviral toxicities identified from structured EHR data. The detection of 
antiretroviral toxicities by the prototype is based on the “Possible” causal category of the WHO-
UMC (World Health Organization-Uppsala Monitoring Center) system for standardized causality 
assessment [125]. The assessment criteria for this category requires the ascertainment of 
reasonable temporal association between medication administration and the occurrence of a 
toxicity. Therefore, causality by other medications or disease states cannot be ruled out. 
The prototype detects possible antiretroviral toxicities in EHR data via several steps as follows. 
First, the prototype queries longitudinal EHR data to select the list of medications that constitute 
the patient’s active antiretroviral regimen and the dates when each drug was first prescribed. Next, 
the prototype queries the longitudinal EHR data to select the clinical observations (signs, 
symptoms, clinical findings and laboratory findings) recorded in the EHR. Subsequently, for each 
pair of antireroviral drug and clinical observation, the prototype computes the difference between 
the date when the clinical observation was recorded and the date when the antiretroviral drug was 
ordered. It then compares the date differences to predetermined time frames and selects the 
observations having reasonable temporal relationships to medication orders. Lastly, the prototype 
matches the lists of selected medications and observations with the antiretroviral toxicity concept-
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concept relationships in its knowledge base to generate a list of possible antiretroviral toxicities as 
output. Accordingly, if the medication abacavir with the recording date 2017-01-14 is identified 
as active, and the observation rash with recording date 2017-01-25 is found in the EHR, then the 
prototype generates the output abacavir hypersensitivity since rash is a manifestation of 
hypersensitivity due to abacavir. 
The detection of possible risk factors proceeds similarly. However, some risk factor observations 
do not require temporal association with the administration of medications. For such risk factors, 
the prototype select lists of active medications and the list of observations (regardless of the dates 
when they were recorded) and matches these to the antiretroviral toxicity risk factor knowledge in 
its knowledge base. For example, if the medication nevirapine is identified as active and the 
observation female gender is also identified, then the prototype generates the output female gender 
is a risk factor of nevirapine hepatoxicity. 
Both outputs of the antiretroviral toxicity and toxicity risk factor detection are provided in the same 
summary report generated by the prototype. These reports are intended to assist professional 
clinicians conducting a symptom-directed assessment of antiretroviral toxicities within ambulatory 
HIV workflows. 
b) Generation of checklists for documenting antiretroviral toxicity 
The prototype generates checklists for documenting patient-reportable symptoms of antiretroviral 
toxicity. The contents of the checklists are tailored to the antiretroviral regimen in a patient’s 
current medication list. Accordingly, two patients on different treatment regimens would use 
different checklists. To generate a checklist, the prototype queries the patient’s longitudinal EHR 
data to select all antiretroviral medications in the patient’s current medication list. Next, it queries 
its knowledge base to select a list of ingredient-toxicity-toxicity observation triples that match the 
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previously identified antiretroviral toxicities. Accordingly, If abacavir was selected from the 
patient’s medication list, examples of triples selected from the knowledge base include abacavir-
hypersensitivity-fever, abacavir-hypersensitivity-rash, and abacavir-hypersensitivity-fatigue. This 
output is used to generate a checklist of symptoms matched to possible antiretroviral toxicities 
through many-to-many mappings. 
The checklists generated by the prototype are designed for use by lay health workers to collect 
data about the symptoms associated with possible antiretroviral toxicities during routine clinic 
visits. The collected data could then be used by clinicians to confirm or rule out possible 
antiretroviral toxicities or to guide further clinical evaluation of the patient. 
c) Additional functionalities 
The prototype has observation checker which enables the user to match symptoms and 
antiretroviral drugs to identify possible antiretroviral toxicities. The prototype also serves as a 
repository for general browsing of information about antiretroviral regimens including their 
constituents. This repository provides information about specific antiretroviral drug interactions 
and adverse reactions, as well as the guideline-based recommendations for their management. 
5.2.3. Development Process 
The overall goal of the development was to create a stable and functional knowledge-based 
application prototype that meets the objectives described in the previous section. The development 
of the prototype followed the the knowledge engineering cycle [122]. The key components of this 
process include knowledge acquisition, knowledge representation, system implementation, and 
system verification and validation [122]. Figure 5.1 illustrates knowledge engineering steps 




Figure 5.1: Illustration of the knowledge engineering process used to develop and evaluate the 
knowledge-based application prototype used in the dissertation 
a) Knowledge Acquisition 
Knowledge acquisition refers to the process of eliciting information from domain expert 
knowledge to create electronic knowledge bases [121]. Three key data sources from which the 
knowledge content of the prototype was derived were identified during knowledge acquisition. 
The WHO clinical practice guidelines on the use of antiretroviral drugs [2] was identified as the 
primary source of information about the key antiretroviral drugs, antiretroviral drug regimens, 
major antiretroviral toxicities, risk factors, and suggested management of antiretroviral toxicities. 
AIDSinfo, a United States government service that provides up-to-date information on federally 
approved HIV/AIDS medical practice guidelines and HIV/AIDS-related drugs [126] was 
identified as the primary reference for approved drug label information. It was used to provide 
knowledge about the clinical observations (signs, symptoms, clinical findings and laboratory 
findings) as well as their temporal associations with specific antiretroviral toxicities. Lastly, the 
United States National Library of Medicine (NLM) LiverTox® website [127] was identified as a 
resource for characterizing drug-induced liver injury. Information from the three data sources was 
primarily available in the form of unstructured and unannotated textual narratives. Table 5.1 
illustrates information from the three data sources using nevirapine hepatoxicity as an example. 
All the acquired information was manually analyzed and used to create a specification from which 
the knowledge-based application prototype was designed. 
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Table 5.1: Example of information in data sources illustrated using nevirapine hepatotoxicity 
Source Category Example 
WHO 
Guidelines 
Antiretroviral drug Nevirapine 
Regimen Tenofovir Disoproxil + Lamivudine + Nevirapine 
Major types of toxicity Hepatotoxicity 
Risk factors 
High baseline CD4 cell count (CD4 count >250 
cells/mm3 in women or >400 cells/mm3 in men) 
Suggested Management 
If hepatotoxicity is mild, consider substitution with 





The risk of symptomatic hepatic events regardless of 
severity is greatest in the first 6 weeks of therapy. The 
risk continued to be greater in the nevirapine groups in 
controlled clinical trials through 18 weeks of treatment. 
However, hepatic events may occur at any time during 
treatment. In some cases, patients presented with non-
specific, prodromal signs or symptoms of fatigue, 
malaise, anorexia, nausea, jaundice, liver tenderness or 
hepatomegaly, with or without initially abnormal serum 
transaminase levels. Rash was observed in approximately 
half of the patients with symptomatic hepatic adverse 
events. Fever and flu-like symptoms accompanied some 




Therapy with nevirapine is associated with significant 
elevations in ALT levels (above 5 times the upper limit 
of normal) in 4% to 20% of patients and symptomatic 
elevations in 1% to 5% of patients. These elevations are 
usually transient but can be symptomatic and may require 
discontinuation of nevirapine. 
 
b) Knowledge Representation 
Knowledge representation refers to the use of symbols to denote external facts in a form that 
facilitates reasoning and decision-making by an intelligent being or computer. According to Davis 
et al., a knowledge representation serves five key roles: a) It is a surrogate that supports inference 
through reasoning about things rather than by taking action upon them, b) It is a set of ontological 
commitments that determines what and how the world is perceived, c) It is a fragmentary theory 
of intelligent reasoning comprised of three components including the representation’s conception 
of intelligent reasoning, the set of inferences it sanctions, and the set of inferences it recommends, 
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d) It serves as a medium for pragmatic, efficient computation, and e) It serves as a medium of 
human expression that provides a language in which people can communicate about things [128]. 
The goal of the knowledge representation in the development of the prototype was to identify 
relevant entities and relationships from the data sources described in the knowledge acquisition 
step and to subsequently create a model that captures the semantics of the content of the data 
sources. The purpose of creating the model was to support reasoning about possible antiretroviral 
toxicities and their manifestations that could be inferred from both individual antiretroviral drugs 
and regimens (combinations of individual drugs). The knowledge representation task proceeded 
manually and iteratively. Concepts and relationships were identified from the knowledge resources 
selected for the development process. The information was modeled in a labeled property graph in 
which the concepts are represented as vertices (nodes), binary relationships between concepts are 
represented as edges, and labels represented concept categories. The labeled property graph was 
selected as the knowledge representation formalism as it provides an intuitive and easy to 
understand approach for modeling highly connected information [129]. 
c) Knowledge-based System Implementation 
The graph model was implemented in a knowledge base stored in a MySQL database. The content 
of this knowledge base was derived from the data sources identified during knowledge acquisition. 
Ingredients, multiple ingredients, and clinical drugs concepts and their relationships were 
described using RxNorm terms and codes [130]. Toxicities and the observations associated with 
toxicities were described using MedDRA (Medical Dictionary for Regulatory Activities) terms 
and codes [131]. Since both RxNorm and MedDRA are source vocabularies in the Unified Medical 
Language System (UMLS) [132], Concept Unique Identifiers (CUIs) and Atomic Unique 
Identifiers (AUIs) from the UMLS were also used to describe concepts in the prototype’s 
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knowledge base. Concepts and relationships that were not found in standard vocabularies were 
manually curated and incorporated into the prototype’s knowledge base. 
The knowledge-based application prototype was designed to be compatible with OpenMRS, an 
open-source medical record system that is widely used in underserved settings [64]. OpenMRS 
stores demographic, clinical, laboratory, and pharmacologic information as structured (coded) 
observations of concepts from a formal concept dictionary [133]. This dictionary is centrally 
maintained by the Columbia International eHealth Laboratory (CIEL) and maps concepts in 
OpenMRS to standard terminologies including SNOMED-CT (Systematized Nomenclature of 
Medicine – Clinical Terms) and RxNorm [133, 134]. To enable compatibility with OpenMRS, 
one-to-one mappings between the concepts in the prototype’s knowledge base and the concepts in 
the CIEL dictionary were identified and incorporated into the knowledge base. This was achieved 
by converting the UMLS CUIs in the prototype’s knowledge base to SNOMED-CT and RxNorm 
codes using relationships present in the UMLS, and subsequently converting these to CIEL codes 
using relationships present in OpenMRS. String-matching and manual comparisons were 
attempted for concepts that could not be mapped automatically using unique identifiers. Additional 
rule tables and queries were created to map CIEL concepts with categorical or numeric data types 
to single concepts in the prototype’s knowledge base. Accordingly, an observation in OpenMRS 
of the CIEL concept serum glucose having a numeric value less than 4 mmol/L is mapped to the 
MedDRA concept blood glucose decreased in the knowledge base. 
The prototype was implemented as a two-tier web database application. The web application 
interface of the prototype runs on a Java Client, while its knowledge base and inference engine run 




Figure 5.2: Two-tier web database application architecture of the knowledge-based prototype 
 
The web application employs a variety of technologies including JavaServer Pages (JSP), JSP 
Standard Tag Library (JSTL), JavaScript, HTML5, and Cascading Style Sheets (CSS). It 
communicates directly with the prototype’s MySQL database via the Java Database Connectivity 
(JDBC) Application Programming Interface (API) to enable user interaction with the prototype. 
Reasoning in the knowledge-based application prototype is achieved by ontology query. Ontology 
querying involves applications traversing the relationships linking individual entities in an 
ontology to answer questions about the entities’ relationships [120]. For example, to identify 
possible antiretroviral toxicities and toxicity risk factors of a given patient, the prototype queries 
the OpenMRS database and selects data from different tables in OpenMRS. For example, 
demographic information (e.g. age, and gender) is selected from the patient table, while encounter 
ids and encounter dates are selected from the encounter table. Clinical observations are selected 
from the observation table. Using the selected information, the query traverses relationships in its 
rule engine and knowledge base to arrive at the relevant conclusions about possible antiretroviral 
toxicities and risk factors. 
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d) Knowledge-based System Evaluation Plan  
Two investigations were proposed to validate the structure and behavior of the knowledge-based 
application (Chapter 6). The purpose of these evaluations was to prove that the prototype behaves 
as intended, and to identify design and implementation flaws that should be addressed in 
subsequent development iterations. Additionally, a study investigating the usability of checklists 
generated by the prototype was proposed (Chapter 7). 
5.3. Results 
5.3.1.  Knowledge Representation 
Figure 5.3 illustrates a high-level graph model that describes the term types (labels) and 
relationships in the prototype’s knowledge base. This model uses 15 term types and 22 
relationships to organize medication, regimen, and toxicity domain knowledge in a manner that 
support seamless reasoning through traversals of the relationships in the model. Medication 
knowledge (color-coded in green) is represented using the term types Ingredient, Multiple 
Ingredient, and Clinical Drug, and the relationships has_ingredient and has_part. Antiretroviral 
regimen knowledge (color-coded in blue) is represented using the term type Regimen and several 
abstract term types and relationships that describe how regimens are composed of sets of 
ingredients or sets of clinical drugs, and how they are used clinically. Antiretroviral toxicity 
knowledge (color-coded in red) is represented using the node Ingredient Toxicity which denotes 
a fact which describes the interaction of several term types engaged in the fact. Accordingly, a 
given ingredient toxicity fact would be comprised of the ingredient causing the toxicity, the actual 
toxicity caused, the risk factors of the toxicity, the clinical observations of the toxicity, and the 




Figure 5.3: High-level graph model for the antiretroviral toxicity domain. Vertices and edges shown in 
green are related to medications and their ingredients, those in blue are related to antiretroviral 
regimens, and those in red are related to ingredient toxicities 
 
Figure 5.4 is a more-detailed labeled graph model using an example of abacavir to illustrate how 
the actual entities and relationships in the knowledge base are conceptually organized. As evident 
from the model, the Ingredient, Multiple Ingredient, and Clinical Drug, together with the 
has_ingredient and has_part relationships are described using standard RxNorm terminology 
[130]. Some clinical drugs have single ingredients while others have multiple ingredients. For 
example, the clinical drug abacavir 300 mg oral tablet has the single ingredient abacavir, while 
the clinical drug abacavir 600 mg / dolutegravir 50 mg / lamivudine 300 mg oral tablet has the 
multiple ingredient abacavir / dolutegravir / lamivudine. Intuitively, each multiple ingredient is 
comprised of several single ingredient parts. For example, the multiple ingredient abacavir / 





Figure 5.4: Illustration of the knowledge base specification using entities and relationships associated 
with abacavir-containing medications and regimens. Vertices and edges shown in green are related to 
medications and ingredients, those in blue are related to antiretroviral regimens, and those in red are 




The vertex Clinical Drug Set denotes the fact that individual antiretroviral drugs are elements of 
unique sets of clinical antiretroviral drugs, and that each set constitutes a specific antiretroviral 
therapy regimen. For example, abacavir 600 mg oral tablet is an element of the set [abacavir 600 
mg oral tablet, dolutegravir 50 mg oral tablet, lamivudine 300 mg oral tablet], and this set 
constitutes the regimen Abacavir (ABC) + Lamivudine (3TC) + Dolutegravir (DTG). Similarly, 
the vertex Ingredient Set was introduced to denote the fact that individual antiretroviral 
ingredients or multiple ingredients are elements of unique ingredient sets that, in turn, constitute 
specific antiretroviral therapy regimens. For example, the abacavir is an element of the set 
[abacavir, lamivudine, dolutegravir] which constitutes the regimen ABC + 3TC + DTG. 
The vertex Regimen denotes a clinically useful combination of antiretroviral drugs. Each 
Regimen has at least one use and can intuitively be thought of as containing more than one 
ingredient. The vertex Regimen Use in the graph denotes the guideline-recommended uses of each 
regimen. In the model, this vertex represents a regimen use case fact that arises from combination 
of the vertices Regimen Preference, Regimen Line, and Regimen Age Group that denote the 
preference (e.g. preferred vs alternative), the line of therapy (e.g. first line vs second-line) and the 
age group (e.g. Adult vs adolescent) respectively. As an example, the regimen ABC + 3TC + DTG 
is recommended for use as an alternative first-line therapy for adolescents. A regimen use case 
may have a substitute regimen. For example, among adolescents, ABC + 3TC + DTG can be 
substituted with the first-line Tenofovir (TDF) + Emtricitabine (FTC) + and Efavirenz (EFV) or 
the second-line regimen Zidovudine(AZT) + Lamivudine (3TC) + Atazanavir / Ritonavir (ATV/r). 
As previously described, the vertex Ingredient Toxicity denotes a fact associated with a specific 
antiretroviral toxicity instance. This fact relates the Ingredient, Toxicity, Risk Factor, Toxicity 
Observation and Suggested Management vertices to denote the causal agent of a given toxicity, 
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the actual toxicity caused, the risk factors of the toxicity, the clinical observations of the toxicity, 
and the suggested management of the toxicity respectively. For example, abacavir may cause 
abacavir hypersensitivity. Here, the toxicity is hypersensitivity, the risk factor is the presence of 
the HLA-B*5701 allele, and examples of toxicity observations include rash and fever. The 
recommendation for this toxicity is do not use abacavir in the presence of HLA-B*5701 allele. 
Lastly, abacavir can be substituted with zidovudine. 
5.3.2. System Implementation 
Table 5.2 summarizes the pertinent information in the prototype’s knowledge base. The knowledge 
base contains 47 major antiretroviral toxicities caused by 11 antiretroviral ingredients and 
associated with 41 risk factors. The knowledge base also contains 126 unique manifestations of 
antiretroviral toxicities that are comprised of 75 signs and symptoms, 11 clinical findings and 40 
laboratory findings. In addition to using MedDRA’s preferred terms, the signs and symptoms are 
described using low-level terms and their Swahili translations for local use by lay health providers. 
For example, the preferred term pyrexia is also described using the low-level term fever and its 
Swahili translation homa. The knowledge base provides information about 74 unique sets of 
ingredients that compose 38 different antiretroviral regimens. These regimens are associated with 
20 unique uses defined by 4 age group categories (adults (older than 19 years) vs adolescents (10 
years to 19 years) vs children (3 years to 9 years), children(younger than 3 years)), 3 preference 
categories (preferred vs. alternative vs. special circumstance) and 2 therapy line (first-line vs 
second-line). 
A total of 707 out of 974 (72.6%) unique identifiers were created to describe entities in the 
knowledge base that could not be found in existing standard vocabularies. Majority of these 
pertained to the characterization of the composition and use of antiretroviral regimens. 
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Table 5.2: Definitions, examples, counts (n), sources of term types, and concept identifies in the 
prototype’s knowledge base 





Ingredient The moiety giving a 
drug its properties 
Abacavir 11 WHO RxCUIs 
Multiple 
Ingredient 
Preparation with two 
or more ingredients 
Abacavir /dolutegravir / 
lamivudine 
13 RxNorm RxCUIs 
Clinical Drug A consumable product 
(Ingredient + Strength 
+ Dose Form) 
Abacavir 300 MG Oral 
Tablet 
72 RxNorm RxCUIs 
Toxicity An adverse drug 
reaction 




An adverse drug 




47 WHO Identifiers 
Created 
Risk Factor Attribute increasing 
the likelihood of an 
ingredient toxicity 
Presence of the HLA-
B*5701 (risk factor for 
abacavir hypersensitivity) 




Manifestations of an 
ingredient toxicity 







an ingredient toxicity 
Do not use abacavir in the 
presence of HLA-B*5701 
27 WHO Identifiers 
Created 
Regimen Combined use of three 
or more drugs  
Abacavir + Lamivudine + 
Dolutegravir 















Set of two or more 
clinical drugs 
[abacavir 600 mg oral 
tablet, dolutegravir 50 mg 
oral tablet, lamivudine 
300 mg oral tablet] 





Regimen Use A fact defining the use 
of a particular regimen 
Abacavir + Lamivudine + 
Dolutegravir as an 
alternative first-line 
regimen for adolescents 





group for a regimen 
Adolescents (10 to 19 
years) 




Priori of a regimen for 
an age group 





sequence of therapy 




Table 5.3: Proportion of standard vocabulary concepts in the prototype’s knowledge base not found in the 
CIEL dictionary used in OpenMRS stratified by term type 
Term Type Proportion Missing Concepts 




Abacavir / Dolutegravir / Lamivudine; Emtricitabine / Rilpivirine / 
Tenofovir Disoproxil; Cobicistat / Elvitegravir / Emtricitabine / 
Tenofovir Disoproxil; Atazanavir / Cobicistat; Cobicistat / Darunavir 
Toxicity 12/45 (26.7%) 
Allergic Hepatitis; Bone Density Decreased; Gastrointestinal 
Toxicity; Haematotoxicity; Hepatic Enzymes Increased; Hepatitis 
Flare; Hypersensitivity; Lipohypertrophy; Mixed Liver Injury; 




Signs and Symptoms: Blisters; Cold sweat; Fat atrophy; Limb 
lipoatrophy; Liver tenderness; Peripheral lipodystrophy;  
Lab Findings: Alanine aminotransferase increased; Ammonia 
increased; Amylase increased; Aspartate aminotransferase increased; 
Blood albumin decreased; Blood alkaline phosphatase increased; 
Blood bicarbonate decreased; Blood creatine phosphokinase 
increased; Blood creatinine increased; Blood lactic acid increased; 
Blood phosphorus decreased; Blood uric acid decreased; 
Eosinophilia; Fractional excretion of phosphate; Glomerular filtration 
rate decreased; Hepatitis B DNA increased; Hepatitis C RNA 
increased; High density lipoprotein increased; Lipase increased; Low 
density lipoprotein increased; Mean corpuscular volume increased; 
Urinary beta2 microglobulin increased; Urine protein/creatinine ratio 
increased; Urine retinol binding protein increased 
 
Table 5.3 describes the standard vocabulary concepts in the prototype’s knowledge base that were 
not found in the CIEL dictionary used in OpenMRS through mapping. The missing ingredient and 
multiple ingredient concepts represent medications such as rilpivirine and elvitegravir not 
commonly found in underserved settings (at the time of development of the prototype). Most of 
the missing toxicity observations concepts were attributable to categorical interpretations of 
laboratory findings using MedDRA terms but which could be described using concepts of the 
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numeric datatype in the CIEL dictionary. For example, amylase increased in MedDRA would have 
a similar meaning to test amylase in CIEL having a value larger than its upper limit of normal. 
5.4. Discussion 
Summary of findings 
This chapter describes the objectives and process used for the development of a knowledge-based 
application prototype designed to address challenges associated with the collection and analysis of 
antiretroviral toxicity data within HIV care workflows in underserved settings. The prototype 
functions as diagnostic decision support system [124] and generates outputs that can be used by 
care providers to confirm or rule out antiretroviral toxicities from patient-reported data. Whereas 
efforts have been made to apply clinical decision support tools at the point-of-care in underserved 
settings [14, 15], the work presented in this chapter is one of the first to focus on improving the 
quality of antiretroviral toxicity monitoring. 
The key innovative contribution of this research is the creation of a conceptual model that related 
knowledge about regimens, ingredients, and toxicities. This is a key addition to the traditional drug 
information models which describe drug use knowledge based on individual drugs rather than 
combinations of drugs. Since prescriptions are usually regimen-based, it is critical to understand 
how toxicities to individual drugs impact the regimen selection. Models like the one described in 
this chapter would provide a good basis for providing and automating such reasoning.  
Other researchers have developed knowledge representations for medication-related information. 
For example, Sharp ME developed a database of drug-indication relations by aggregating 
information from raw data in 12 drug information evidence sources [135]. Bousquet et al. created 
an ontology that maps adverse drug reactions to anatomical locations described in the Foundational 
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Model of Anatomy (FMA) [136, 137]. The Observational Health Data Sciences and Informatics 
(OHDSI) collaborative developed a standardized drug knowledge base system called LAERTES 
that provides pharmacovigilance evidence about the associations between drugs and health 
outcomes of interest [138]. While all these research efforts have significantly contributed to 
understanding medication domain knowledge, none of them explicitly models relationships among 
medications, medication regimens, and adverse reactions as described in this chapter. Accordingly, 
the model created in this dissertation presents valuable opportunities for future research in 
medication knowledge management. 
Development Challenges 
The application of automated CDS technologies at the point-of-care holds the promise of 
improving care delivery efficiency and effectiveness [100]. However, the construction of 
knowledge-based applications for supporting antiretroviral toxicity monitoring presents major 
challenges. For example, knowledge about antiretroviral medications and the toxicities they cause 
were obtained from different evidence sources. The variations in definitions, meanings, 
granularities, and interpretations used in the evidence sources, and the lack of automated methods 
to support knowledge acquisition made the development process difficult and time-consuming. 
Furthermore, variations were also identified within different sections of the same resources. For 
example, similar facts were expressed using varied semantics in different sections of structured 
product labels (e.g., black box warning vs. prescribing section vs. patient counseling information 
section). Such variations may affect the behavior and analysis of knowledge-based applications 
[138]. Moreover, in some instances, evidence sources such as clinical guidelines provided vague 
information that introduced additional work. For example, the WHO guidelines describe the 
concomitant use of hepatotoxic drugs as a risk factor for nevirapine hepatotoxicity. Additional 
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time and effort was required to identify the list of hepatotoxic drugs whose concomitant use with 
nevirapine would increase the probability of nevirapine hepatotoxicity. 
The need to target diverse groups of users who are likely to have different skills, knowledge, and 
experiences also presented a challenge in the development of knowledge bases. For example, to 
facilitate use by both clinicians and lay health workers in the targeted underserved setting, it was 
necessary to incorporate interface terms and synonyms that closely represents how these cadres 
would perceive antiretroviral toxicity knowledge. Accordingly, low-level terms and their Swahili 
language translations were required for the symptom data collection forms intended for use by lay 
health workers, while more technical terms were used for the reports intended for clinicians. 
Challenges in the development of the knowledge base also arose from difficulties associated with 
the integration of concepts and relationships into the knowledge base. Textual information from 
evidence sources had to be processed and mapped to MedDRA, RxNorm and UMLS concepts. 
Additionally, content such as risk factors and antiretroviral regimen information which did not 
have concepts in standard vocabularies had to be manually curated. Furthermore, due to imperfect 
mapping between source vocabularies, some relationships between concepts from different 
sources, e.g., ingredients in RxNorm and toxicities in MedDRA had to be created. 
Lastly, the choice of the implementation formalism has a bearing on the difficulty of knowledge 
base development. For example, implementing complex knowledge models and reasoning in 
structured query language (SQL) databases may be time intensive and error prone due to the 






The development process described in this chapter had some limitations. First, due to time and 
resource constraints, the development of the prototype was conducted by few individuals, over a 
short period of time, and with minimal involvement of potential end users. However, the goal of 
the development was to create a viable prototype that forms the foundation upon which future 
development iterations would be based. Additionally, the development proceeded iteratively with 
close supervision and crosschecking from domain experts. Second, domain knowledge sources 
were limited to clinical care guidelines, approved product labels, and domain expert knowledge. 
However, the selected information sources were relevant, from reputable institutions, and up-to-
date. Even so, it is possible that using different sources would result in different structure and 
behavior of the developed knowledge-based application. Lastly, the current version of the 
application does not have uncertainty management functionalities. This limits the potential for 
actual clinical use of the prototype before further development iterations. 
5.5. Conclusions 
Knowledge-based CDS tools could play a fundamental role in improving the quality of point-of-
care antiretroviral toxicity monitoring. However, the success of such tools not only depends on the 
rigor of their development but also on how they represent domain knowledge. An innovative 
contribution of the work described in this chapter is the creation and implementation of a model 
that enables automated reasoning about antiretroviral toxicities caused by medication and 
regimens. The development process resulted in a stable, functional prototype which could be useful 
for facilitating the documentation and analysis of antiretroviral toxicity data at the point-of-care. 
Moreover, the models and artifacts generated from the development process could serve as a basis 
for the development of similar systems in other disease domains. Additional research is needed to 
 101 
 
study uncertainty management functionalities in the application and to investigate more efficient 
approaches for updating the knowledge base in the prototype. Future work should also focus on 






Chapter 6. Validating the structure and behavior of a knowledge base implementing 
clinical guidelines for point-of-care antiretroviral toxicity monitoring 
6.1. Introduction 
As previously described in Chapter 5, the term ‘knowledge base’ refers to a repository of facts, 
methods, and models that represent domain knowledge that can be used for problem-solving and 
analysis of organized data [119]. Consequently, the term ‘knowledge-based system’ refers to a 
software system that utilizes the knowledge stored in a knowledge-base to analyze problems and 
provide advice within a restricted domain and in a manner similar to human experts [121]. 
Knowledge-based systems are foundational applications in biomedical informatics that have 
remained popular to date [121-123]. Part of the reason for the popularity of knowledge-based 
systems is the fact that they are particularly useful where symbolic problem solving is preferred 
over arithmetic or numerical reasoning, as exemplified by the deduction of clinical diagnoses from 
observations of symptoms and laboratory findings [120, 121]. 
During the development of a knowledge-based application and before it is deployed for actual use, 
it is essential to validate that its structure and behavior are free of detrimental design flaws [139]. 
Validation studies assess the quality of a knowledge-based application by examining the functional 
completeness and the predictive accuracy of its knowledge base [140]. These evaluations assess 
whether the knowledge base satisfactorily represents domain knowledge and whether domain 
experts who did not participate in the development of the knowledge-base application agree that 
the information, rules, and procedures in the knowledge base are complete and accurate [140]. 
While structural comparisons evaluate the similarities in how a knowledge base and non-design 
experts conceptualize and structurally represent knowledge, behavioral validation uses test cases 
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to evaluate the similarity and compare the accuracy of outputs made by the knowledge base and 
by non-design experts [139, 140]. 
In this dissertation, a knowledge-based application prototype that implements standard clinical 
guidelines for the point-of-care monitoring of antiretroviral toxicities was developed (Chapter 5). 
The prototype analyzes structured data in a patient’s longitudinal electronic health records (EHR) 
to identify the antiretroviral drugs that the patient is currently using. It then generates a report that 
describes the risk factors, signs, symptoms, and laboratory findings observed in the EHR that could 
be related to possible toxicities associated with the identified antiretroviral drugs. 
In this chapter, the validation of the structure and behavior of the prototype’s knowledge base is 
described. The goals of the analyses were to ascertain that the prototype’s knowledge base contains 
the correct antiretroviral toxicity domain knowledge and generates patient-specific antiretroviral 
toxicity reports that are sufficiently accurate for clinical use. The purpose of the structural 
validation was to quantitatively evaluate whether the concept-concept relationships between the 
medications, toxicities, and toxicity observations asserted in the prototype’s knowledge base were 
accurate structural representations of domain knowledge. The purpose of the behavioral validation 
was to quantitatively evaluate the similarity and accuracy of the detection of antiretroviral 
toxicities, toxicity risk factors, and toxicity observations by the prototype and by non-design 
experts for a random sample of test cases. 
6.2. Methods 
6.2.1. Structural Validation 
The goal of the structural validation was to compare the concept-concept relationships in the 
prototype’s knowledge base to those provided in publicly available domain drug evidence sources. 
The smallest unit of the evaluation was defined as a distinct ingredient-condition pair consisting 
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of an ingredient and an associated health condition of interest, e.g., Abacavir and Fever. The main 
outcome was defined as the proportion of ingredient-condition pairs in the prototype’s knowledge 
base that existed in one or more of the evidence sources used in the study. 
The structural validation procedure involved several steps. First, candidate drug knowledge 
evidence sources for the structural comparisons with the prototype were identified and 
preprocessed for analysis. After an informal search of published and gray literature, two 
knowledge sources were identified and included in the study: the Large-Scale Adverse Effects 
Related to Treatment Evidence Standardization (LAERTES) and the Side Effect Resource 
(SIDER) 4.1 database. LAERTES is a standardized drug knowledge base system that provides 
evidence about the associations of drugs with different health outcomes of interest [138]. 
LAERTES provides evidence from different sources including structured product labels, 
spontaneous reporting, and biomedical literature [138]. The SIDER 4.1 database provides 
information extracted from public documents and product labels about marketed medicines and 
their recorded adverse reactions [141, 142]. In both resources, evidence on adverse drug reactions 
are identified as pairs of drugs and the associated health conditions (e.g., Nevirapine-Fever), and 
the data can be downloaded via online web portals. In this study, only the data associated with the 
11 antiretroviral drugs coded in the prototype’s knowledge base (Chapter 5) were extracted from 
the two knowledge source datasets. 
Next, the extracted data were preprocessed by remapping the concept identifiers used in the source 
knowledge bases to unique RxNorm and UMLS concept identifiers. Ingredient and health 
condition concepts in the LAERTES dataset are described using unique concept identifiers in the 
Standard Vocabulary provided by the Observational Health Data Sciences and Informatics 
(OHDSI) consortium [138, 143]. In this study, the ingredient concept identifiers in LAERTES 
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were converted to their equivalent RxNorm concept unique identifiers (RxCUIs) using 
relationships present in the OHDSI Standard Vocabulary. The health condition concepts in 
LAERTES were first converted to their equivalent SNOMED-CT (Systematized Nomenclature of 
Medicine – Clinical Terms) codes using relationships present in the OHDSI Standard Vocabulary, 
and subsequently, to the UMLS concept unique identifiers (CUIs) using relationships present in 
the UMLS. Ingredient concepts in the SIDER dataset are described using codes derived from 
PubChem compound identifiers, while the health condition concepts are described using UMLS 
CUIs associated MedDRA terms. The ingredient identifiers in SIDER were manually converted to 
the equivalent RxNorm RxCUIs by comparing ingredient names, while the adverse reaction 
concepts in SIDER were used as provided. 
Preprocessing also involved transforming the data set from the prototype’s knowledge base from 
the ingredient-toxicity-toxicity observation triple format to the ingredient-condition pairs format 
to enable direct comparisons with relationships present in the evidence sources used in the study. 
For example, the triple Abacavir-Hypersensitivity-Fever was transformed into the ingredient-
toxicity pair Abacavir-Hypersensitivity and ingredient-observation pair Abacavir-Fever. 
The final step of the structural validation process was the comparison of the ingredient-condition 
pairs selected from the prototype and from the evidence sources. The analysis was done in R [144] 
and involved describing the proportion of ingredient-condition pairs in the prototype that could be 
found in the evidence sources used. This proportion was computed as the number of ingredient-
condition pairs in common between the prototype and a given evidence source divided by the total 
number of ingredient-condition pairs in the prototype. The analyses were also stratified by 
knowledge base system (LAERTES vs. SIDER), and by evidence source type (literature vs. 
spontaneous reporting vs. product label). Manual semantic similarity assessments were conducted 
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for the ingredient-condition relationships in the prototype that could not be matched to the 
relationships in LAERTES or SIDER automoatically. Lastly, the test for one proportion was used 
to assess the research hypothesis that >80% of the ingredient-condition relationships in the 
prototype are equivalent to ingredient-condition relationships present in LAERTES or SIDER. 
6.2.2. Behavioral Validation 
The goal of the behavioral validation was to evaluate the prototype’s ability to detect antiretroviral 
toxicities, risk factors, and toxicity observations (symptoms, signs, and laboratory findings) from 
structured patient data. This was achieved by comparing the similarities and the accuracies reports 
generated by the prototype and by human experts for test cases selected at random. The 
comparisons were conducted in two forms: a) an unrestricted form in which the universe of 
possible responses was not restricted, and b) a restricted form in which possible responses were 
constrained to the knowledge content available in the prototype’s knowledge base. The procedural 
steps used in the study was loosely based on the framework for validation of rule-based systems 
by Knauf et al. [145] and was in concordance with standard procedures for evaluating knowledge 
bases [140]. The Knauf framework describes a process involving the generation of test scenarios 
and the use of a Turing Test-like approach to evaluating the responses of a rule-based system to 
the test scenarios [145]. The key steps applied in this study were test case generation, test case 
presentation and experimentation, and data analysis. These steps are described below. 
a) Test Case Generation 
The first step of the behavioral comparisons was the creation of test cases. In this study, the test 
cases were derived from raw data in published case reports on antiretroviral toxicities. In October 
2016, a literature search was conducted to identify published case reports on antiretroviral 
toxicities. This search was based on the major types of antiretroviral toxicities described in the 
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World Health Organization’s Consolidated Guidelines [2]. Table 6.1 lists the antiretroviral 
toxicities of interest. The case reports were identified by electronically searching the Ovid 
Medline® database. The search strategy involved the use of medical subject heading (MeSH) 
terms and search strings associated with the antiretroviral toxicities of interest and was limited to 
case reports having abstracts and published in English between the year 2000 and 2016. Table 6.2 
lists the queries used to obtain the case reports. A total of 114 case reports were identified out of 
which 6 duplicates were removed. 
Four reviewers independently reviewed the titles and abstracts of the case report articles retrieved 
from the search. Each article was independently reviewed by two reviewers, and each reviewer 
reviewed 54 articles. A fifth reviewer (myself) reviewed all the 108 articles and acted as a tie-
breaker during the selection of the articles. The goal of the review was to identify antiretroviral 
toxicity case reports in which the responsible medication, as well as the patient biodata, signs, 
symptoms and laboratory findings, were reported. Reviewers were asked to include an article if 
and only if an adverse drug reaction was reported or described, the culprit drug was mentioned, 
and the reported case was about HIV/AIDS. They were also asked to identify the case reports that 
described patient characteristics such as age, gender, and weight as well as signs, symptoms, and 
laboratory findings. The reviewers were asked to exclude case reports that were solely about the 
use of antiretroviral medications for the management of hepatitis infections, reports that only 
addressed treatment efficacies and reports that were about genetics, tumors, or immunotherapy. 
The consensus between pairs of reviewers who reviewed the same case reports was estimated using 
percent agreement and Cohen’s Kappa (Table 6.3). The ratings from reviewer 1 were dropped 
based on the high rate disagreements with the other reviewers. A total of 62 cases were identified 
from the 55 articles that were eventually included in the study.  
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Table 6.1: Major antiretroviral toxicities described in the WHO HIV guidelines 
ARV Toxicity 
Abacavir • Hypersensitivity reaction 
Atazanavir/r • Electrocardiographic abnormalities (PR and QRS interval prolongation) 
• Indirect hyperbilirubinemia (clinical jaundice) 
• Nephrolithiasis 
Zidovudine • Severe anemia, neutropenia 




Darunavir/r • Hepatotoxicity 
• Severe skin and hypersensitivity reactions 
Dolutegravir • Hepatotoxicity 
• Hypersensitivity reactions 
Efavirenz • Persistent central nervous system toxicity (such as dizziness, insomnia, abnormal 
dreams) or mental symptoms (anxiety, depression, mental confusion) 
• Convulsions 
• Hepatotoxicity 
• Severe skin and hypersensitivity reactions 
• Gynecomastia 
• Severe skin and hypersensitivity reactions 






Nevirapine • Hepatotoxicity 
• Severe skin rash and hypersensitivity reaction, including Stevens-Johnson syndrome 
Raltegravir • Rhabdomyolysis, myopathy, myalgia 
• Hepatitis and hepatic failure 
• Severe skin rash and hypersensitivity reaction 
Tenofovir • Chronic kidney disease 
• Acute kidney injury and Fanconi syndrome 
• Decreases in bone mineral density 




Table 6.2: Terms and strategy for literature search in Ovid Medline 
 
Search Results 
1 (Abacavir or ABC or Atazanavir or ATV or "ATV/r" or Dolutegravir or DTG or 
Darunavir or DRV or "DRV/r" or Efavirenz or EFV or Etravirine or ETV or ETR or 
Lopinavir or LPV or "LPV/r" or Nevirapine or NVP or Raltegravir or RAL or Tenofovir 
or TDF or Zidovudine or ZDV or AZT).ti. 
15423 
2 ("Drug-Related Side Effects and Adverse Reactions" or "Acidosis, Lactic" or "Acute 
kidney injury" or "Bone density" or "Drug Hypersensitivity" or "Drug-Induced Liver 
Injury" or "Fanconi syndrome" or "Fatty Liver" or "Heart Conduction 
System/abnormalities" or "Muscular Diseases" or "Renal Insufficiency, Chronic" or 
"Sleep Initiation and Maintenance Disorders" or Anemia or Anxiety or Confusion or 
Depression or Diarrhea or Dizziness or Dreams or Dyslipidemias or Gynecomastia or 
Hepatomegaly or Hyperbilirubinemia or Jaundice or Lipodystrophy or Nephrolithiasis or 
Neutropenia or Pancreatitis or Rhabdomyolysis or Seizures).sh. 
593315 
3 ("adverse drug reaction" or "adverse reaction" or "adverse drug event" or "adverse 
reaction" or "adverse event" or "toxicity" or allerg$ or "Abnormal Dreams" or "Acute 
kidney failure" or "Acute kidney injury" or "Acute renal failure" or "An?emia" or "Bone 
density" or "bone mineral density" or "breast enlargement" or "Central Nervous System 
Toxicity" or "Chronic Kidney Disease" or "Chronic Kidney Failure" or "Chronic Kidney 
Insufficiency" or "Chronic Renal Disease" or "Chronic Renal Failure" or "Chronic Renal 
Insufficiency" or "Drug-Induced Liver Injury" or "Electrocardiographic abnormalities" 
or "Enlarged Liver" or "Fanconi syndrome" or "Fatty Liver" or "Heart Conduction 
disorder" or "Hepatic failure" or "Hepatic Injury" or "Hepatic toxicity" or 
"Hepatomegaly" or "Hyperbilirubin?emia" or "Icterus" or "Jaundice" or "Kidney Stone" 
or "Kidney Stones" or "Lactic Acidosis" or "Liver Enlargement" or "Liver failure" or 
"Liver injury" or "Liver toxicity" or "loose bowel movement" or "Mental symptoms" or 
"Muscular Disease" or "Nephrolithiasis" or "Neutrop?enia" or "PR interval prolongation" 
or "QRS interval prolongation" or "QT interval prolongation" or "Renal colic" or "Renal 
Lithiasis" or "Skin reaction" or "Steatosis" or allerg$ or Anxiety or Cholesterol or 
Cholesterol?emia or Confusion or Convulsion? or Depression or Diarrh?ea or Dizziness 
or Dyslipidemia or Eruptions or Gyn?ecomastia or Hepatitis or Hepatotoxicity or 
Hypercholesterol?emia or Hypersensitivity or Hypertriglycerid?emia or Insomnia or 
Lipoatrophy or Lipodystrophy or Myalgia or Myopathy or Pancreatitis or Rash or 
reaction or Rhabdomyolysis or Seizure? or Triglycerid?emia or Triglycerides).ti,ab,kw. 
2315763 
4 (Didanosine or ddI or Stavudine or d4T or Saquinavir or SQV or Indinavir or IDV or 
Tipranavir or TPV or Fosamprenavir or FPV or Rilpivirine or RPV or Cobicistat or 
COBI or Elvitegravir or EVG or Pharmacokinetics or Pregnancy or "Postpartum Period" 
or Postpartum or Infant or Child or "in vitro" or Prophylaxis or transplant or 
Transplantation or neonate or "chronic hepatitis B" or Efficacy).ti. 
4470056 
5 animal/ not (human/ and animal/) 4285612 
6 (1 and (2 or 3)) not (4 or 5) 2137 
7 limit 6 to (abstracts and english language and "case reports" and yr="2000 - 2016") 114 





Table 6.3: Inter-rater reliability between reviewers 
Raters Percent Kappa 
rater1 & rater2 61.1 0.2 
rater1 & rater5 70.4 0.4 
rater2 & rater5 90.7 0.8 
rater3 & rater4 92.6 0.8 
rater3 & rater5 92.6 0.8 
rater4 & rater5 96.3 0.9 
 
The 62 cases, available as raw textual narratives, were structured and annotated to enable input 
and analysis by the prototype developed in the dissertation. The annotation was done using the 
National Center for Biomedical Ontology (NCBO) Annotator. The NCBO Annotator is an 
ontology-based web service for annotating raw texts with ontology concepts from several 
biomedical terminology vocabularies in the Unified Medical Language (UMLS) Metathesaurus 
and the NCBO Bioportal repositories [146, 147]. For example, the text “A female patient using 
Amoxicillin complained of Rash” would be annotated with several UMLS concepts including 
female (CUI C0086287), amoxicillin (CUI C0002645), rash (CUI C0015230). The annotation 
process in this study was done via the NCBO Annotator’s Representational State Transfer (REST) 
Web Service, with the ontology sources restricted to RxNorm, MEDDRA, and LOINC. 
The resulting annotations for each of the 62 cases were manually categorized into 5 categories: 
descriptive characteristics (e.g., age, weight, gender), comorbidities, medications, 
signs/symptoms/findings, and laboratory test results. Two reviewers independently reviewed the 
structured annotations for each case. The goals of this review were to counter check if the 
annotated concepts were indeed present in the raw text of the case, to identify redundant and 
synonymous concepts, to add concepts that were not identified by the annotator, and to fill in 
numeric values and reference ranges for concepts that had numeric values. The two reviewers 
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compared their reviews for each case with discrepancies solved by consensus after confirmation 
with the raw text for the case in question. A stratified random sampling procedure was used to 
select the 15 test cases that were presented to the prototype and the experts in the study. 
Stratification by the type of antiretroviral medications and the type of antiretroviral drug toxicities 
was used to minimize sample selection bias. 
b) Test case presentation and experimentation 
Each test case was described as a pair of input test data and the corresponding output responses. 
An example of a test case is illustrated in Figure 6.1. The input test data for a given test case was 
comprised of structured lists of the biodata, comorbidities, medications, signs/symptoms/findings, 
and laboratory test results. The input data was presented in two formats. In the first format, the test 
data was presented as observations in an OpenMRS database (MySQL) to enable analysis by the 
prototype. In the second format, the input data for a given test case was presented as a structured 
clinical vignette for the human experts using Google Forms. The output for a given test case was 
defined as lists of 1) Possible antiretroviral toxicities, 2) Possible antiretroviral toxicity risk factors, 
and 3) Possible antiretroviral toxicity observations (signs, symptoms, and laboratory results). 
All the 15 selected test cases were processed by the prototype and 5 human experts who did not 
participate in the development of the prototype. The prototype processed the input data by querying 
its knowledge base and generating lists of 1) Ingredient-Toxicity pairs, 2) Ingredient-Toxicity-
Risk Factor triples and 3) Ingredient-Toxicity-Toxicity Observation triples. The human experts 
processed the input data by selecting choices to three multi-answer questions about each test case: 
1) What antiretroviral toxicities could plausibly be identified from the case above? 2) What 
antiretroviral toxicity risk factors could plausibly be identified from the case above? 3) What 




Figure 6.1: Example of the input data (blue) and corresponding output data (green) that constitute a Test 
Case used in the study. 
c) Data Evaluation 
The evaluation methodology applied in this study was leveraged from Hripcsak et al.’s 
foundational work on evaluating the automated detection of clinical conditions from narrative 
reports using natural language processing [148]. As previously described, the evaluation entailed 
comparing responses generated by 5 experts and 1 prototype for 15 randomly selected test cases. 
An additional algorithm that randomly guessed responses with 50% chance of getting the correct 
answer (based on a majority vote by the experts) was added for comparison. The primary outcome 
of the behavioral evaluation in this study was the pairwise inter-subject judgmental dissimilarity 
quantified by the Jaccard distance. Specifically, this distance was defined as one minus the number 
of response elements in common between the sets of responses by a subject 𝑗 and a subject 𝑘 
divided by the number of response elements by the two subjects for a given test case 𝑖 as described 
in the equation below. The Jaccard distance has a range 0 ≤ 𝑑𝑖𝑗𝑘(𝑋, 𝑌) ≤ 1 with a higher value 
implying greater dissimilarity. 
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The average Jaccard distance between each pair of subjects was computed as the mean Jaccard 
distance across all the 15 test cases in the study. For each expert, the mean Jaccard distance from 
the other 4 experts was computed. For non-expert subjects, the mean Jaccard distance from all the 
5 experts was computed. The research hypothesis that the mean Jaccard distance to the group of 
experts was different for at least one of the subjects was tested using analysis of variance. 
The secondary outcome of the behavioral evaluation was the proportion of responses by each 
subject that were correct, relative to a reference standard based on the majority opinion of the 
experts. The correctness of responses for a given test case 𝑋𝑖 was defined as the number of 
responses in common between a subject 𝑗 and the reference standard 𝑘 divided by the number of 





Analogous to the dissimilarity evaluation, an expert’s reference standard was based on the majority 
vote of the remaining 4 experts, while the prototype’s and random guessing reference standard was 
based on the majority vote of all the 5 experts. The research hypothesis that there was a difference 
in the mean correctness of the prototype and the mean correctness of the experts was tested using 
analysis of variance. In addition to the correctness evaluations, pairwise Kappa statistics were 






6.3.1. Structural Validation Results 
Table 6.4 shows the ingredients, conditions and ingredient-condition pairs from the 3 knowledge 
bases compared in this study. A total of 314 ingredient-toxicity-observation relationships were 
identified from the prototype’s knowledge base. These included 47 ingredient-toxicity pairs and 
284 ingredient-observation pairs whose union generated 318 unique ingredient-condition pairs. 
Seventy-nine ingredient-condition pairs (25%) in the prototype could not be found in LAERTES 
or SIDER (Figure 6.2). A majority of the ingredient-condition pairs were confirmed by evidence 
sourced from spontaneous reporting of adverse effects that were available in the LAERTES 
knowledge base (Figure 6.3). Only 50% of the relationships were confirmed when using the 
structured product label knowledge source type, and only 9% were confirmed when using the 
literature source type (Figure 6.3). Inspection of the 79 ingredient-condition pairs revealed that the 
discrepancies were due to relationships between 11 ingredients and 42 conditions. However, 42 
pairs (53% of the 79 pairs, 13% overall) were confirmed to be genuine relationships described 
using concepts with different unique identifiers but with similar meanings. For example, the pair 
Atazanavir (RxCUI 343047) and blood bilirubin increased (CUI C0311468) in the prototype is 
semantically similar to Atazanavir (RxCUI 343047) and hyperbilirubinemia (CUI C0020433) in 
the evidence sources. Similarly, the pair tenofovir disoproxil (RxCUI 300195) and blood lactic 
acid increased (CUI C0795692) in the prototype could be interpreted as tenofovir disoproxil 
(RxCUI 300195) and lactic acidosis (CUI C0001125). Accordingly, only 37 (12%) of the 
ingredient-condition pairs could not be verified as existent in the evidence sources used. This 
provided enough evidence to conclude that the proportion of ingredient-condition relationships in 
the prototype that existed in either LAERTES or SIDER was >80% (p-value <0.001).  
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Table 6.4: Structural comparison set sizes stratified by knowledge base 
Set Ingredients Conditions Ingredient-Condition Pairs 
Prototype 11 117 318 
SIDER 10 283 604 




Figure 6.2: Overlaps between the sets of ingredient-condition pairs in the prototype and in selected 




Figure 6.3: Proportion of ingredient-condition pairs in the prototype verified as existent in selected 





6.3.2. Behavioral Validation Results 
The 5 experts and the prototype generated 314 unique responses from the 15 test cases. Of these 
responses, 66 were about antiretroviral toxicities, 109 were about risk factors, and 139 were about 
toxicity observations. Based on the majority opinion of the experts, 199 responses (63%) were 
considered correct. Of the 314 responses generated, 70 responses (22%) did not exist as evidence 
in the prototype’s knowledge base. 
The mean Jaccard distances of each subject from the experts are illustrated in Figure 6.4. The 
comparisons between the mean Jaccard distances of each subject and the mean Jaccard distance of 
the experts are provided in Table 6.5. Although the experts differed in their interpretation of the 
test cases for at least 25% of the time, the differences in the Jaccard distances of the experts from 
each other was not statistically significant. This observation was confirmed by a Fleiss’s Kappa 
score of 0.77 that indicated substantial agreement among the 5 experts. When all the responses 
were accounted for (unrestricted), the mean Jaccard distance of the experts from each other was 
0.312 (95% CI, 0.283 to 0.342), while the mean Jaccard distance of the prototype from the experts 
was 0.424 (95% CI, 0.382 to 0.466). The difference between these two distances was 0.112 (0.06 
to 0.163, p-value <0.001) suggesting statistically significant differences between responses by 
experts and by the prototype. However, the distance of the prototype and the experts was smaller 
than the distance between the prototype and random guessing at 50% chance of being correct 
(Figure 6.4 - unrestricted). Interestingly, restricting the universe of responses (by ignoring the 70 
responses that did not exist in the knowledge base for all subjects) resulted in the difference 
between the distance of the prototype from the experts and the average distance among the experts 
becoming statistically indiscernible. The removal of the responses did not appear to significantly 




Figure 6.4: Mean Jaccard Distance (and 95% Confidence Interval) of Subjects from Experts for 
unrestricted responses (top) and restricted responses (bottom) 
  
Table 6.5: Differences between Mean Subject and Mean Expert Jaccard Distances 
Category Subject Difference (95% CI) p-value 
Unrestricted 
Expert 1 -0.025 (-0.081 to 0.03) 0.357 
Expert 2 -0.003 (-0.059 to 0.052) 0.904 
Expert 3 -0.018 (-0.073 to 0.038) 0.52 
Expert 4 0.051 (-0.004 to 0.107) 0.067 
Expert 5 -0.005 (-0.06 to 0.05) 0.851 
Prototype 0.112 (0.06 to 0.163) <0.01* 
Guessing 0.321 (0.27 to 0.372) <0.01* 
Restricted 
 
Expert 1 -0.01 (-0.059 to 0.039) 0.685 
Expert 2 0.004 (-0.045 to 0.053) 0.88 
Expert 3 -0.03 (-0.078 to 0.019) 0.227 
Expert 4 0.025 (-0.024 to 0.074) 0.312 
Expert 5 0.011 (-0.038 to 0.06) 0.648 
Prototype 0.037 (-0.009 to 0.082) 0.108 




Figure 6.5: Proportion of Correct Responses (and 95% Confidence Interval) of Subjects from Experts for 
unrestricted responses (top) and restricted responses (bottom) 
 
Figure 6.5 illustrates the means and 95% confidence intervals for the proportion of correct 
responses by a subject. When responses were unrestricted, the mean correctness of the prototype 
across all test cases was 79.5% (95% CI, 71.9 to 87.2). Based on inspection of the confidence 
interval overlaps and on the one-way ANOVA model using all subjects, there was insufficient 
evidence to conclude that difference between the mean correctness of the prototype and the mean 
correctness of the human experts was statistically significant (p-value>0.5). Similar conclusions 
were found when the responses were restricted. Lastly, a Cohen’s Kappa score of 0.68 indicated 
moderate agreement between the prototype’s responses and reference standard responses derived 
from the majority opinion of the experts. These observations collectively suggest that the fact 






6.4.1. Structural Validation 
The structural validation conducted in this study entailed comparing the semantic representation 
of ingredient-condition relationships in the prototype to representations in two publicly available 
adverse drug reaction evidence knowledge bases. The findings of the investigation suggest that up 
to 88% of antiretroviral ingredient-condition pairs independently curated and standardized from 
current treatment guidelines and drug labels could be verified through direct structural 
comparisons (75%) and additional manual semantic similarity comparisons (13%) with the 
concept-concept relationships in publicly available drug safety evidence knowledge bases. 
The fact that about 12% concept-concept relationships in the prototype’s knowledge base could 
not be validated by comparisons between existing knowledge evidence sources can be explained 
by three main reasons. First, it is plausible that some of the relationships in the prototype’s 
knowledge base were valid despite not being structurally equivalent to the comparable 
relationships in the evidence sources used. Structural differences between some relationships in 
the prototype and in the evidence sources used were attributable to concepts assigned different 
unique identifiers despite being similar in meaning (e.g., blood bilirubin increased (CUI 
C0311468) and hyperbilirubinemia (CUI C0020433)). This redundancy could be due to semantic 
heterogeneity – where schema and data set development by independent parties within the same 
domain introduces differences in meaning and interpretation of data elements [149]. This 
observation is backed by the fact that significant proportions of the different evidence sources used 
in this study did not overlap. Boyce and his colleagues outline several sources of variability during 
the process of extracting, translating, and loading drug safety information into knowledge bases 
and how these could influence downstream analysis [138]. For example, when extracting drug 
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toxicity information from product labels, decisions such as whether to obtain information from 
anywhere on the label or from specific sections of the label (e.g. black box warning vs. prescribing 
section vs. patient counselling information section) could determine the types of concepts and 
relationships that are eventually included in a drug safety knowledge base. Knowledge acquisition 
decisions to use technical terms such as ‘angioedema’ in the prescribing section, to use lay terms 
such as ‘lip swelling’ in the patient information section, or to include both could introduce semantic 
heterogeneity among different evidence sources without necessarily making the information 
invalid. A second plausible explanation for the variations in ingredient-condition relationships 
among different evidence sources is the novelty of the asserted associations. Voss et al. explain 
that novel ingredient-condition associations are likely to appear faster in source evidence source 
types such as spontaneous reporting evidence sources compared to other sources types such as 
literature [150]. Using a similar reasoning, because the content of the knowledge base evaluated 
in the study was derived from the drug labels and clinical guidelines that were more recent (2016) 
compared to the evidence sources (e.g., current version of SIDER was released in 2015), it is 
possible that the relationships that were not found in the sources were legitimate but are yet to be 
updated in the evidence sources. Lastly, it is possible that the relationships in the evaluated 
knowledge base could not be confirmed because they were genuinely erroneous. 
Structural comparison studies are usually conducted to evaluate the similarities in how a 
knowledge base and non-design experts conceptualize and structurally present knowledge [140]. 
This study demonstrates that in the absence of domain experts, it is possible to use existing 
informatics evidence resources to evaluate independently-constructed knowledge bases. Domain 
experts could complement this evaluation approach by delineating sources of variability that 
cannot be directly explained by structural comparisons between knowledge base contents. 
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6.4.2. Behavioral Validation 
The behavioral validation conducted in this study involved comparing the detection of 
antiretroviral toxicities, risk factors, and observations (signs, symptoms, and laboratory findings) 
by the prototype and by non-design experts for a random sample of test cases. The findings of this 
study suggest that knowledge base of the prototype developed in this dissertation behaves as 
human domain experts albeit to a moderate degree. 
There was sufficient evidence to conclude that there was a statistical difference in the detection of 
antiretroviral toxicities, risk factors, and observations (sign, symptoms, and laboratory findings) 
from structured data between the prototype and human experts. Nonetheless, the reports generated 
by the prototype tended to be more similar to human expert reports than to reports generated 
through random guessing. The accuracies of the prototype and the human experts were 
indistinguishable. 
Interestingly, when the universe of responses was restricted to the knowledge that was available 
in the prototype, the dissimilarities between the reports generated by the prototype and the human 
experts became indistinguishable, while the dissimilarities among reports generated by the experts 
remain unchanged. This observation confirms the well-known assertion that for a knowledge base 
to be considered functionally complete, it must not only be structured appropriately and contain 
accurate knowledge, but it must also have adequate coverage of the domain knowledge [140]. 
However, as was the case with the development of the prototype in this dissertation, it is not always 
possible or reasonable to ensure complete domain coverage particularly in the early stages of the 
development of knowledge-based applications. Furthermore, when using standard guidelines as 
the basis for the content of the knowledge base of knowledge-based applications, inadequate 
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domain coverage is likely. This is because care guidelines tend to provide content about key 
treatment-limiting conditions that are most impactful in clinical care. 
It was also interesting to observe that although the dissimilarities of reports among the experts 
were statistically indistinguishable, the proportion of time they disagreed with each other was as 
high as 25%. This suggests variability in the manner in which experts interpret antiretroviral 
toxicity information albeit the fact that no single expert is significantly different from the others. 
Hripcsak et al. reported a similar observation among expert physicians identifying conditions from 
radiology reports [148]. In the study described in this chapter, it was not clear why the experts 
interpreted the reports differently and if this affected the performance of the prototype. Future 
research should investigate this phenomenon further. A plausible approach would involve 
comparing the performance of the prototype against a set of true reference standard responses 
rather than one based on the majority opinion of experts working independently. 
6.4.3. Limitations  
This study had several limitations. First, for the structural validation, only two publicly available 
knowledge bases were used. It is possible that using different evidence sources would result in 
different conclusions. Second, for the behavioral validation, only pharmacists were used as expert 
subjects. Using experts from other cadres could have resulted in different conclusions. 
Nonetheless, the experts used were carefully selected, had sufficient experience, and did not 
participate or have vested interests in the development of the prototype. The results generated by 
the study are, therefore, credible but may not be extended to other health cadres. Lastly, the 
evaluated application was an initial prototype. It is possible that as the iterative development of 




Overall, this study suggests that it is possible to implement antiretroviral toxicity domain 
knowledge in knowledge-based applications successfully and that such applications have the 
potential to support automated detection of antiretroviral toxicities, risk factors and observations 
(signs, symptoms, and laboratory findings) from structured patient records. The research also 
points to the potential value of using disparate evidence sources to validate the structure and 
content of independently-developed knowledge bases. This is, however, with the caveat that 
factors such as semantic heterogeneity and novelty of associations are likely to affect the outcomes 
of such endeavors, and that future research is needed to investigate the role of informaticians in 
addressing these concerns. Finally, future informatics research should investigate the impact of the 





Chapter 7. Assessing the Usability by Peer Health Workers of Computer-Generated 
Checklists for Point-of-Care Antiretroviral Toxicity Symptom Documentation 
7.1. Introduction 
Point-of-care antiretroviral toxicity monitoring promotes the detection and early intervention of 
antiretroviral side effects and adverse drug reactions [2]. The World Health Organization (WHO) 
encourages HIV care programs to conduct routine antiretroviral toxicity monitoring. This would 
provide more accurate data for the determination of incidence, clinical relevance, and impact of 
antiretroviral toxicities [2]. Current clinical practice guidelines recommend a symptom-directed 
approach to antiretroviral toxicity monitoring [2, 22]. This involves the clinical assessment of signs 
and symptoms attributable to specific antiretroviral toxicities at the point-of-care, with laboratory 
testing suggested but not mandatory for high-risk patients using certain drugs [2]. 
The symptom-directed approach to routine antiretroviral toxicity monitoring is particularly useful 
in underserved settings which lack the capacity to conduct laboratory testing [2]. However, the 
approach is laborious and, therefore, difficult to implement in underserved settings which are 
characterized by poor healthcare infrastructure and competition for scarce human and financial 
resources [11, 12]. Accordingly, in order to successfully implement the symptom-directed 
approach in underserved settings, practical methods that address setting-specific workforce 
challenges would be required. 
A plausible approach to alleviating the workforce-related barriers to symptom-directed 
antiretroviral toxicity monitoring is task shifting. Task shifting refers to the delegation of tasks 
from skilled professionals to more readily available lay health workers and is an accepted strategy 
for mitigating health workforce challenges in underserved settings [16, 17]. An increasingly 
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popular task shifting approach involves the use of peer health workers [23, 37]. A peer is a person 
who has a shared living experience as another person [23]. Consequently, peer health workers have 
similar clinical and medication experiences as the persons they care for [37]. For example, in HIV 
care, peer health workers would be HIV-positive persons who have demonstrated competence in 
HIV self-management, clinic attendance, and medication adherence [38]. They would be trained 
and remunerated to take up new responsibilities such as counseling, education, and data collection 
[23]. Previous studies have demonstrated that delegating tasks to peer health workers could 
improve clinical data collection and enhance patient engagement through education and 
psychosocial support [151-154]. 
It is, therefore, reasonable to postulate that point-of-care antiretroviral toxicity monitoring using 
the symptom-directed approach could be enhanced by redistributing symptom data collection tasks 
to peer health workers. Furthermore, it is logical that the efficiency and effectiveness of such task 
delegation could be enhanced using standardized documentation tools such as checklists. 
Unfortunately, research on leveraging peer health workers to support point-of-care data collection 
using standardized documentation tools has received little attention. For example, although several 
data collection instruments including scales, profiles, and checklists are well-described in the 
biomedical literature [24, 25], neither their usability, nor their feasibility, nor their impact when 
used by lay health workers collecting antiretroviral toxicity data has been studied adequately. 
This chapter reports the findings of a study that investigated the usability of computer-generated 
checklists for documenting antiretroviral toxicity symptoms as perceived by peer health workers 
based in an underserved setting in western Kenya. The objectives of the study were to assess the 
level of satisfaction with the checklists and the cognitive mental effort required to complete the 
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checklists as perceived by peer health workers. The study also identified the main sources of 
documentation errors that informed the redesign of the checklists. 
7.2. Methods 
7.2.1. Study Design 
This study was designed as a quantitative usability test. The goal of usability testing is to determine 
end-user satisfaction with a product or service and to identify usability problems that need to be 
addressed [155]. In this study, the usability of computer-generated checklists for documenting 
antiretroviral toxicity symptoms was investigated. Testing consisted of peer health workers using 
the checklists to document symptoms described in 5 case scenarios and providing feedback on 
their usability experiences. The primary outcome of the study was the level of satisfaction with the 
checklists as measured by the System Usability Scale (SUS) [156, 157]. To determine if the 
usability of the checklists was acceptable, the research hypothesis that the mean SUS score is >68 
was tested. The secondary outcome of the study was the level of mental effort needed to complete 
checklist documentation case scenarios as measured by the Subjective Mental Effort Question 
(SMEQ) [157, 158]. To determine if the checklists are not difficult to use, the research hypothesis 
that median SMEQ score is <20 was tested. Other outcomes investigated included time to case 
completion, case completion rates, and sources of documentation errors [159]. 
7.2.2. Checklists 
In this dissertation, an electronic knowledge-based application prototype that implements standard 
guidelines for antiretroviral toxicity monitoring was developed (see Chapter 5). In addition to other 
functionalities, this prototype generates checklists that can be used for documenting symptoms and 
subsequently recognizing possible antiretroviral toxicities experienced by individual patients. The 
contents of the checklists are based on antiretroviral toxicities described in the standard clinical 
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guidelines on the use of antiretroviral drugs [2, 6] and in approved drug labels [126]. The contents 
of the checklists are customized based on the antiretroviral regimen used by a patient. For example, 
the checklist for a patient using a regimen consisting of Tenofovir + Lamivudine + Efavirenz is 
different from the checklist for a patient using a regimen consisting of Abacavir + Emtricitabine + 
Nevirapine. To create a checklist for a given patient, the prototype queries a the patient’s 
longitudinal electronic health record (EHR) data and identifies the antiretroviral medications 
currently used by the patient. The prototype uses the identified medications to query its knowledge 
base and subsequently generate the contents of the checklist. 
Figure 7.1 shows an example of a printable checklist generated by the prototype. To use this ‘low-
tech’ version of the checklist, the user first checks off entries in the signs/symptoms list. Next, 
guided by the colored lines mapping the symptoms to adverse reactions, the user tallies the 
symptom counts associated with each possible adverse drug reactions, and inserts the counts in the 
appropriate field. Completed checklists are intended for use by clinicians to confirm or rule out 
possible adverse reactions and guide subsequent management. 
7.2.3. Case Scenarios 
The case scenarios used in this study were presented as clinical vignettes depicting patients 
complaining of symptoms experienced after using specific antiretroviral therapy. The contents of 
the clinical vignettes were derived from data provided in published antiretroviral toxicity case 
reports. To generate the case scenarios, a stratified random sample of 5 test cases was selected 
from the 62 antiretroviral toxicity test cases created in Chapter 6 (section 6.2.2) of this dissertation. 
Stratification was based on the drug regimen type and the number of symptoms per test case to 
mimic variations in real clinical scenarios. Next, the 5 selected test cases were used to create the 5 




Figure 7.1: Example of a checklist generated from the record of a single patient. The records used are 




Table 7.1: Usability testing case scenarios 
Id Clinical Vignette 
Case 1 I am Hamish Rugendo, and my person ID number is A0123453. I have been using 
Zidovudine, Lamivudine, and Efavirenz for about 10 days. I decided to come to the clinic 
today because I noticed a rash on my trunk and arms after taking my medications. My skin 
feels itchy, and my eyes are reddish. In addition, I started having muscle pains and feeling 
very tired which is not normal for me. Also, I feel like I have a fever. 
Case 2 I am Lucy Cheptoo, and my person ID is A26744789. I was started on Abacavir, 
Lamivudine, Atazanavir, and Ritonavir two years ago and I have been using the regimen 
since then. Recently, I have been feeling pain on the left side of my body between my 
abdomen and my back. I have also been vomiting and feeling like I have a fever. 
Case 3 My name is Kelly Rukira. My person ID is A12312863. I had been using Abacavir, 
Lamivudine, and Efavirenz for about 15 days when I started having feelings of tiredness and 
general sickness. I later developed a rash, fever, and muscle pains, and decided to come to 
the clinic to be evaluated. 
Case 4 My name is Darius Manyika, and my person ID is A0756908. I was started on Zidovudine, 
Lamivudine, and Nevirapine three weeks ago. I have now developed fever, pain in the right 
upper part of my abdomen, nausea, vomiting, and diarrhea. My skin has started turning 
yellowish, and I think my liver is getting larger. 
Case 5 My name is Susan Virunga, and my ID is A50121845. I have been using Tenofovir, 
Emtricitabine, Lopinavir / Ritonavir and Septrin for more than 1 year. I recently started 
feeling a lot of pain in my bones. My muscles have also been feeling weak. 
 
7.2.4. Study Setting 
This study was conducted at the Academic Model Providing Access to Healthcare (AMPATH) in 
Eldoret western Kenya. AMPATH is an umbrella healthcare organization formed as a result of the 
collaboration between Moi University College of Health Sciences, Moi Teaching and Referral 
Hospital and a consortium of North American Academic Medical Centers led by Indiana 
University School of Medicine [77]. The academic centers that constitute AMPATH pursue the 
tripartite mission of care, training, and research with the overarching goal of addressing short- and 
long-term challenges in global health. AMPATH works in partnership with the Government of 
Kenya to provide HIV care at its primary site in Eldoret, Kenya and via more than 25 satellite 
clinics throughout western Kenya. Since its inception, AMPATH has provided care to about 
180,000 HIV/AIDS patients, with almost 2,000 new HIV patients being enrolled each month [78]. 
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AMPATH has expanded from its initial clinical focus on HIV/AIDS to encompass chronic disease 
care, primary health care, and specialty healthcare. To address the healthcare workforce challenge 
brought about by this scale up, AMPATH is actively researching and implementing different task 
redistribution paradigms including peer-driven HIV counseling and pharmacovigilance [160]. 
7.2.5. Study participants 
Participants in this study were peer health workers trained and remunerated by AMPATH. All peer 
health workers at AMPATH were eligible for participation regardless of their qualifications, work 
experience, or job functions. All potential participants were invited to participate in the study. The 
recruitment target was set to at least five participants as this sample size is sufficient for usability 
testing during the early stages of the development of the tool to be tested [161]. 
7.2.6. Data Collection  
A high-level description of the data collection procedure is shown in Figure 7.2. First, participants 
completed a demographics questionnaire that was administered to collect information about the 
age, gender, level of education, and job roles (Appendix 7.1). Next, participants completed a 
symptom knowledge questionnaire which asked participants to describe 10 randomly-selected 
antiretroviral toxicity symptom terms in English or Swahili (Appendix 7.2). Prior to attempting 
the actual usability task, participants received practice on reading case scenarios and completing 
checklists as was intended (Appendix 7.3). Actual testing consisted of each participant completing 
each case scenarios included in the study as follows. First, the participant read the case scenario’s 
vignette to identify the reported symptoms. Next, participant checked off the identified symptoms 
on a checklist provided for the case scenario. Finally, guided by the colored lines mapping the 
symptoms to adverse reactions on the checklist, participants tallied the symptom counts associated 




Figure 7.2: High-level description of the data collection workflow (participant’s perspective) 
 
Immediately after completing each case scenario, participants completed SMEQ questionnaire to 
score the level of mental effort they required to complete the case. The SMEQ is a single item 
cognitive workload questionnaire that assesses perceived task difficulty on a scale of 0 to 150 
points that correspond to nine labels ranging from “Not at all hard to do” to “Tremendously hard 
to do”(Appendix 7.4) [157]. A research assistant recorded the start time (when a case was handed 
over to the participant) and the finish time (when the finished case was received back from the 
participant) to collect data for analyzing time to case completion. 
Immediately after completing all 5 case scenarios, participants completed the SUS questionnaire 
to collect data on the participant’s perceived satisfaction with the checklists. The SUS is a ten-item 
post-study questionnaire with responses coded as five-level Likert items from “Strongly Disagree” 
to “Strongly Agree” (Appendix 7.5) [157]. 
7.2.7. Data Analysis 
Quantitative statistical analyses were conducted in R [144]. Descriptive statistics of the 
participants’ characteristics were expressed as proportions, medians, and interquartile range. To 
generate the symptom knowledge score, two assessors independently reviewed each participant’s 
symptom knowledge questionnaire responses. The assessors assigned a score of 1 for each correct 
description of a symptom term or a score of 0 otherwise. The assessments were compared and 
discrepancies resolved by consensus. 
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The primary outcome of the study was the level of satisfaction with the checklists. This was 
determined by computing the mean SUS Score from the participant’s SUS questionnaire responses 
as follows. First, each questionnaire item’s score contribution was defined as a discrete score 
ranging from 0 to 4. If 𝑥𝑖 represents the position on the 5-point Likert response scale of a single 
questionnaire item 𝑖, then the score contribution was (𝑥𝑖 − 1) for positively worded items (odd-
numbered items) and (5 − 𝑥𝑖) for negatively worded items (even-numbered items) in the 
questionnaire [157]. Next, the overall SUS score of a single participant’s responses was computed 
by multiplying the item score contributions by 2.5 such that the overall SUS scores range from 0 
to 100 in 2.5-point increments. Lastly, the one-sample Student’s t-test was used to test the research 
hypothesis that the mean SUS score was >68, corresponding to above average usability. 
The secondary outcome was the level of mental effort required to complete case scenarios which 
was described using the overall median and range of all SMEQ scores. The Wilcoxon signed rank 
test was used to test the research hypothesis that the overall median SMEQ was <20, corresponding 
to “Not very hard to do”. The research hypothesis that the SMEQ scores for the case scenarios 
were non-identical was tested using the Kruskal-Wallis rank sum test. The Mann-Whitney-
Wilcoxon Test was used to test the research hypothesis that there was a difference in the SMEQ 
scores for each pair of case scenarios. 
Time to case completion was analyzed using an approach similar to the one used for the SMEQ 
tests described above. Case completion rates were measured as the proportion of users who 
successfully completed each case scenario. For each case scenario completed by a participant, 
completion data was coded as a binary measure of success (1) or failure (0) based on the similarity 
of the participant’s responses to the corresponding reference standard responses. The adjusted 




7.3.1. Participant Characteristics 
The characteristics of the 12 study participants are shown in Table 7.2. Seven of the 12 participants 
were male, and all participants were above 35 years. Ten participants had a college-level education. 
Eight participants were peer counselors and educator, while 4 participants were retention and 
outreach workers. The median work experience was 9 years. Three participants reported prior 
experience using checklists. Most participants had an acceptable knowledge of common 
antiretroviral toxicity symptoms. There were no significant differences in usability findings 
between the subgroups defined by the participant characteristics. Consequently, the findings 
reported in this study were based on analysis of data from all the 12 participants. 
7.3.2. Usability Findings 
Figure 7.3 illustrates the participant’s responses to the SUS questionnaire. The SUS showed a 
mean usability score of 72.3 (95% CI, 67.6 to 77.0, p-value <0.001). The observed data provided 
enough evidence to reject the null hypothesis and conclude that the true mean SUS score was >68 
(p-value = 0.035), implying above-average usability [157]. The mental effort associated with each 
case is illustrated in Figure 7.4. The SMEQ showed an overall median mental effort of 10 (Range, 
0 to 85). There was enough evidence to conclude that the overall median SMEQ score was <20 
(p-value <0.001) implying that the task was “Not very hard to do”. The SMEQ scores for Case 1, 
which was first to be attempted by all participants, were higher than the scores for the rest of the 
cases. Case 4, which was the most task-intensive, also received high SMEQ scores. A Kruskal-
Wallis p-value of 0.005 suggested that the mental effort for different cases was non-identical. The 
Mann-Whitney-Wilcoxon test confirmed statistical differences in mental effort in 3 comparisons 
involving Case 5 and 1 comparison involving Case 3 (Table 7.3). 
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Table 7.2: Characteristics of Usability Study Participants (N=12) 
Variable N (%) 
Gender  
 Female 5 (42%) 
 Male 7 (58%) 
Age  
 35 to 44 years 5 (42%) 
 45 to 54 years 5 (42%) 
 55 to 64 years 2 (16%) 
Level of Education  
 Secondary School 1 (8%) 
 College Certificate 4 (33%) 
 College Diploma 6 (50%) 
 University Degree 1 (8%) 
Current Role  
 Peer Counseling & Education 8 (67 %) 
 Retention and Outreach 4 (33 %) 
Work Experience in Years  
 Median(IQR) 7 (5-11) 
Prior Experience Using Checklists  
 Yes 3 (25%) 
 No 9 (75%) 
Symptom Knowledge Score  
 Median (IQR) 80% (77.5%-90%) 
 
 




Figure 7.4: Mental effort associated with the 5 checklist documentation case scenarios. 
 
Table 7.3: Differences in SMEQ and in Time to Case Completion between Case Scenarios 
  SMEQ Score  Time to Case Completion (Seconds) 
Pair  Difference (95% CI) p-value  Difference (95% CI) p-value 
Case 1 & Case 2  0 (-5 to 5) 0.894  180 (0 to 420) 0.039* 
Case 1 & Case 3  0 (0 to 10) 0.12  180 (0 to 360) 0.036* 
Case 1 & Case 4  -5 (-15 to 0) 0.2  0 (-180 to 180) 0.977 
Case 1 & Case 5  5 (0 to 15) 0.012*  240 (60 to 480) 0.011* 
Case 2 & Case 3  5 (0 to 15) 0.182  0 (-120 to 120) 0.977 
Case 2 & Case 4  -5 (-20 to 5) 0.177  -180 (-300 to -60) 0.002* 
Case 2 & Case 5  5 (0 to 15) 0.026*  60 (-60 to 180) 0.26 
Case 3 & Case 4  -15 (-25 to 0) 0.016*  -180 (-300 to -60) 0.006* 
Case 3 & Case 5  0 (0 to 10) 0.334  60 (-60 to 180) 0.317 
Case 4 & Case 5  15 (5 to 25) 0.002*  240 (120 to 360) 0.001* 
 
The times to case completion results are illustrated in Figure 7.5. The overall median time to case 
completion was 360 seconds (Range, 120 to 1560). The Kruskal-Wallis test indicated that the time 
taken to accomplish different cases was non-identical (p-value =0.001). The Mann-Whitney-
Wilcoxon test confirmed that statistically significant difference in time to case completion 
comparisons involving Case 1 and Case 4 (Table 7.3). The binary case completion rates ranged 
from 7% to 78% and appeared to vary with the number of symptoms-to-toxicity mappings that had 
to be identified (Table 7.4). For example, Case 5 which only had 2 symptoms and 1 possible 
adverse reaction was completed by 10 of the 12 participants, while no participant successfully 




Figure 7.5: Time to case completion associated with 5 checklist documentation case scenarios 
 
Table 7.4: Case Completion Rates with Adjusted Wald Confidence Intervals 
Task Symptoms Toxicities Mappings Completion Rate (95% CI) 
Case 1 5 3 6 57%(32% to 80%) 
Case 2 3 2 5 71% (46% to 92%) 
Case 3 5 2 7 28%(9% to 54%) 
Case 4 6 4 16 7% (0% to 22%) 
Case 5 2 1 2 78%(54% to 97%) 
 
7.3.3. Error Analysis  
The cause-of-error analysis revealed two main causes of errors that inform the redesign of the 
checklists. First, transcription errors were introduced by the presence of concepts described on the 
checklist using terms that looked similar and were possibly confusing to participants (Table 7.5). 
For example, some participants confused the concept muscle pain and muscle weakness and 
checked both entries for the same vignette excerpts. Similarly, the concept nausea which was 
described using the term feeling like vomiting (nausea) on the checklist, was confused with the 
term vomiting. Interestingly, this observation seems to contradict the perspectives of the 
professional provider about language as a barrier to the provision of monitoring services (Chapter 
3). Second, and perhaps more consequential, a majority of the errors that were associated with low 
case completion rates were introduced through mistakes committed during the manual mapping 
and tallying of identified symptoms to the possible adverse reactions. 
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Table 7.5: Example of Concept-Related Sources of Transcription Errors 
Vignette Text Excerpt Term Selected  Correct Term Error Counts 
I noticed a rash on my trunk and 
arm 
Fat accumulation in the 
trunk of the body 
Rash 1 
I started having muscle pain Muscle weakness Muscle Pain 2 
I have also been vomiting Feeling like vomiting 
(Nausea) 
Vomiting 2 
…and feeling like I have a fever Generally feeling sick Fever 1 
….and diarrhea. Pale Stools Diarrhoea 1 
My muscles have also been 
feeling weak 
Feeling tired Muscle 
weakness 
1 
My muscles have also been 
feeling weak 





The findings of this study suggest that peer health workers in an underserved setting are likely to 
find the use of checklists for the documentation of antiretroviral toxicities as generally satisfactory 
and easy to use. The SUS showed a mean usability score of 72.3 which corresponds to above 
average usability. The SMEQ showed an overall median mental effort of 10, implying that peer 
health workers found the use of the checklist to be easy. The median time to case completion was 
6 minutes. Interestingly, although there was a general consensus among the peer health workers 
that the checklists were satisfactory and easy to use, the case completion rates for relatively 
complex case scenarios was low. Errors in the documentation process were traceable to slips and 
mistakes in the interpretation of concepts described in the checklists, and in mapping symptoms to 
adverse drug reactions. 
The two sources of errors yielded redesign and implementation recommendations. First, it will be 
useful to avoid the presence of potentially confusing, yet distinct concept descriptions such as 
muscle pain and muscle weakness in the checklists. The use of single pre-coordinated concepts 
such as nausea and vomiting could also be considered. Alternatively, the symptoms in the checklist 
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could be grouped using meaningful categories such as by body systems (e.g., head and neck 
symptoms vs. abdominal symptoms) to limit potential confusion. Additionally, the users of the 
checklists could be adequately trained to ensure that they are knowledgeable with respect to 
terminology used in the checklists. Second, mapping and tallying counts of symptoms associated 
with possible adverse reactions manually should be reconsidered as this is only feasible for less-
complex mappings. A plausible alternative to the manual mapping requirement is the use of 
electronic checklists that automatically update possible adverse reaction counts as symptoms are 
checked off. However, this approach was not investigated in this study and is a suitable subject for 
future research. 
Checklists are tools that could be used to standardize the documentation of clinical care. However, 
the use of standardized checklists as a formal approach to monitoring adverse drug reactions has 
primarily been limited to few specific clinical domains such as psychiatry [24] and diabetes [25]. 
This study not only demonstrated the plausibility of extending the use of checklists to the 
monitoring of adverse drug reactions in HIV but also attempted to validate their usability among 
non-mainstream lay care providers whom could be crucial in solving documentation challenges in 
underserved settings. Additionally, this research demonstrates the application of quantitative 
methods for measuring usability. 
This study had several limitations. First, only 5 case scenarios were used in the usability testing, 
possibly introducing bias in the selection of case scenarios and variability in the results of the 
study. However, appropriate statistical analyses were used to ensure the correct interpretation of 
the findings. Second, the results of this study should be interpreted with caution as it is not possible 
to ascertain the honesty of the participants or the factuality of the information they provided when 
responding to the SMEQ and SUS questionnaires. Third, participants hailed from one clinical 
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setting, and it is, therefore, plausible that the results cannot be effectively generalized beyond the 
study setting without additional research. 
7.5. Conclusions 
The findings of this study suggest that peer health workers perceive computer-generated checklists 
for screening antiretroviral toxicity symptoms as satisfactorily useful and easy to use. However, 
measures should be taken to minimize possible errors in documentation. Future research should 
focus on evaluating the practical feasibility and impact of using peer health workers as 






Appendix 7.1: Demographics Questionnaire 
DEMOGRAPHICS QUESTIONNAIRE 
Please attempt all questions in the Questionnaire  
All answers are strictly confidential and will be used for the purposes of research only 
 
Question 1: What is your age group? 
•  18 to 24 years   25 to 34 years   35 to 44 years   45 to 54 years   55 to 64 years   Age 65 or older 
Question 2: What is your gender? 
Male     Female 
Question 3: What is your highest degree or education level? 
 Primary School   
 Secondary School   
 College Certificate in __________________________________ 
 College Diploma in ____________________________________  
 University Degree in ___________________________________   
 Other: ______________________________________________ 
Question 4: What is your current role at AMPATH? 
Current Role: ___________________________________________ 
Question 5: For how long have you worked in your current role at AMPATH? 
Years: _____________________ Months: ____________________  
Question 6:  What previous roles have you played at AMPATH in the past? 
Previous Roles: 1) __________________________________________________________________ 
                          2) __________________________________________________________________ 





Appendix 7.2: Symptom Knowledge Questionnaire 
SYMPTOM KNOWLEDGE QUESTIONNAIRE 
 Please attempt all questions in the Questionnaire  
All answers are strictly confidential and will be used for the purposes of research only 
The following terms refer to side effects of antiretroviral medications. Please briefly define or describe 
each term. If you know a term but cannot define or describe it in English, please feel free to use Kiswahili: 
1) Abnormal dreams: _______________________________________________________________ 
_______________________________________________________________________________ 
2) Blisters: ________________________________________________________________________ 
_______________________________________________________________________________ 
3) Diarrhoea: _____________________________________________________________________ 
_______________________________________________________________________________ 
4) Difficulty in Swallowing: ___________________________________________________________ 
_______________________________________________________________________________ 
5) Difficulty Sleeping: _______________________________________________________________ 
_______________________________________________________________________________ 
6) Fainting: _______________________________________________________________________ 
_______________________________________________________________________________ 
7) Fatigue: ________________________________________________________________________ 
_______________________________________________________________________________ 
8) Rash: __________________________________________________________________________ 
_______________________________________________________________________________ 
9) Suicidal tendency: ________________________________________________________________ 
_______________________________________________________________________________ 





Appendix 7.3: Case Scenario Completion Example 
I am Chris Wamukole, and my Id is A3425673. I have been using Combivir (Zidovudine and 
Lamivudine) and Nevirapine for four weeks now. Since last week, I have been feeling as if I am 
sick which is unusual for me. I also noticed a rash on my back, and I have been having a high fever 
for a few days now. My eyes and palms started looking yellowish, and I have been vomiting too. 




Appendix 7.4: Subjective Mental Effort Question (SMEQ) 
 
Instructions: Please draw a line through the numeric scale to indicate the mental effort you think 




Appendix 7.5: System Usability Scale (SUS) Questionnaire 
 
1. I think that I would like to use the checklists frequently. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
2. I found the checklists unnecessarily complex. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
3. I thought the checklists were easy to use. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
4. I think that I would need the support of a technical person to be able to use the checklists. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
5. I found the various functions in the checklists were well integrated. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
6. I thought there was too much inconsistency in the checklists. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
7. I would imagine that most people would learn to use the checklists very quickly. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
8. I found the checklists very difficult to use. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
9. I felt very confident using the checklists. 
☐ Strongly Disagree   ☐ Disagree   ☐ Neutral   ☐ Agree   ☐ Strongly Agree 
10. I needed to learn a lot of things before I could get going with the checklists. 





Chapter 8. Conclusions and Future Work 
8.1. Summary of Findings 
This dissertation research was informed by the view that to promote the point-of-care monitoring 
of antiretroviral toxicities in underserved settings that are characterized by health workforce 
challenges, it is critical to reconsider the current paradigm which requires clinicians to be the 
collectors, analyzers, and consumers of antiretroviral toxicity information all at the same time. 
Instead, better monitoring could be achieved by supporting clinician assessments of antiretroviral 
toxicities through the delegation of data collection tasks and the use of guideline-based 
antiretroviral toxicity decision support at the point of care. Consequently, this dissertation 
responded to several research questions that attempted to fill gaps in knowledge about leveraging 
task delegation and informatics solutions to overcome barriers associated with point-of-care 
monitoring of antiretroviral toxicities in underserved settings. 
The research strategy adopted in this dissertation generated knowledge about antiretroviral toxicity 
monitoring in underserved settings. In particular, this dissertation produced empirical evidence 
about the motives and strategies for medication therapy management (MTM) services in 
underserved settings. It also identified key barriers and facilitators of antiretroviral toxicity 
monitoring within ambulatory HIV care workflows in underserved settings. Additionally, the 
dissertation described the objectives, process, and challenges associated with the construction of a 
software prototype implementing antiretroviral toxicity domain knowledge. It also provided 
evidence on the structure and behavior of the prototype’s knowledge base. Lastly, the research 
provided previously unavailable empirical evidence about the perceptions of lay health workers 
on the use of checklists for the documentation of antiretroviral toxicities. A summary of the main 
findings of this dissertation vis-à-vis the research questions it asked is provided in Table 8.1 below.  
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Table 8.1: Summary of research questions and Key findings 
Question Key Findings 
What are the perspectives of 
healthcare providers based in 
an underserved setting on the 
motives and strategies for the 
provision of MTM services in 
such settings? 
• Enhancement of medication adherence, safety and effectiveness is 
motivated by the desire to improve individual patient outcomes and to 
avert public health risks posed by suboptimal use of medications  
• Service delivery is influenced by the provider’s perceptions of having 
the knowledge, skills, and time to provide the services adequately, and 
by the patient’s willingness and ability to self-manage and engage in 
MTM processes  
• Strategies for overcoming workforce and patient engagement 
challenges are likely to require collaboration between professionals 
care providers and lay health workers 
What constitutes the 
ambulatory HIV care 
workflow in an example of an 
underserved setting? 
• Workflows are primarily designed to document care observations 
using structured encounter forms 
• Clinicians are the primary collectors, analyzers, and consumers of 
clinical data including those pertaining to antiretroviral toxicity 
What are the barriers to and 
facilitators of point-of-care 
antiretroviral toxicity 
monitoring in underserved 
settings? 
• Barriers can be pinpointed to processes involving the documentation 
and analysis of antiretroviral toxicity data. These include clinician 
time and workload constraints, limitations in data collection form 
design, and the failure to capture the reasoning of clinicians. 
• Opportunities for improving data collection include the availability of 
peer health workers whom could take up data collection roles and 
considerable patient wait times that could be utilized for additional 
data collection. Opportunities for improving data analysis and 
interpretation include the adoption and use of electronic health records 
and clinical decision support in underserved settings 
To what extent are the 
ingredient-condition 
relationships in a prototype 
knowledge base similar to 
those in existing drug safety 
knowledge bases? 
• Up to 88% (75% through automated comparison and 13% through 
manual semantic similarity assessment) of paired ingredient-
condition relationships extracted from clinical guidelines and current 
drug labels and implemented in a prototype knowledge base are 
equivalent to ingredient-condition relationships provided in existing 
drug safety evidence knowledge bases.  
To what extent is the 
detection of antiretroviral 
toxicity by a prototype 
knowledge base comparable 
to the detection by human 
experts for a random sample 
of test cases? 
• The difference in Jaccard distance between antiretroviral toxicity 
reports generated by the prototype and reports generated human 
experts was 0.112 (0.06 to 0.163, p-value <0.001) suggesting 
inferiority of the prototype in detecting possible antiretroviral toxicity 
associations from structured data. The reason for dissimilarities was 
attributable to inadequate domain coverage by the prototype. 
• The differences in the accuracy of reports between the prototype and 
human experts were not distinguishable  
To what extent do lay peer 
health workers perceive 
checklists for screening 
antiretroviral toxicity 
symptoms as satisfactorily 
useful and easy to use? 
• The SUS showed a mean usability score of 72.3 suggesting that lay 
peer health workers have above average satisfaction with the use of 
checklists for the documentation of antiretroviral toxicity symptoms. 
• The SMEQ showed an overall median mental effort of 10 (Range, 0 
to 85) corresponding to “Not very hard to do”, but ranging from “not 




Overall, this dissertation demonstrates that the problem of inadequate antiretroviral toxicity 
monitoring during routine clinic visits in underserved settings could be mitigated by leveraging 
task shifting and knowledge-based clinical decision support to enhance information acquisition, 
information analysis, and decision-making. Such an endeavor would, however, require the 
combined effort of several stakeholders including patients, non-mainstream care providers such as 
peer health workers, clinicians, and informaticians, as well as considerable workflow process 
redesigns. Patients should be willing and able to actively participate in the antiretroviral toxicity 
monitoring activities, while care programs should direct efforts towards promoting patient 
engagement in care processes. More readily available personnel including lay health workers 
would need to take up new roles such as gathering and documenting patient information during 
clinical encounters. Concomitantly, clinicians should have the skills necessary for symptom-
directed monitoring and would be required to focus on analyzing patient-reported data rather than 
on data collection. Informaticians should direct their efforts towards developing more effective 
workflow tools that support symptom-directed antiretroviral toxicity monitoring. A summary of 
the overall conclusions of the dissertation are discussed as folows. 
Setting-specific barriers hinder the point-care monitoring of antiretroviral toxicity. As 
inferred from the findings of the study described in Chapter 3 of this dissertation, possible 
provider-related barriers to the antiretroviral toxicity monitoring include inadequate knowledge, 
skills, or time to provide the services. From the same study, it was also evident that stigma and 
passivity are important patient-related barriers which would hinder engagement in antiretroviral 
toxicity monitoring. In Chapter 4, workflow-specific barriers were pinpointed to processes 
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involving the documentation and analysis of patient-reportable and clinician-identified 
antiretroviral toxicity data. 
Task shifting could be an essential strategy for improving point-of-care antiretroviral 
toxicity monitoring in underserved settings. The research conducted in this dissertation 
provided evidence to suggest that task shifting, defined as the delegation of clinical responsibilities 
from professionals to more readily available but less-skilled care providers, could be leveraged to 
improve point-of-care antiretroviral toxicity monitoring in underserved settings. In particular, task 
redistribution models in which professionals and lay health care providers work together are likely 
to succeed. Evidence in support of task shifting in this dissertation is as follows. The review of 
literature conducted in this dissertation (Chapter 2) identified task shifting as a universal strategy 
for mitigating workforce challenges in underserved settings. Task shifting also emerged as a 
strategy for enhancing medication adherence, safety, and effectiveness in underserved settings in 
the explorative study described in Chapter 3 of this dissertation. Chapter 4 of the dissertation 
describes a workflow analysis study from which task shifting roles in the form of peer counseling, 
patient education, and outreach could be identified. Lastly, the findings of the usability study 
described in Chapter 7 of the dissertation suggest that antiretroviral symptom data collection could 
be satisfactorily achieved through task shifting. 
Point-of-care antiretroviral toxicity monitoring in underserved settings could potentially be 
enhanced using knowledge-based applications implementing care standard guidelines. In 
Chapter 4 of this dissertation, it was evident that key workflow barriers to the point-of-care 
monitoring of antiretroviral toxicities pertained to the inadequate documentation and analysis of 
antiretroviral toxicity data. Chapter 5 demonstrated how the identified workflow barriers could be 
mitigated through the construction of a knowledge based application system that supports 
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automated reasoning about antiretroviral medication, medication regimens, and toxicities. The 
findings of the study in Chapter 6 of the dissertation confirmed that knowledge-based applications 
have the potential to support automated detection of antiretroviral toxicities, risk factors and 
observations (signs, symptoms, and laboratory findings) from the analysis of structured patient 
records. On the other hand, the findings in Chapter 7 demonstrate that computer-generated 
checklists could be used to not only improve data collection but to do so using the task shifting 
approach.  
8.3. Contribution to Informatics 
This dissertation contributes to informatics in several ways. First, it demonstrated the application 
of the contextual design methodology as an approach for gaining insight into and modeling 
workflows based in underserved settings. This approach could be used by informaticians to 
understand drivers of suboptimal performance within clinical workflows in underserved settings 
and how informatics tools could be designed and integrated to address the identified barriers. The 
workflow analysis approach used in this dissertation also demonstrated that the rapid review of 
published literature targeting study settings in which workflows are investigated could be effective 
complements to the traditional approaches used to conduct workflow analyses. 
Second, this dissertation investigated the extent to which antiretroviral toxicity domain knowledge 
could be implemented in a knowledge-based application to support point-of-care antiretroviral 
toxicity monitoring. In so doing, the dissertation described a systematic process for acquiring 
antiretroviral toxicity domain knowledge and representing the knowledge formally in an intuitive 
graph model that supports inference about toxicities from different levels of abstractions including 
regimens, ingredients, and clinical drugs. The model developed and the approach used are 
important resources for informatics research. Additionally, this dissertation research demonstrated 
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how the structure and behavior of independently-developed knowledge base applications could be 
systematically evaluated. In particular, the dissertation demonstrated how existing evidence 
knowledge bases could be used to validate the structure of independently developed prototypes. It 
also demonstrated how a reliable set of test cases for validating the behavior of prototypes could 
be generated from published case reports using a semi-automated process involving natural 
language processing and expert review. 
Lastly, this dissertation demonstrated how quantitative standard usability tests could be applied to 
assess the satisfaction and mental effort associated with the completion of usability tasks. 
Particularly, and unlike a majority of usability testing that involve tech-savvy users using 
electronic interfaces, this dissertation contributes to the body of knowledge of usability testing by 
assessing usability as perceived by less tech-savvy peer health workers using low-tech paper-based 
checklists. 
8.4. Contributions to Clinical Care 
This dissertation contributes to clinical care in a variety of ways. It addressed the lack of research 
evidence on the provision of MTM services in underserved settings. This was achieved by 
triangulating the perspectives of care providers working in an example of an underserved setting 
to characterize the motives and strategies for improving medication adherence, safety, and 
effectiveness that are applicable in such settings. Accordingly, a major clinical contribution of this 
dissertation research is that it provides much-needed evidence on why MTM services are important 
in underserved settings, who needs such services, components required to deliver the services, and 
how the services can be delivered. This information is particularly important because the provision 
of MTM services is a relatively new paradigm that is yet to diffuse into underserved settings. For 
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example, stakeholders could compare different motives and strategies and identify the ones that 
are best aligned to their setting-specific needs. 
Another important clinical implication of this dissertation research is that it provides analytic 
insight into the manner in which HIV workflows in underserved care settings operate. This 
dissertation research is one of the first to specifically visually illustrate models that describe the 
different dimensions of the ambulatory HIV care workflows in an example of an underserved 
setting. It is also one of the first research endeavors to describe specific workflow-related barriers 
to and opportunities for improving point-of-care monitoring of antiretroviral toxicities. The 
evidence generated from these workflow analyses could prove useful to HIV care programs and 
policymakers by informing the redesign of clinical workflows to improve point-of-care 
antiretroviral toxicity monitoring in underserved settings. Such undertakings would be particularly 
crucial in settings which lack the capacity to conduct stand-alone pharmacovigilance. 
Additionally, this dissertation provides evidence in support of the integration of peer health 
workers into ambulatory HIV care workflows to assist with data collection tasks. This could have 
a direct impact on the manner in which care is delivered in underserved settings. While the 
approach could be useful in improving the data collection processes, HIV care programs would 
have to consider the tradeoffs between enhancing patient safety using this approach and mitigating 
the potential costs associated with additional monitoring. 
Lastly, as part of this dissertation, a knowledge-based application prototype that has the potential 
to improve antiretroviral toxicity data collection and analysis was developed. With additional 
refinement, this prototype could prove useful as a clinical documentation resource, a decision-
making aid, and a drug information repository for clinicians working in ambulatory HIV care 




This dissertation research had several general limitations. First, due to the shortcomings of the 
study designs employed in this research work, accurate causal inferences may not be made out of 
the studies conducted in the program of research. The findings of this dissertation should, 
therefore, be viewed as exploratory rather than confirmatory. Second, the qualitative designs 
involving self-reporting by human subjects in the program of research are subject to internal 
validity and reliability limitations. It is neither possible to prove the honesty of the participants and 
factuality of the information they provided, nor is it guaranteed that replicating the qualitative 
studies would generate similar findings. Third, due to time and resource constraints, the studies 
involving human subjects had small sample size. Although appropriate statistical analysis 
approaches were used, the inference from these studies may not be generalizable beyond the 
specific populations from which the participants were drawn. Fourth, the problem awareness 
studies (chapters 3 and 4) primarily focused on characterizing contextual barriers to and facilitators 
of antiretroviral monitoring. This approach inadvertently led to the inadequate investigation of the 
intrinsic perceptions of clinicians and patients on antiretroviral toxicity management. It is, 
therefore, possible that the findings of this study do not reflect the opinions of all healthcare 
stakeholders. Fifth, only one setting was used for the field studies. The choice of this site was 
based on familiarity with the setting and the fact it actively researches strategies for improving 
care delivery in underserved settings. However, being a large collaboration between different 
institutions, this setting may not be a true representation of other underserved settings. It is, 
therefore, plausible that findings of this study underestimate the true challenges of antiretroviral 
monitoring in underserved settings, and that solutions generated by this dissertation may not be 
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universally applicable. Lastly, focusing on antiretroviral toxicities limits the generalizability of the 
findings to other diseases or drug therapy problems. 
8.6. Future Work 
This dissertation research is generally exploratory and, therefore, raises a number of opportunities 
for future research. For example, this dissertation identified several broad strategies that could be 
used to improve medication adherence, safety, and effectiveness in underserved settings. Future 
research could investigate the feasibility and comparative effectiveness of these different 
strategies, especially with respect to the monitoring antiretroviral toxicities. Further research is 
also needed to delineate the workflow-related barriers and facilitators of antiretroviral toxicity 
monitoring that are intrinsic to human actors such as patients and clinicians. Additionally, this 
dissertation shed some light on the potential use of peer health workers as collectors of 
antiretroviral toxicity information via checklists. However, the usability investigations applied in 
the dissertation relied on written vignettes rather than real-life scenarios. Future research is, 
therefore, needed to assess the practical feasibility of peer health workers using checklists to 
document antiretroviral toxicity symptoms. Additional research is also needed to clarify whether 
the performance of peer health workers using checklists could be improved through interventions 
such as training and education. With respect to the development of the prototype created in this 
dissertation, additional testing of its performance when in actual clinical use is required. Also, 
future informatics research should focus on delineating ways in which the prototype deals with 
uncertainty and inadequate domain coverage. Lastly, the implementation of knowledge-based 
systems using traditional methods such as relational database systems could be complex and 
challenging. Future informatics research should investigate ways in which newer technologies 
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